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ABSTRACT 
Schizophrenia is a common psychiatric disorder with a complex aetiology that has a 
strong genetic component as well as a major contribution from non-genetic factors. 
Whilst GWAS studies have not yielded substantial evidence of DNA variants linked to 
schizophrenia, microarray expression studies, which reflect both genetic and 
environmental factors, have provided evidence of candidate genes whose expression 
changes significantly in schizophrenia. The present thesis is based on a prospective 
microarray study carried out on two brain regions implicated in schizophrenia: frontal 
cortex and superior temporal cortex (Maycox et al., 2009; Barnes et al., 2011). SNP 
variants in six of these genes were genotyped and allele, genotype and haplotype 
analysis carried out initially to investigate associations with levels of expression found 
in these microarray studies. Subsequently SNP associations with disease were 
investigated in an extended case-control cohort from the East UK region. The 
selected candidates genes, highlighted from microarray studies, reflected two main 
functional categories: synaptic plasticity and the Wnt signalling pathway. Initial 
ANOVA revealed a significant interaction of disease status with genotype/haplotype 
in ZnT3 with respect to levels of expression. Significant effects of specific genotypes 
and haplotypes in CACNA1E and FRZB on expression were also observed. 
Furthermore, ZnT3 was the gene for which the strongest evidence of association 
with schizophrenia was obtained in the East UK cohort, with four SNPs associated at 
the allelic and genotypic level. Significant associations of a number of haplotypes of 
ZnT3 with disease status were also identified. In addition, modest evidence of 
statistical epistasis between genes within both functional groups was identified. 
Finally, a method for analysis of CpG island methylation was developed based on 
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bisulphite sequencing and methylation specific PCR (MSP) using previously validated 
primers for DKK3 (Yue et al., 2008). Although DKK3 showed a low density of 
methylation, the application of this method may prove useful for other candidate 
genes. 
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CHAPTER 1 General Introduction 
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Schizophrenia is a common psychotic disorder characterized by a diversity of 
symptoms that usually vary from patient to patient and some of which may be 
shared by other disorders. However, consensus has been reached regarding those 
symptoms that appear to be characteristic of schizophrenia under the criteria that if 
they appeared in isolation they would lead almost certainly to the diagnosis of this 
particular disease (McKenna, 1994). 
Schizophrenia has a lifetime risk of 1% in the general population and the onset 
occurs in most cases in late adolescence or early adulthood. It has been observed in 
a number of studies that male patients tend to have an earlier age of onset, however 
these findings are not consistent across different populations (Wong et al., 2003). 
The age of onset has been also related to the severity of disability since a number of 
studies have reported a differences in cognitive impairment of late-onset 
schizophrenia patients compared to youth-onset individuals (Rajji et al., 2009; Kao 
and Liu, 2010). 
Although numerous family, twin and adoption studies have revealed a strong genetic 
component to the pathogenesis of schizophrenia, the fact that there is only 50% of 
co-transmission in monozygotic twins suggests a high contribution of non genetic 
factors, such as environmental factors, to the development of the disorder. However, 
there is still limited information on how these factors interact and to which extent are 
they contributing to the outcome.  
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1.1 Diagnosis and characterisation of Schizophrenia 
Schizophrenia is characterised by a variety of symptoms that include psychosis but 
that also extend to impairment of cognitive function and mood disorder. Moreover, 
there are a number of other disorders that, like schizophrenia, have a strong 
psychotic component making it harder to provide an accurate diagnosis for each 
case. Therefore the correct diagnosis of schizophrenia requires the identification of a 
combination of signs and symptoms that not only account for the alterations of 
perception but also the impaired cognitive and social function and ultimately the 
incapacitating character of the disease. The procedure followed currently for the 
identification of schizophrenia is fully described in the Diagnostic and Statistical 
Manual of Mental Disorders on its fourth edition (DSM-IV-TR; American Psychiatric 
A., 2000). Although the criteria contained in this manual are used as a standard 
method of diagnosis for research around the world another commonly used guide, 
particularly in Europe is the Chapter V: Mental and behavioural disorders from the 
International Classification of Diseases on its tenth edition (ICD-10; World Health 
Organization).  
The method for diagnosis described in the DSM-IV-TR consists of six diagnosis 
criteria: Criterion A defines the characteristic symptoms of the disease while criterion 
B describes the signs involved in social and occupational dysfunction. Criterion C 
specifies the duration of the disturbance necessary for the diagnosis of schizophrenia 
over other psychotic disorders. The three first criteria are complemented by criterion 
D designed to rule out schizoaffective and mood disorders. Finally, criterion E is 
aimed to assess the possible effect of substances or general medication while 
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criterion F explores the additional diagnosis of schizophrenia in individuals suffering 
from, or with a history of, pervasive developmental disorders such as autism. 
1.1.1 Characteristic symptoms of Schizophrenia  
Symptoms regarded as characteristic of Schizophrenia are generally described as 
contained into one of two broad categories: Positive and negative symptoms. The 
symptoms comprised in these two groups constitute what is known as active-phase 
symptoms. The presence of two or more of the aforementioned symptoms for a 
period of at least 1 month when they are accompanied by other signs leading to 
impaired function. 
Symptoms referred to as positive are commonly presented in intermittent and acute 
episodes and represent ‘an excess or distortion of normal function’. Positive 
symptoms are broadly a reflection of distorted or intensified functions such as 
perception (hallucinations) or inferential thinking (delusions) and therefore, represent 
the psychotic component of the disease. However, other symptoms representing the 
disorganized component of the disease are also listed as positive.  
Delusions  
Delusions are defined as misinterpretations of perceptions or experiences. They 
usually manifest as a strong belief that cannot be substantiated and that is held in 
spite of evidence to the contrary. While these can be related to a variety of themes 
the most common in schizophrenia cases are those delusions where the individual 
holds the strong conviction of being tormented, followed or spied on even against 
clear contradictory evidence. Especially characteristic of the disease are delusions 
that for the lack of correlation with ordinary life experiences are considered to be 
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clearly implausible. These delusions have been identified as bizarre and include loss 
of control over mind and body (e.g. belief of thoughts being taken away from the 
mind of the patient by an external force). Although these are difficult to assess and 
depend generally on the context, the presence of bizarre delusions is considered to 
be sufficient to satisfy criterion A in the diagnosis of schizophrenia. 
It is important to note that for the purpose of diagnosis, delusion must be recognised 
from dogmatic ideas or illusions. There is also a distinction between delusion and a 
belief that is based on incomplete information or on information that due to its 
nature may not be easily deemed as false (e.g. religious and spiritual beliefs). Finally, 
the cultural context plays an important role in the diagnosis of delusion. Indeed, this 
cultural component to the identification of delusion is subjective and it has become a 
source of debate on whether it is necessary to define more precise models for 
diagnosis (Mujica-Parody and Sackeim, 2001). 
Hallucinations 
Hallucinations are considered distortions in perception and it is possible to find them 
in any sensory modality. Auditory hallucinations however have been reported to be 
the most common in schizophrenia and are usually perceived as voices 
distinguishable from the patient’s own thoughts. In most cases the content the 
hallucinations tends to be pejorative or threatening and in particular cases they 
consists of two or more voices conversing with one another or holding a permanent 
commentary over the affected person. When this specific type is present it is 
considered to be the only requirement needed to satisfy criterion A of the diagnosis.  
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Disorganisation Syndrome 
The second component of the positive symptoms includes disorganised speech, often 
been referred to as formal thought disorder. Regarding this component the criteria 
indicates that the impediment must be severe enough, at least during the active 
phase of schizophrenia, to account for largely impaired communication. The final 
component to the disorganisation dimension of the positive symptoms is 
disorganised behaviour and is commonly manifested as clearly inappropriate 
behaviour or unpredictable and untriggered agitation among others. In addition, 
catatonic motor behaviour could also be present and in some cases to the extreme 
degree denoted by complete unawareness to external inputs, adoption of rigid 
postures and resistance to be moved or purposeless and unstimulated excessive 
motor activity. 
The negative symptoms of schizophrenia are regarded as ‘diminution or loss of 
normal function’ they usually occur early before the onset of the disease and are 
more enduring and difficult to treat which makes them a reflection of the chronic 
disability of the disorder. Symptoms referred as negative often include affective 
flattening, decreased fluency of speech (alogia), lack of motivation to perform goal-
directed activities (abolition) and diminished capacity to experience pleasant 
emotions (anhedonia) among others. The presence of sever negative symptoms may 
lead to cognitive dysfunction represented by confusion, disorientation and memory 
and attention impairment. It is particularly important to consider the possibility of 
some of these negative symptoms manifesting as a response to medication or the 
experience of positive symptoms.  
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1.1.2 Schizophrenia Subtypes 
Because of the broad spectrum of symptoms associated with schizophrenia the 
definition of subcategories has been a helpful tool for the diagnosis and treatment of 
the disorder. Moreover it has been suggested that definition of schizophrenia 
subtypes might be key in the identification of underlying mechanisms that could be 
particular to the pathophysiology of defined groups of cases. From the clinical point 
of view there are five recognised subtypes of schizophrenia described in the DSM-IV 
and defined on the basis of the predominant symptoms present in each case.  
Paranoid   
Paranoid schizophrenia is diagnosed when there is prevalence of prominent delusions 
and hallucinations but relatively normal cognitive function and affection. Delusions in 
paranoid schizophrenia can be multiple but generally share a common theme to 
which hallucinations are generally related as well. When compared to other subtypes, 
the onset for paranoid schizophrenia is presented at a late stage and the 
characteristic features tend to be more stable with time. Although this subtype is 
considered as one of the most severe and the chances of prognosis tend to be low, 
due to an inclination to suicidal and/or violent behaviour, the fact that there is little 
or no impairment in cognitive function suggests that the possibility of independent 
living for individuals that respond positively to treatment more likely than for other 
subtypes.  
Disorganised 
Disorganised or hebephrenic schizophrenia is characterised by disorganised speech 
and behaviour and signs of emotional flattening over other symptoms. In individuals 
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suffering from this type hallucinations and delusions, if present, are generally not 
associated with one another and do not share a common theme and in most cases 
there is no evidence for neuropsychological or cognitive impairment. Along with 
paranoid, disorganised type is deemed to be highly incapacitating due to the inability 
of most of the affected patients to perform daily-life activities such as preparing 
meals or dressing as a result of disorganised behaviour. The onset of this subtype is 
usually an early one with significant remissions being rare. 
Catatonic 
Diagnosis of catatonic type of schizophrenia only takes when the patient presents a 
distinctive psychomotor disturbance that cannot be attributed to medication or any 
other general medical condition. In addition, the individual must meet the full criteria 
for schizophrenia in order to rule out major manic-depressive disorder. Motor 
disturbance may be manifested in a number of ways ranging from excessive activity 
to immobility. The former is usually untriggered and it tends to lack purpose while 
the latter can be present itself as muscle rigidity (catalepsy) or stupor. Other 
common symptoms present in this type include voluntary assumption of 
inappropriate postures, continuous repetition of words or phrases (echolalia) and 
repetitive imitation of others (echopraxia). In severe cases of catatonic schizophrenia 
there is an increased risk of patients harming themselves or others. Other potential 
risks associated with this type include hyperpyrexia, exhaustion and malnutrition. 
Undifferentiated and Residual 
The two final subtypes of schizophrenia refer to cases that present enough 
symptoms to meet the criteria for diagnosis of the disease but that do not fall into 
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any of the three main schizophrenia types previously described. Thus in the 
undifferentiated type is used to describe cases where the individual presents enough 
symptoms to comply with criterion A while residual type describes cases where, with 
the exception of an initial episode, there are virtually no positive symptoms. 
However, for the latter to be applied continued presence of the disturbance must be 
observed and might be enunciated by the presence of negative symptoms and/or 
two ore more attenuated positive symptoms. It is not uncommon for the occurrence 
of residual type to represent a transition between a “full-blown” episode and 
remission. 
1.2 Neuropathology of Schizophrenia 
The once accepted notion of the lack of defined neuropathology to schizophrenia has 
proved to be inaccurate by the collective evidence from imaging, histological and 
neurochemical studies. However, some obstacles remain mainly due to the fact that 
defined and quantifiable morphological abnormalities have been difficult to identify 
and replicate. However, when considered in the context of other genetic and 
molecular findings, data collected from imaging and histology studies have provided 
important insights into the pathogenesis of the disorder. 
1.2.1 Macroscopic findings  
The possibility conferred by magnetic resonance imaging (MRI) and other imaging 
techniques to analyse live tissue has proven to be a great advantage in the study of 
changes in the brain morphology in schizophrenia compared to healthy individuals. 
Among the most replicated features reported from these studies are: ventricular 
enlargement, more specifically the third and lateral ventricles, and small reductions 
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in whole brain volume and weight (Weinberger et al., 1983; Lawrie and Abukmeil, 
1998; Wright et al., 2000; Hirayasu et al., 2000; Shenton et al., 2001; Harrison et 
al., 2003; Steen et al, 2006; Velakoulis et al., 2006; Arnone et al., 2009; Ellison-
Wright and Bullmore 2009). These volume differences have been reported to be 
present in first-episode and drug-naïve patients (Steen et al., 2006) and in 
unaffected relatives (Lawrie et al., 1999), a fact that seems to link the described 
macroscopic changes with a genetic predisposition to the illness.  
Other notable findings from imaging studies are reductions in volume of 
hippocampus, amygdala, parahippocampal gyrus and superior temporal gyrus as well 
as the temporal horn portion of the lateral ventricles, which results in an increase in 
cerebrospinal fluid (CSF) in the region surrounding these structures (Bogerts et al., 
1990; Nelson et al., 1998; Lawrie et al., 1998; Niemann et al., 2000; Matsumoto et 
al., 2001; Sim et al., 2006) prefrontal and superior temporal cortices (Pearlson et al., 
1999; Davidson et al., 2003) and thalamus (Andreasen et al., 1994; Konick and 
Friedman, 2001). However, these findings are not entirely specific for schizophrenia 
and some of them may not be present in all cases (Wright et al., 2000; Shenton et 
al., 2001; Harrison and Weinberger, 2005; Wong and Van Tol, 2003), which makes it 
difficult to define a neuropathological profile that could be used in diagnosis.  
In spite of the differences between studies, advances in brain imaging have and will 
undoubtedly continue to contribute in the identification of the important structural 
abnormalities that are key in the understanding of the neurobiology of schizophrenia. 
Perhaps the most evident conclusion that can be drawn from the number of brain 
regions affected is that the disturbance of connectivity as a pathological feature of 
the disorder. As an attempt to identify the origin of this defect a number of theories 
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have been formulated, many of them proposing the idea that schizophrenia could be 
regarded as a neurodevelopmental disorder. Some of the data collected from 
imaging studies seems to support this notion. For instance, many of the structural 
abnormalities that have been reported from the limbic and temporal region seem to 
be present particularly in the left side of the brain, which is consistent with the 
language-related symptoms that characterise the disorder (Crow, 1998; Sommer et 
al., 2001). This idea has been further extended to the investigation of disrupted 
connectivity within a neuronal network not only relevant for language but also for 
memory formation (Nestor et al., 1993; McCarley et al., 1999).  
1.2.2 Histological findings 
In addition to the macroscopic findings collected from imaging studies on the 
structural abnormalities present in schizophrenia, post mortem brain studies have 
provided insight into more detailed neuropathological characteristics of the disease. 
Although, positive findings have been limited, important information has been 
gathered from negative studies regarding the nature of the disorder. Such is the case 
of the consistent lack of evidence for the association of schizophrenia with 
neurodegenerative processes or gliosis, even in schizophrenia cases presenting 
dementia (Arnold et al., 1996; Baldessarini et al., 1997; Arnold et al., 1998; Jellinger 
et al., 1999; Bernstein et al., 2009). These data provide further support to the idea 
of schizophrenia as a neurodevelopmental disorder rather than a progressive one. 
Consistent with this idea of an important developmental component to schizophrenia 
are histological findings of aberrant location of clusters of neurons in entorhinal 
cortex (Arnold et al., 1991a; Akil and Lewis, 1997; Falkai et al., 2000) and other 
cortical regions (Akbarian et al., 1993a; 1993b; 1996; Kirkpatrick et al., 1999; 
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Eastwood et al., 2003) suggesting dysfunctional cell migration affecting connectivity. 
However, attempts to reproduce these data have not always been successful, which 
has led to questions about the origin of these aberrations when present (Beasley et 
al., 2002a). 
Other well replicated data collected from histological studies in post-mortem brain of 
schizophrenia cases are observations of reduced cell body size of pyramidal neurons 
in hippocampus and neocortex of cases compared to controls (Benes et al., 1991a; 
1991b; 1992; Arnold et al., 1995; Zaidel et al., 1997; Rajkowska et al., 1998; Pierri 
et al., 2001; Sweet et al., 2003). In addition, these neurons have been reported to 
have fewer dendritic arborisations and spines (Glantz and Lewis, 2000; Rosoklija et 
al., 2000; Black et al., 2004). Furthermore, these findings have been supported by a 
number of studies reporting dysfunctional regulation of expression of two dendritic 
molecular markers, microtubule-associated protein 2 (MAP2) and spinophilin in 
hippocampus of schizophrenia subjects (Arnold et al., 1991b; Law et al., 2004). 
Downregulation of genes coding for presynaptic markers in these regions has also 
been observed (Young et al., 1998; Thompson et al., 1998; 2003a; 2003b; Halim et 
al., 2003). Moreover, reductions in density of interneurons and their synaptic 
projections have also been reported in schizophrenia cases as well as alterations in 
GABAergic and glutamatergic synaptic populations in dorsolateral prefrontal cortex 
(DPFC) of affected individuals (Beasley et al., 2002b; Reynolds et al., 2002; 
Bitanihirwe et al., 2009). Finally, changes in dopaminergic signalling have also been 
observed (Akil et al., 1999) and the importance of interactions between glutamate 
and dopamine in the mechanisms underlying neurotransmitter dysfunction in 
schizophrenia have become apparent (Carlsson and Carlsson, 1990)  
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Although there are some inconsistencies across studies, overall these findings have 
provided evidence for deficient synaptic connectivity in schizophrenia. This approach 
has consistently been supported by following studies pointing to the conclusion that 
this abnormality of synaptic terminals seems to be mainly molecular and only in part 
morphological. This is idea is particularly interesting in the context of gene 
expression and association studies and it suggests an important role of synaptic 
plasticity processes in the pathophysiology of the disorder.  
1.2.3 Neurochemical studies 
The analysis of the mechanisms of action of antipsychotic and psychotomimetic 
drugs has been a useful tool in the attempt to unveil the molecular basis of 
schizophrenia. These studies provided support for two main theories involving 
neurotransmitter dysfunction in the aetiology of the disorder: The glutamate hypo-
function hypothesis and the dopamine hyperactivity hypothesis. 
The first theory was mainly supported by observations of the effects of phencyclidine 
(PCP) and ketamine, two non competitive antagonists of N-methyl-D-aspartate 
(NMDA)/glutamate receptors known for inducing not only schizophrenia-like 
psychosis but also cognitive dysfunction in healthy individuals (Rainey and Crowder, 
1975; Snyder, 1980; Javitt and Zukin, 1991) and for exacerbating positive and 
negative symptoms in schizophrenic patients (Krystal et al., 1994; Lahti et al., 1995). 
These and other similar drugs have been used subsequently in the development of 
animal models of schizophrenia (Mouri et al., 2007; Javitt, 2007; Dyck et al., 2007; 
Broberg et al., 2008; Pedersen et al., 2009; Amann et al., 2010).  
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In addition to support from imaging and genetic studies, the dopamine hyperactivity 
hypothesis partly originated from observations of blockade of dopamine D2 receptors 
by neuroleptic agents (Seeman et al., 1975; Seeman and Lee, 1975; Creese et al., 
1976). It was therefore proposed that overstimulation of the dopamine system was 
likely to be associated with the pathophysiology of psychiatric disorders. This premise 
has been the basis of extensive research in the search for better and more efficient 
antipsychotics and to the realization of a correlation between the D2 receptor affinity 
and the potency of the drug (Seeman and Tallerico, 1999; Kapur et al., 1999; 
Tauscher et al., 2004). The nature of the dopamine hyperactivity in schizophrenia 
remains to be fully elucidated. A number of studies have suggested the involvement 
of dopamine receptor-interacting proteins (Koh et al., 2003; Bai et al., 2004) while 
other researchers have examined whether the over activity is presynaptic or post-
synaptic and what are the implications of each of these possibilities to the aetiology 
of schizophrenia (Abi-Dargham et al., 2000; Narendran et al., 2006; Graff-Guerrero 
et al., 2009; Kegeles et al., 2010).  
In recent years, attention has turned to the possible intersection of these two 
hypotheses. The well documented role of dopamine in regulation of cognitive 
function (Gao et al., 2001; Seamans and Yang, 2004) and the close resemblance of 
the dysfunction induced by NMDA-receptor antagonists to the negative syndrome of 
schizophrenia have led to the conclusion of a possible dopaminergic dysregulation in 
striatal and prefrontal regions of the brain resulting from NMDA hypofunction (Balla 
et al., 2009; Li et al, 2010). 
Serotonergic dysfunction in schizophrenia has also been proposed from 
neurochemical studies initially from the observation that lysergic acid diethylamide 
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(LSD), an antagonist of serotonin-2A receptor (5-HT2A), had hallucinogenic 
properties although, unlike PCP however, LSD-induced psychosis is not accompanied 
by the negative symptoms characteristic of the disorder (Woolley and Shaw, 1954). 
However, the basis of more recent studies concerning the role of serotonin in 
psychiatric disorders is the fact that many neuroleptic drugs seem to be strong 
5HT2A antagonist but have relatively reduced affinity for D2 receptors (Meltzer and 
McGurk, 1999).  
1.3 Identification of genetic risk factors for Schizophrenia 
In spite of extensive investigation the exact mechanisms underlying the 
pathophysiology of schizophrenia have remain elusive. Heritability of the disorder 
calculated from family and twin studies has been reported to be between ~80% 
which highlights a strong genetic component to its aetiology (McGuffin et al., 1984; 
Tsujita et al., 1998; Cannon et al., 1998; Franzek and Beckmann, 1998; Cardno et 
al., 1999; Kläning et al., 2002). However, another important observation from these 
studies is that in pairs of discordant monozygotic twins the risk of psychosis for 
offspring of both siblings is similar. Moreover, concordance for schizophrenia in MZ 
pairs has been calculated as ~50%. Overall, these data suggest an important 
contribution of non-hereditary factors contributing to the expression of the 
schizophrenic phenotype. 
Although the genetic epidemiology of schizophrenia is yet to be fully understood, it 
has become clear that the transmission of susceptibility genes occurs in a complex 
way and that it is likely to involve multiple loci conferring risk for the disorder 
(Gottesman and Shields, 1967; McGue and Gottesman, 1989). Perhaps one of the 
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main challenges that the polygenic nature of schizophrenia is the elucidation of the 
number of susceptibility loci involved and the extent of the risk associated with each 
of them. In an attempt to answer these questions, two main models have been 
proposed. The first one considers that there are multiple genetic variants with a 
small additive or multiplicative effect contributing to the risk of developing the 
disorder. This common-disease/common-variant hypothesis has proved to be valid 
for various common complex disorders including Crohn’s disease, type II diabetes 
and obesity (Zeggini et al., 2007; Hampe et al., 2007; Rioux et al., 2007; Wellcome 
Trust Case Control Consortium et al., 2010). Unlike these examples in the case of 
schizophrenia, in spite of a number of studies supporting the implication of common 
polymorphisms with a small effect in the pathophysiology of the disease, there is still 
some debate as to whether this theory is the more suitable for the investigation of 
genetic factors conferring risk for the development of the disorder.  
A second hypothesis has been proposed based on a growing body of evidence 
pointing to a significant association of rare large variants with the disease (Basset et 
al., 2008; Walsh et al., 2008; Xu et al., 2008; ISC, 2008; Stefansson et al., 2008). 
This common-disease/rare variant hypothesis attributes genetic predisposition to 
schizophrenia to rare alleles with highly penetrant effects. There is still no consensus 
regarding which of these models is the most appropriate for the study of 
schizophrenia. However, evidence seems to suggest that these theories might not be 
mutually exclusive and that the combination of both in a more general model is more 
fitting for the study of schizophrenia and other psychiatric disorders.  
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1.3.1 Candidate genes from Linkage and Association studies 
Traditionally, linkage analyses have been regarded as the starting point in the search 
for genes associated to common complex disorders. This analysis is based on the 
assumption that two alleles that are close to each other in a specific region of a 
chromosome are likely to be inherited together. Therefore, by genotyping of 
polymorphic markers in related individuals it is possible to identify loci associated 
with risk of a particular disease phenotype. Linkage studies have been applied 
successfully to Mendelian inherited disorders, but this method has some limitations 
when applied to complex disorders where it is expected that each of the loci 
implicated will account for only a small increment in risk. Moreover, epistatic and 
additive effects among genes are expected to have an implication in the accurate 
identification of associations (Bureau et al., 2009).  
A number of susceptibility loci for schizophrenic phenotype have resulted from 
linkage analysis including 6p24-22 (Straub et al., 1995) 8p22-21, 13q14-q33 (Blouin 
et al., 1998; Gurling et al., 2001) 1q21-22 (Brzustowicz et al., 2000), 1q32.2-41 
(Hovatta et al., 1999; Ekelund et al., 2001) 10q25.3-26.3, 2p12-22.1 (Lewis CM et al., 
2003) and 22q (Williams et al., 2003), although in many cases attempts to reproduce 
these results in other genomewide studies have not been successful. Possible 
reasons for this lack of replication are varied, from differences in diagnosis to 
heterogeneity of the samples analysed (Owen et al., 2005). In spite the difficulties, 
three meta-analyses have been able to identify some interesting patterns (Badner 
and Gershon, 2002; Lewis CM et al., 2003; Ng et al., 2009). Amongst the most 
strongly supported regions are 8p, 22q, 1q, 6p, 2q, 3p, 5q, 14p and 20p.  
Although undoubtedly valuable the limited capacity of linkage studies to detect weak 
linkage (Risch, 1990a; 1990b) has led to suggestions that the positive findings 
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reported might be representing segregation of rare alleles with a large effect. 
Alternatively, it is possible that the loci identified might contain several genes 
conferring small increments in risk.  
The availability of information about the human genome has provided the possibility 
of determining the risk to schizophrenia conferred by specific candidate genes, both 
within previously identified linkage regions and in other chromosomal regions, thus 
complementing linkage studies. Association studies are usually performed by 
comparing frequencies of common allelic variants in affected and unaffected 
individuals. Common polymorphisms are variations in the DNA sequence that appear 
with a frequency of at least 1% in a certain population. Single nucleotide 
polymorphisms (SNPs) and copy number variants (CNVs) are examples of these 
variations that have been of great relevance to the investigation of genes implicated 
in complex diseases. Copy number variants are large-scale polymorphisms, this is 
large fragments of DNA (one kilo base or greater) whose copy-number have been 
found to contribute to the phenotypic variation in humans and it has been proposed 
that they also have an important role in susceptibility to disease (Iafrate et al., 2004; 
Sebat et al., 2009).  
The basic premise of these association studies is that when significant differences in 
frequencies of these polymorphisms are observed in cases compared to controls it is 
considered that the variant is associated to disease status or is in linkage 
disequilibrium with another risk variant. Evidence for SNPs associated with 
schizophrenia has been reported for a number of genes, although further validation 
has not been successful for all cases and functional relevance is still not clear even 
for some of the most robust findings.  
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Amongst the most interesting and most extensively studied candidates genes from 
linkage and association studies are:  
- Dysbindin (DTNBP1) on chromosome 6p22.3 (Straub et al., 2002), also 
relevant for its importance for presynaptic and glutamate function (Numakawa 
et al., 2004; Talbot et al., 2004)   
- Neuregulin (NRG1) on 8p21-22 (Stefansson et al., 2002; 2003). NRG1 
includes cell signalling, axon guidance, synaptogenesis, glial differentiation, 
myelination and neurotransmission (Corfas et al., 2004; Roy et al., 2007; 
Buxbaum et al., 2008). 
-  D-amino-acid oxidase activator (DAOA, G72) in the linkage region of 
chromosome 13q22-34 (Chumakov et al., 2002). Implication of this gene with 
the aetiology of schizophrenia has also been supported by previous 
association studies (Schumacher et al., 2004) 
- Regulator of G-protein signalling 4 (RGS4) on 1q22 (Chowdari et al., 2002). 
RGS4 is an interesting candidate gene for schizophrenia from a functional 
perspective for a number of reasons: Expression of the gene appears to be 
regulated by dopaminergic transmission (Taymans et al., 2004). Moreover, 
evidence of regulation of serotonergic and metabotropic glutamatergic 
receptors by RGS4 has been reported (De Blasi et al., 2001; Beyer et al., 
2004) as well as evidence of interaction of RGS4 and ERBB3 in the brain 
(Thaminy et al., 2003). 
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- Catechol-O-methyl transferase (COMT) on chromosome 22q11.2 (Kunigi et al., 
1997; Ohmori et al., 1998; Kotler et al., 1999; Murphy et al., 1999; Li et al., 
2000; Egan et al., 2001; Murphy, 2002; Wonodi et al., 2003; Chen et al., 
2004). Most of the association of COMT with schizophrenia has been related 
to a particular SNP in exon 4 of the gene, a G→A nucleotide change that 
results in an amino-acid substitution from valine (val) to methionine (met) at 
codon 158 of the transcript coding for MB-COMT. This change of amino-acids 
results in lower stability of the met-COMT enzyme, which implies lower activity 
compared to the val-COMT allele (Lotta et al., 1995). The importance of 
COMT in the catabolism of dopamine, especially in the prefrontal cortex (PFC) 
has further highlighted the possibility of the gene as a risk factor for the 
disease (Tenhunen et al., 1994; Lotta et al., 1995). 
- Disrupted in schizophrenia (DISC1) in chromosome 1q42 (Ekelund et al., 
2001; 2004; Hennah et al., 2003; Hodgkinson et al., 2004; Hashimoto et al., 
2006; Qu et al., 2007; Chubb et al., 2008). The first suggestion of the 
implication of DISC1 in schizophrenia came from the observation that the 
gene was disrupted a balanced chromosomal translocation (1;11)(q42;q14.3) 
initially identified a Scottish family and strongly associated with the risk of 
schizophrenia, bipolar disorder and recurrent depression (St Clair et al., 1990; 
Millar et al., 2001; Blackwood et al., 2001). The implication of DISC1 in 
regulation of neurodevelopment (Miyoshi et al., 2003; Johnston et al., 2011) 
and neuronal progenitor proliferation in the adult brain (Kim et al., 2009) as 
well as the evidence for implications of the genetic variability of this gene in 
cognitive function in normal and schizophrenic individuals, has made the 
investigation of this gene more interesting (Hennah et al., 2005; 2009; 
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Callicott et al., 2005; Burdick et al., 2005; Cannon et al., 2005; Thomson et 
al., 2005; Liu et al., 2006).  
- Brain-derived neurotrophic factor (BDNF). This gene has been considered as a 
candidate gene for schizophrenia from a number of association and expression 
studies (Weickert et al., 2003; 2005; Knable et al., 2004; Angelucci et al., 
2005; Torrey et al., 2005). The hypothesis that disruption of BDNF might be 
implicated in the pathophysiology of the disorder is a compelling one due to 
the importance of the gene in cognition, learning and memory (Linnarsson et 
al., 1997; Hall et al., 2000) amongst other processes essential for normal 
neural function. 
In addition to the candidate genes identified from point mutation analyses and 
chromosomal abnormalities, a number of other genes have been considered for 
association studies on the basis of their functional relevance. The most notable 
examples are metabotropic glutamate receptor-3 (GRM3) and dopamine receptors 
D2 (DRD2) and D3 (DRD3). Positive reports for GRM3 include evidence for 
associations a SNP in intron 3, as well as a number of two and three marker 
haplotypes, with schizophrenia (Fujii et al., 2003). Report of association of a second 
SNP in intron 2 with disease also came later (Egan et al., 2004). The author also 
demonstrated association of this SNP with impaired cognitive function in 
hippocampus and prefrontal cortex of both affected and unaffected individuals. In 
addition, they found a strong correlation of the presence of the high-risk allele of the 
SNP with downregulation of the glial glutamate transporter EAAT2.  
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In the case of dopamine receptors, reports suggests have implication of a functional 
SNP in the DRD3 gene responsible for an amino-acid substitution in residue 9 of the 
protein (Ser9Gly). Although the variation seems to confer small risk to disease, 
various studies have confirmed an association of the Ser/Ser homozygote with poor 
response to antipsychotic treatment (Williams et al., 1998; Jonsson et al., 2003; 
2004; Hwang et al., 2010). Moreover, one study reported synergistic effect of the 
Ser9Gly variant and other three polymorphisms, all of which were found to be in 
strong linkage disequilibrium (Sivagnanasundaram et al., 2000). Finally, other studies 
have reported significant association of the Ser311Cys polymorphism in the DRD2 
gene with schizophrenia (Glatt et al., 2003; Glatt and Jonsson, 2006) 
1.3.2 Microarray technology applied to the analysis of 
Schizophrenia risk factors 
Within the last three decades, the development of new and improved techniques as 
well as the construction of large genomic databases has enabled researchers to 
perform studies on a larger scale and in a hypothesis-free manner. This has provided 
a new approach to the investigation of the aetiology of schizophrenia through the 
use of microarray technology to carry out genome-wide association and expression 
studies in larger samples in order to increase the power of the analysis. Genome-
wide analyses have been a valuable tool not only for the identification of candidate 
genes for schizophrenia but also for the elucidation of the disruption of certain 
functional pathways. Notably the data collected so far using microarray technology 
has confirmed findings that are consistent with previous hypotheses on the 
pathophysiology of schizophrenia, formulated from other studies. 
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Microarray technology works on the basis of the chemical composition of DNA and 
RNA molecules and their properties. Both molecules have the same basic structure, 
which consists in a chain of sugar molecules linked together by phosphate groups 
conforming what is called the backbone to which nucleotide bases are attached. 
Each nucleic acid molecule is constituted by a combination of four different 
nucleotide bases that are capable of forming hydrogen bonds with only one other 
base. Thus, thymine (or uracil in RNA) will bind to adenine and cytosine to guanine. 
This principle creates the possibility of using complimentary sequences for a variety 
of applications such as genotyping of single nucleotide polymorphisms (SNPs) or 
quantifying the amount of a given mRNA transcript being expressed in a given tissue 
or cell sample. In most of the platforms currently available, a number of known 
probes are attached to a solid substrate (commonly glass) in order to be 
immobilized. These probes can either be the complementary DNA sequence (cDNA 
for a specific mRNA transcript) or a synthetic oligonucleotide. The dimensions of the 
analysis depend on the design of the arrays and range from a few hundred probes to 
106 samples in a high-density microarray. It is therefore possible to apply microarray 
technology to a number of applications that include resequencing, detection and 
genotyping of single nucleotide polymorphisms, identification of specific protein 
binding sites and analysis of epigenetic mechanisms such as DNA methylation or 
small RNA-DNA interactions (Brent and Ausubel, 2005).  
Microarray technology has been extensively used for the identification of genetic 
factors contributing to risk of schizophrenia in genome-wide association studies 
(GWAS). In addition, microarrays have been used for the quantification of mRNA 
transcript levels in large numbers of tissue or blood samples. This approach has 
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provided the possibility of identifying differentially expressed genes when comparing 
groups of samples from controls and affected individuals.  
1.3.3 Schizophrenia risk factors identified from genome-wide 
association studies  
Linkage and association have been extremely valuable in the identification of 
genomic regions associated to schizophrenia. They have also provided a basis for 
more detailed analysis of the role of candidate genes in the disease through 
functional analyses. However, this approach has proven to have considerable 
limitations in the study of common complex traits. As an example of these limitations 
we can mention that the selection of candidate genes has depended either on their 
location in previously reported linkage regions or on their participation in functional 
pathways that are considered relevant to the disorder. This introduces the need for 
numerous hypothesis-based candidate gene association and expression studies in 
order to single out particular genes within a broad region. One other important 
drawback is the reduced power of linkage analysis in the identification of modest 
effects of common genetic variants. Thus, considering these and other previously 
discussed factors, the need for improved complementary techniques became evident. 
Within recent years the development of faster and more accessible genotyping 
techniques along with the possibility of using a selected set of polymorphisms as 
markers as well as the completion of the International HapMap project (International 
HapMap Consortium, 2005; 2007) have made it possible to perform these studies in 
a genome-wide manner and without the need of previously established hypotheses.  
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This genome wide association studies (GWAS) have the advantage over linkage 
studies that they provide information not only on specific loci associated to 
schizophrenia but also on groups of genes potentially related through specific 
pathways. An additional advantage is that GWAS are able to detect small effects with 
greater power than other previously used techniques when the appropriate 
considerations are made (Barret and Cardon, 2006). However it is important to note 
that there are also some limitations associated with this type of studies that need to 
be considered for the interpretation of data (Wang et al., 2005).  
The first important difficulty to be address when performing GWAS is to determine 
how to limit the occurrence of false positive associations and therefore increasing the 
possibility of replication. The starting point in approaching this dilemma is the 
calculation of the threshold for genome-wide significance, in order to address the 
issue of multiple testing when a large number of markers (typically around 500,000 
SNPs) are compared (Thomas et al., 2005). However, the parameters considered in 
each case to perform these calculations tend to vary and this has to be taken into 
account when interpreting the data. Recently Dudbridge and Gusnato (2008) 
performed an estimation of a genome-wide significance threshold for the UK 
Caucasian population using genotypes from the Wellcome Trust Case-Control 
Consortium (WTCCC). They proposed a threshold value of p < 7.2 x 10-8 and an 
additive odds ratio (OR) of 1.5. According to this calculation, at least 12000 samples 
of each group, controls and cases, is necessary in order to achieve a power of 0.8. 
Furthermore, following this model it has been calculated that a GWAS that has been 
carried out in approximately 1000 cases and controls still could identify a risk allele, 
even at a lower threshold (p < 10-5) if there is a relatively large number (> 100). 
However, replication of these results, even at a nominal level of 0.05, is still only 
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expected when using samples larger than 2500 cases and controls of these alleles to 
be detected (O’Donovan et al., 2009). While these calculations are to be considered 
merely as guidelines they point out the importance of large cohorts in order to 
minimise false positives and improve the chances of identifying small effects. 
SNP-based GWAS 
There are to date eight genome wide association studies in schizophrenia (Table 
1.1). An initial study was performed using 320 schizophrenia cases and 325 controls 
of European ancestry. Over 25000 SNPs were screened in this study using a 
combination of pooled DNA approach and individual genotyping but with no 
significant genome-wide association reported (Mah et al., 2006). A second GWAS in 
two small groups of Caucasian samples of 178 cases and 144 controls reported 
association (p=3.7 x10 -7) of a SNP located in the pseudoautosomal region of 
chromosome Y to disease (Lencz et al., 2007).  
A following larger study of a heterogeneous group of 738 cases and 733 controls 
failed to identify any significant association to the disorder (Sullivan et al., 2008). 
Similar results were obtained from two additional studies performed using pooled 
DNA samples. The first one of these was performed using Bulgarian samples 
consisting on 574 schizophrenia trios and 605 controls (Kirov et al., 2008a) while the 
second one used 600 cases and 2,777 controls, all Ashkenazi Jews (Shifman, et al., 
2008). It is noteworthy that although no evidence for association with schizophrenia 
was reported from either of these studies Shifman et al. observed a genre-specific 
association of an intronic SNP in the reelin gene (RELN) with an increased risk of 
schizophrenia in women. They were further able to support this finding in a meta-
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analysis of 2,000 cases and 4,000 controls. Furthermore a recent study has been 
able to replicate this sex-specific association in an independent group of 721 
schizophrenia and schizoaffective disorder cases and 1455 controls of Ashkenazi 
Jewish background (Liu et al., 2010). The association of this SNP to schizophrenia is 
an interesting one, particularly considering previous reports of down-regulation of 
the RELN gene in schizophrenia (Knable et al., 2004) as well as evidence suggesting 
that this might be a product of epigenetic mechanisms (Grayson et al., 2005; 
Tamura et al., 2007)  
In a more recent GWAS O’Donovan and colleagues (2008) compared an initial group 
of 479 cases to 2,937 controls from the Wellcome Trust Case Control Consortium 
(WTCCC). The most significant loci observed from this initial study (p < 10-5) were 
subsequently validated in two additional cohorts for a total of samples of up to 6,829 
cases and 9,897 controls. The best-supported association with schizophrenia was 
that of an intronic SNP (rs1344706) in the zinc finger protein 804A gene (ZNF804A). 
Although this association did not reach genome-wide significance (p= 1.6 x 10-7) in 
the schizophrenia samples, this was achieved (p=1.0 x 10-8) when a bipolar disorder 
cohort from the WTCCC was included leading to the conclusion that the variations is 
more likely to be associated with a general psychotic phenotype. Because the precise 
function of the ZNF804A protein in the brain is still not clear nor are the mechanisms 
through which this variant contributes to psychosis predisposition. However, an 
insight was obtained from recent imaging study that reported association of the 
same SNP with the degree of correlation of hippocampus and dorsolateral prefrontal 
cortex activities suggesting a role in the disturbance of connectivity across these 
brain regions (Esslinger, et al., 2009). 
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Consistent with O’Donovan et al., replication of the association of rs1344706 was 
observed (p=0.029) from a later study performed by the International Schizophrenia 
Consortium (ISC, 2009) where 3,322 cases and 3,587 controls were genotyped for a 
large number of SNPs (> 1 million). However, the most significant finding from this 
study was the genome wide association (p= 3.4 x 10-7) of a SNP in the myosin 18B 
gene (MYO18B). The second most significant association observed from this study 
was that of a group of 450 SNPs spanning a region in the major histone compatibility 
complex (MHC) on chromosome 6. Interestingly this association has been further 
supported by two more GWAS. The first one of these was performed using the 
Molecular Genetics of Schizophrenia (MGS) samples of 2,681 cases and 2,653 
controls or European ancestry in addition to 1,286 cases and 973 controls of African-
American ancestry with no genome-wide significant associations reported. However, 
a meta-analysis performed using the MGS European samples, the ISC and the SGENE 
datasets (for a total of 8,008 cases and 19,077 controls) yielded a significant 
association (p= 9.54 x 10-9) of a locus within the 6p22.1 region, which includes the 
MHC and other immunity related genes (Shi et al., 2009). The second GWAS was 
performed using the SGENE dataset (2,663 schizophrenia cases and 13,498 controls 
from eight different European locations) for genotyping a total of 314,868 SNPs. 
Although no significant genome-wide association was observed from this study, 
further inclusion of the genotyping information obtained from the ISC study resulted 
in association of several SNPs in the MHC region (p values ranging from 1.1 x 10-9 to 
1.4 x 10-12). In addition, significant association was observed for a polymorphism 
located upstream of the neurogranin gene (NRGN) on the 11q24.2 region (p= 2.4 x 
10-9) as well as for the SNP in intron four of the T cell transcription factor 4 (TCF4) 
on 11q24.2 (p=4.1 x 10-9) (Stefansson et al., 2009).  
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Interestingly both these genes are involved in neurodevelopmental and cognitive 
processes (Huang FL et al., 2007; Flora et al., 2007) with NRGN encoding for a 
postsynaptic protein kinase substrate abundantly expressed in brain regions relevant 
to cognitive functions and especially enriched in CA1 pyramidal neurons in the 
hippocampus (Huang FL et al., 2007). NRGN is known to bind to calmodulin (CaM) 
and it has been proposed as its reservoir in the postsynaptic compartment for the 
regulation of NMDA-receptor signalling through calcium/calmodulin-dependent 
protein kinase II (CAMKII) action in (long-term potentiation in the hippocampus) 
synaptic plasticity and formation of associative memories in the brain (Bliss and 
Collingridge, 1993; Lee SJ-R et al, 2009; Rose et al., 2009). TCF4 is in turn involved 
in a number or important processes including differentiation of neural progenitors 
through Wnt signalling pathway activation (Hirabayashi et al., 2004) 
Finally, a SNP-based GWAS (Need et al., 2009) was performed comparing an initial 
group of 871 unrelated schizophrenia cases with 863 controls from European 
background. Further validation of the top 100 SNPs was then carried out using four 
independent cohorts of similar ancestry for a total of 1,460 cases and 12,995 
controls collected from Munich. The authors report a strong association of a SNP 
(rs2135551) in the 3’ UTR of the ADAMTSL3 gene. Although this association did not 
reach genome-wide significance, it is noteworthy that the small size of the replication 
sample has a very limited power for the detection of small effects.  
There is no doubt that GWAS have provided a valuable insight into genetic risk 
factors for schizophrenia and possible functional pathways whose disruption might be 
underlying the pathophysiology of the disease. However, it is also clear from the lack 
of replication in most cases, even with the use of large cohorts, that there are still 
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obstacles to overcome before it is possible to determine the extent to which small 
effects from common variants are able to explain the genetic variation of the 
disease.  
CNVs in Schizophrenia 
Chromosomal mutations contributing to susceptibility to schizophrenia have been 
identified in affected individuals and families from studies previous to GWAS and 
include disruptions in genes such as DISC1 (Blackwood et al., 2001) and the deletion 
in the 22q11.2 region of chromosome 6 (Murphy et al., 1999; Liu et al., 2002; Basset 
et al., 2008). In later years, the use of microarrays provided the means to identify 
smaller events. An important point on this subject was the limited capacity of the 
arrays used to perform GWAS in detecting the effects of rare SNPs but their ability to 
identify large rare copy number variants (CNVs) of moderate effect, even if they are 
only present in one or very few individuals. The result has been the increasing 
interest in CNVs associated with schizophrenia with a number of genome wide 
association studies assessing their incidence in affected individuals (Table 1.2).  
One such study performed by Kirov et al. (2008b) using 93 schizophrenia trios and 
372 matched controls reported two variations likely to be pathogenic. The first one of 
these was a deletion in the 2p16.3 region that results in a disruption of the neurexin 
1 (NRXN1) gene. The second one is a de novo duplication affecting amyloid 
precursor-binding protein A2 (APBA2) gene at 15q13.1. Both of these genes encode 
for proteins involved in synaptic development (Sudhof, 2008). Further support for the 
disruption of neurodevelopmental pathways by CNVs was provided by a later study 
performed in a cohort of 150 schizophrenia cases and 268 matched controls (Walsh 
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et al., 2008). From this study, the authors identified mutations affecting type I 
transmembrane tyrosinekinase receptor for neuregulins (ERBB4) and solute carrier 1 
A3 (SLC1A3), a glutamate transporter.  
Other studies have provided evidence for the increased frequency of rare variant in 
individuals with schizophrenia. In their study in Xu et al. (2008) observed a number 
of de novo CNVs with an increased frequency in sporadic cases of schizophrenia as 
compared to familial. They analysed 359 schizophrenia trios and 154 control trios 
collected from the Afrikaner population in South Africa. Amongst the most notable 
polymorphisms reported by this study are microdeletions in the 22q11.2 region 
disrupting DGCR8, a gene with an important function in miRNA processing 
(Beveridge et al., 2010). Another member of this pathway, DICER1, was found to be 
affected in one individual by a duplication in the chromosomal region 14q32.13-32.2.   
Two more recent GWAS show the effect of large rare variants. Kirov et al. (2009) 
used a group of 471 UK recruited cases and 2792 controls from the Wellcome Trust 
Case Control Consortium (WTCCC) to survey large CNVs (> 100 Kb). From this study, 
the authors observed that only CNVs larger than 1Mb, particularly deletions, were 
significantly increased in cases. Two of these deletions were observed in more than 
one case and include the previously identified 22q11.2 region as well as a deletion in 
the 17p12 region. In addition they report significant association with schizophrenia of 
a duplication on 16p13.1 previously reported as a susceptibility region for autism 
(Straub et al., 1995). Finally, in the previously discussed study of SNPs and CNVs in 
schizophrenia Need and colleagues (2009) observed 8 large deletions (>2 Mb) in 
cases but not in controls in a subset of 1,013 cases and 1,084 controls. These 
deletions also included the previously observed 1q21.1 and 22q11.2 regions and two 
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more newly reported on 8p22 and 16p13.11-12.4. However overrepresentation of 
large duplications in this study failed to reach significance. Therefore this data does 
not provide strong support for the hypothesis proposing a greater frequency of large 
rare CNVs in schizophrenia. 
Although some of these findings are supported from previous studies it is clear that 
very few of them are consistent across GWAS, perhaps due to the already discussed 
need for large samples in order to increase the power of the analysis. With this in 
mind, findings from two larger studies become particularly notable with two CNVs 
significantly associated with schizophrenia reported by both. The first one initially 
identified 66 de novo CNVs from a study performed in a population-based sample of 
9,878 transmissions (2,160 trios and 5,558 parent-offspring pairs) with no history of 
schizophrenia (Stefansson et al., 2008). They later used an initial sample of 1,433 
schizophrenia cases and 33,250 controls of European ancestry to test for associations 
of the identified CNVs with disease. The results from this first stage were 
subsequently followed up using a second cohort of 3,285 cases and 7,951 controls. 
From this study, three CNVs resulted significantly associated with schizophrenia in 
the 1q21.1, 15q11.2 and 15q13.3 regions. Two of these variations (1q21.1 and 
15q13.3) were also reported as conferring risk for schizophrenia by an independent 
study of 3,391 patients and 3,181 matched controls (ISC, 2008).   
From the analysis of these studies it becomes clear that, even with the use of large 
samples and with careful control of confounding factors, there are only a few 
polymorphisms whose implication with schizophrenia has been possible to replicate. 
However when considered collectively this data seems to point to the conclusion that 
both, common and rare variants, are important and they might need to be analysed 
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together in order to obtain a complete view of the genetic factors conferring risk to 
the disorder. Moreover, recent studies have taken this approach to interrogate 
regions previously reported as associated with schizophrenia in more detail. An 
example of this is the study of the region 17q23-17q24 (Carroll et al., 2010) where 
significant linkage to schizophrenia had been previously identified. They screened 
1028 SNPs within that region in 1,755 unrelated schizophrenia cases and 3,580 
controls of European ancestry. Their most notable finding was the significant 
association (p=0.02) of a SNP in the protein kinase C, alpha (PRKCA) gene, although 
comparison with independent groups of samples did not yield the same result.  
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Table 1.1 Summary of most recent findings from SNP based GWAS in 
schizophrenia cases and controls. 
Reference No. Samples Ancestry Genotyping  Notable Findings 
 C S    
Mah et al., 
2006 325 320 European 
Pooled DNA 
and individual 
genotyping 
No significant GW 
association 
Lencz et al., 
2007 144 178 Caucasian (U.S.) 
Individual 
genotyping 
rs4129148 in CSF2RA in 
pseudoautosomal region 
(p=3.7 x 10-7) 
Shifman et 
al., 2008 600 2771 Ashkenazi Jews. Pooled DNA 
No significant GW 
association. 
Genre-specific association 
of a SNP in RELN with risk 
of schizophrenia 
Liu et al., 
2010 
1455 
(834 
female) 
721 
(259 
female) 
Ashkenazi Jews. - 
Genre-specific association 
of a SNP in RELN with risk 
of schizophrenia 
Kirov et al., 
2008a 
605 574 
Bulgarian 
(Schizophrenia 
trios) 
Pooled DNA 
samples. 
Schizophrenia 
trios 
No significant GW 
association 
Sullivan et 
al., 2008 733 738 
African American, 
European American 
and Other 
Individual 
genotyping 
No significant GW 
association 
O’Donovan 
et al., 2008 
479 2937 Caucasian (UK) from WTCCC 
Individual 
genotyping 
Intronic SNP (rs1344706) in 
ZNF804A associated with 
psychosis phenotype (p= 
1x10-8) 
3541 1664 
Caucasian (Irish, 
German and 
Bulgarian) 
7897 6666 
German, European 
Ancestry 
(Australia/USA), 
Han Chinese and 
Ashkenazi Jewish 
ISC, 2009 3587 3322 European Individual genotyping 
• SNP in MYO18B 
(p=3.4 x 10-7)  
• 450 SNPs spanning the 
region of the MHC in 
chr. 6 
• Replication of 
association of SNP in 
ZNF804A 
Shi et al., 
2009 
2,653 2,681 European 
- 
No significant genomewide 
association 973 1,286 African-American 
Meta-analysis 19,077 8,008 European (MGS, ISC, SGENE) 
Locus in 6p22.1 including 
the MHC 
Stefansson 
et al., 2009 13,498 2,663 European (SGENE) 
- 
No significant genomewide 
association 
Meta-analysis   ISC 
• Several SNPs in MHC  
• SNP in NRGN and one 
SNP in TCF4 genes 
Need et al., 
2009 
863 871 
European 
Individual 
genotyping 
No significant GW 
association 
713 298 
12,995 1,460 
Caucasian ancestry 
deCODE 
U.S.A. 
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Reference No. Samples Ancestry Locus Identified 
 C S   
Kirov et al., 
2008b 372 93 
Bulgarian 
proband-parent 
trios 
2p16.3 and 15q13.1. Disrupting NRXN1 
and APBA2 
Walsh et al, 
2008 268 150  
Disrupting genes in neurodevelopmental 
pathways (e.g ERBB4 and SLC1A3) 
Xu et al., 2008 154 359 
Afrikaner 
population, South 
Africa 
Schizophrenia 
and control trios 
Rare de novo CNVs with high 
penetrance associated to schizophrenia 
including 22q11.2 and 14q32.13-32.2 
Stefansson et 
al., 2008 
33,250 1,433 European 
ancestry 
Three significant CNVs: In 1q21.1, 
15q11.2 and 15q13.3  7,951 3,285 
ISC, 2008 3,181 3,391 European ancestry 
Support for association of CNVs in: 
1q21.1 and 15q13.3 
Kirov et al., 
2009 2,792 471 
Cases recruited 
in UK, controls 
from 
WTCCC 
Only large CNVs (> 1Mb) significantly 
increased in cases including deletions in 
22q11.2 and 17p12 and a duplication in 
16p13.1  
Need et al., 2009 1,084 1,013 Caucasian 
No significant CNVs 
8 large (> 2Mb) deletions observed in 
cases but not in controls in regions 
including 1q21.1, 22q11.2, 8p22 and 
16p13.11-12.4 
 
Table 1.2 Summary of copy number variants (CNVs) and large rare 
polymorphisms associated with schizophrenia. 
Most notable associations identified from genomewide microarray studies in schizophrenia 
cases and controls. 
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1.3.4 Use of microarrays for the identification of differential gene 
expression in schizophrenia 
One of the major applications for microarrays in the study of complex disorders has 
been the analysis of differences in gene expression in affected individuals as 
compared to controls. The use of microarray technology for gene expression studies 
relies on the availability of data about the human transcriptome. Probes 
complementary to known sequences can then be used to measure the levels of 
specific mRNA transcripts in a particular tissue sample. Prior to hybridization to the 
probes, the target mRNA is labelled with a fluorescent dye in order to enable 
subsequent quantification of levels of gene expression based on the assumption that 
the level of fluorescence is proportional to the amount of mRNA collected by each 
site on the array.  
While microarray expression profiles have proved to be of great value in the 
elucidation of molecular pathways possibly disrupted in schizophrenia through the 
identification of groups of genes differentially expressed in cases, there are certain 
limitations that need to be considered in the analysis and interpretation of data 
(Mirnics et al., 2006). Many of these limitations come from the fact that in the study 
of psychiatric disorders the comparison of transcript levels in affected individuals and 
healthy controls is commonly performed using post-mortem brain tissue, although 
peripheral blood cells have also been used for a number of studies. The importance 
of carefully controlling these and other factors is highlighted by the fact that 
differences in gene expression in the brain of affected individuals are likely to be 
relatively small and are therefore more likely to be affected by assay noise. 
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The first critical issue to be considered with the use of clinical samples is the integrity 
of the mRNA that could be affected by a number of factors including sample storage 
and freezing. It is commonly assumed that in samples with a post mortem interval 
(PMI) of up to 30 hours most of the tissue contains high-integrity mRNA. However, 
PMI in itself is considered to be a poor predictor of mRNA quality and is often 
complemented with other methods such as the measurement of brain pH and RNA 
degradation. The pH of brain samples is an indirect indicator of mRNA integrity 
because it greatly depends on the terminal state of the patients with low levels 
commonly observed in tissue samples from individuals with prolonged agonal periods 
or death after a coma (Bahn et al., 2001; Li et al., 2004; Mexal et al., 2006). It has 
been recently reported that the pH of post-mortem brain samples seems to have a 
great effect in gene expression (Li et al., 2004; Mexal et al., 2006). Furthermore, it 
was possible from these and other studies to identify a “critical” pH value a below 
which these transcriptional changes occur (Li et al., 2004; Iwamoto et al., 2005). It 
is therefore important to identify this value in each particular sample empirically.  
Moreover, because the samples available for study are in most cases obtained at a 
much later stage following the initial onset of the disease it is possible that the 
changes observed are in fact a product of a normal aging process or a reflection of 
the brain adapting to changes caused by the disease throughout time rather than a 
direct consequence of disease-causing factors.  
One other major limitation that has been encountered when performing microarray 
expression studies in brain tissue is the fact that these samples are composed of a 
mixture of different cell types including subtypes of neurons and glial cells. This 
heterogeneity makes it very difficult to identify certain potentially significant gene 
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expression changes that might only be taking place in a particular group of cells. In 
addition to this, it is possible that the left and right hemispheres of the brain have 
different levels of expression of certain transcripts and this might introduce another 
source of variation.  
Additionally, genetic background, gender and lifestyle as well as neuroleptic 
treatment are likely to have an effect on the transcript levels and it is important to be 
able to differentiate these effects from the ones that could potentially be associated 
with disease. However, in the case of medication, an additional difficulty is presented 
because post-mortem tissue of untreated patients is hardly ever available. Although 
animal models and tissue culture provide valuable information about the effects of 
medication on gene expression in the brain, the question remains on to what extent 
this information translates into the effects of neuroleptic treatment in the diseased 
human brain.  
Finally, in order to minimise the variation it is ideal for controls and cases to be 
correctly matched prior to the analysis with respect to age, ethnicity, medication 
history, post-mortem interval, sex, cause of death and lifestyle amongst other 
factors. However, the reduced availability of post-mortem introduces the need for 
finding a balance and resulting in the need for compromises. One of such 
compromises often implies that the studies are performed with a very limited number 
of samples and therefore with a reduced power for the identification of significant 
expression changes.  
There are a variety of different microarray platforms available that have been used 
so far for expression studies in complex disorders. As is the case with other 
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applications the probes used for hybridization of mRNA transcripts of interest can be 
cDNA or synthetic oligonucleotides. In order to quantify transcript levels target mRNA 
needs to be labelled prior to hybridization, a process that is usually performed by 
reverse transcription of RNA to cDNA and subsequently labelled and transcribed back 
into cRNA. The samples can be labelled with a single tag or double labelled. Single 
labelling is a popular technique when using human samples because it allows the 
comparison of expression data across various experimental groups. Double-labeling 
is used commonly for comparison of matched samples such as case-control samples.  
From the variety of commercially available microarrays perhaps the most commonly 
used is the Affimetrix GeneChip, an oligonucleotide array. This platform consists on a 
series of probe-set representing approximately 39,000 transcripts. Probe-sets are 
conformed by 11 probe-pairs designed for each gene and distributed across the 
array. Each of these pairs consists of one perfect match oligonucleotide and a 
mismatched used to quantify and correct for non-specific hybridization and 
background signals. The chip contains control probes to determine hybridization 
efficiency. In addition to this and other commercially available microarrays, it is 
possible that the use of a custom microarray results more adequate when the 
objective is to study a specific group of genes (e.g. genes involved in a specific 
pathway). An example of this case is the NIA-neuroarray comprised of 1,128 clones 
selected representing families of genes that include: transcription factors, structural 
genes, synaptic, neuronal, glial, cell adhesion molecules, kinases, phosphatases, 
proteases and oncogenes (Vawter et al., 2001).  
As discussed previously, by carefully controlling factors such as quality of the 
mRNA/cDNA, proper matching of samples and clinical history of the subjects it is 
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possible to minimise experimental variability and improve reliability of the data. 
However, even with a rigorous quality control and the application of the appropriate 
algorithms to interpret the signals, validation of the data is crucial. This is regularly 
performed through qPCR analysis and verification in an additional cohort might be 
considered if possible. Moreover, there are still some technical drawbacks associated 
with the use of microarray technology. One of these limitations is the fact that it is 
still not possible for microarray platforms to distinguish between splice variants of a 
gene and therefore it is not possible to identify posttranslational or 
posttranscriptional changes. In addition to this is the limited ability of microarrays to 
uncover differences in expression of genes with low abundance. Thus, it becomes 
important to consider the use of complementary techniques not only for the 
verification of microarray data but also for further investigation of mechanisms 
regulating the observed differences in expression.  
In spite of the fact that replication of results has not been possible for all studies, 
presumably due to the differences in study groups, microarray platforms used and 
methods of analysis, expression microarray studies have provided important 
information about specific pathways potentially disrupted in schizophrenia. Some of 
the most replicated results include genes implicated in synaptic function, 
mitochondria-energy metabolism and ubiquitin degradation and oligodendrocyte 
function (Table 1.3). 
Synaptic function 
Perhaps the first microarray study to report differential expression of genes involved 
in synaptic processes was the one performed by Mirnics et al. (2000) and which 
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consisted of the expression profiling of over 250 genes in post-mortem tissue from 
the prefrontal cortex (Brodmann Area 9) of 11 pairs of matched pairs of 
schizophrenia and control samples. Results from this study revealed a decrease in 
the expression of a group of transcripts encoding for proteins involved in presynaptic 
function in schizophrenia. Amongst the changes most consistently replicated across 
pairs were N-ethylmaleimide sensitive factor (NSF) and synapsin II. In addition 
genes involved in glutamate (GLU) and GABA neurotransmission were also found to 
be decreased in schizophrenia compared to controls. These findings were then 
confirmed by in situ hybridization in a different cohort of schizophrenia samples. 
Consistent with these results, the same group of genes reported by Mirnics et al. 
(2000) were found downregulated in a later microarray study of 1127 genes in the 
same brain region (Vawter et al., 2002). Relative gene expression of 15 pooled 
schizophrenia samples and 15 matched controls was assessed for this study in order 
to identify genes whose expression is consistently changed across schizophrenia 
cases. In addition to reduced expression of genes in the PSYN, GLU and GABA 
groups, histidine triad nucleotide-binding protein (HINT), ubiquitin conjugating 
enzyme E2N (UBE2N) and glutamate receptor, ionotropic, AMPA 2 (GRIA2) were 
found to have reduced expression in schizophrenia.   
Interestingly, in a follow-up study using the same dataset Mirnics et al. (2001) 
observed a number of disease specific changes in the postsynaptic cell. Most notably 
they identified reduced expression of regulator of G-protein signalling 4 (RGS4) as 
the most significant change in schizophrenia, which is consistent with previous 
reports (Bowden et al., 2007). Moreover, in their microarray analysis, Mirnics et al. 
(2000) reported that expression of ten other RGS family members and over 200 
genes involved in G-protein signalling remained unchanged as a group. The 
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relevance of RGS4 in relation to schizophrenia has been considered not only because 
RGS-modulated G-protein-coupled receptors (GPCRs) are targets for antipsychotic 
drugs (Lieberman et al., 1998) but also because it has been identified as a candidate 
gene for schizophrenia from association and linkage studies (Brzustowicz et al., 
2000; Chowdari et al., 2002).  
Two more studies have provided evidence for the dysfunction of synaptic pathways 
in schizophrenia. In the study conducted by Hemby et al. (2002) single-cell 
microdissection technique was used in satellite neurons from the entorhinal cortex of 
8 cases and 9 matched controls (Hemby et al., 2002). A screening of more than 
18,000 transcripts using cDNA custom arrays identified, amongst the most significant 
changes, reduced levels of mRNA encoding for glutamate receptor 3 (GRM3), N-
methyl-D-aspartate receptor 1 (GRIN1), synaptic vesicle amine transporter, 
synaptotagmin I and IV and synaptic plasma membrane proteins SNAP 23 and SNAP 
25. Finally Maycox et al. (2009) reported the result of a comparison between to 
independent microarray expression analyses. In the first study levels of expression of 
30,000 mRNA transcripts were assessed in Brodmann Area 10 of the PFC of post-
mortem tissue from 28 schizophrenia cases and 23 controls. This data was then 
compared with that obtained from a second study in BA9 of post-mortem brain 
samples of 16 schizophrenia cases and 27 controls carefully selected to match 
criteria used in the first group. The authors identified a total of 49 transcripts 
commonly regulated in both cohorts including genes implicated in synaptic vesicles 
recycling/secretion (e.g. ZnT3, VAMP2, SYT5), signal transduction (e.g. CACNB3, 
CACNG3, CAMKK2) and neurodevelopment (PHYHIP). It is noteworthy from this 
study that although no association was observed with genes previously proposed as 
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candidate genes for schizophrenia from genetic studies, some of the changes 
observed are consistent with disruption of DISC1 and dysbindin networks. 
Metabolic function  
Additional expression studies have provided evidence pointing to metabolic 
dysfunction as a possible pathological factor associated to schizophrenia. In an 
expression study carried out in samples from BA9 in the prefrontal cortex of 10 
schizophrenia cases and 10 controls (Middleton et al., 2002) five metabolic pathways 
were found to be downregulated across schizophrenia samples including the 
mitochondrial malate shuttle system and ubiquitin metabolism. In a comprehensive 
analysis Prabakaran et al. (2004) carried out microarray analysis combined with 
proteomics and metabolome (low-molecular weight intermediates) analyses in post-
mortem tissue also from BA9 of 10 schizophrenic samples and 10 matched controls 
from the Neuropathology Consortium of the Stanley brain collection. Significant 
downregulation of several genes involved in glycolysis, including pyruvate 
dehydrogenase (PDH) were detected. Additionally, a group of genes related to 
response to stress, signal transduction and transcriptional regulation were found to 
be upregulated in schizophrenia. Similarly, Iwamoto et al. (2005) have reported 
down-regulation of mitochondria-related genes in schizophrenia and bipolar disorder. 
Samples from the Stanley Array Collection were used for their study for a total of 35 
samples that included post-mortem tissue from PFC (BA46) of individuals diagnosed 
with schizophrenia and bipolar disorder and healthy controls. The observed reduced 
expression of mitochondria-related genes was maintained even after considering the 
effect of pH of the tissue samples. 
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Interestingly, in a cell-specific study performed by Altar et al. (2005) in hippocampal 
granule neurons from the dentate gyrus of schizophrenia, bipolar disorder and 
depression cases the authors reported a group of mitochondrial energy metabolism 
related genes whose expression was decreased exclusively in schizophrenia. The 
study included 9 bipolar, 10 depression and 14 schizophrenic cases as well as 15 
control individuals, from two different groups. Among the genes whose expression 
was reduced in both schizophrenia groups were nicotinamide adenine dinucleotide 
(NADH) and mitochondrial ATPase. In addition, other genes representing 
mitochondrial function, such as mitochondrial ribosomal protein S28 (MRPS28), 
solute carrier family 25 (mitochondrial carrier; oxoglutarate carrier), member 11 
(SLC25A11) and stannin (SNN), were reported by Maycox et al. (2009) as 
consistently downregulated in schizophrenia. 
Oligodendrocytes and myelination genes 
 Although not consistently replicated, a number of microarray studies have identified 
genes implicated in oligodendrocyte function as differentially expressed in 
schizophrenia as compared to controls. An initial study in the BA46 of the PFC of 12 
schizophrenia samples and 12 controls observed decreased expression in 
schizophrenia of a group of 6 genes predominantly enriched in myelin-forming 
oligodendrocytes (Hakak et al., 2001). Among these genes were the neuregulin 
receptor tyrosine kinase (ERBB3) and myelin associated glycoprotein (MAG) and 
lymphocyte protein. In a later microarray study of prefrontal cortex from 10 
schizophrenia cases and 19 matched controls downregulation of the proteolipid 
protein 1 (PLP1) across the majority of the affected individuals was identified 
(Pongrac et al., 2002). To discount the change as a possible result of neuroleptic 
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treatment, data from this study was compared to one carried out in a pair of 
haloperidol and saline treated monkeys (Mirnics et al., 2001) with no replication of 
downregulation of PLP1.  
Consistent with both of these studies were similar findings from microarray 
expression profiling of BA9 of 15 schizophrenia cases and 15 matched controls, 
together with 15 bipolar disorder cases from the Stanley Medical Research Institute 
collection (Tkachev et al., 2003). This data was further confirmed by differential 
display PCR and showed significant downregulation of PLP1 in schizophrenia in 
addition to other oligodendrocyte myelin-related genes, including myelin-associated 
glycoprotein (MAG), oligodendrocyte-specific protein (CLDN11) and myelin 
oligodendrocyte glycoprotein (MOG) which resides within the MHC locus in 
chromosome 6p21.3 (discussed in section 1.4.1). Furthermore, a third study of 1373 
genes in dorsolateral prefrontal cortex (DLPFC) of schizophrenia cases and controls 
reported that the highest frequency of significant transcript expression changes were 
observed in oligodendrocyte and astrocyte-related genes (Sugai et al., 2004). The 
authors also used tissue samples from non-human primates treated and untreated 
(n=3 each) with haloperidol for three weeks prior to the study in an attempt to 
detect effects due to neuroleptic treatment. Amongst the most significant changes 
were myelin basic protein (MBP), myelin associated oligodendrocytic basic protein 
(MOBP), T-cell differentiation protein (MAL) and phosphoprotein enriched in 
astrocytes 15 (PEA15). 
In addition to the changes observed in PFC two more studies reported changes in 
the expression of oligodendrocyte and astrocyte genes in other brain regions. The 
first one was a study in post mortem tissue samples from middle temporal gyrus to 
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BA21 of 12 schizophrenia cases and 14 matched controls (Aston et al., 2004). 
Significantly reduced expression of myelin-related genes in schizophrenia was 
identified, including plasma membrane proteolipid (PLLP) and the previously reported 
MAG and ERBB3. Other notable findings from this study were the significant 
downregulation in schizophrenia of TNF receptor-associated factor 4 (TRAF4), a 
protein involved in neurogenesis, and histone deacetylase 3 (HDAC3), as well as an 
upregulation of a cicardian pacemaker protein (PER1). Finally, a study performed 
using tissue from 15 cortical regions as well as from hippocampus, caudate nucleus 
and putamen of schizophrenia individuals and controls Katsel et al. (2005) identified 
significant changes in a number of genes categorised by function. Amongst the top 
scoring categories, especially in temporal and cingulated gyri and hippocampus, were 
oligodendrocyte and myelin-related genes. Their findings included significant 
downregulation of MAG, PLLP, MAL, ERBB3 and MOG.  
Expression studies have without question proved to be a valuable tool in the 
elucidation of molecular pathways implicated in the pathophysiology of 
schizophrenia. However the question remains as to whether these changes are part 
of the primary aetiology of the disorder or they are part of regulatory mechanisms 
more likely to be a reflection of secondary pathology. It is difficult to conclude that 
expression profiling by itself would be able to give us the answers. It is therefore 
evident that it is necessary to combine this technique with other studies in order to 
improve our understanding of this disorder and to determine how the possible 
combinations of numerous risk factors contribute to its aetiology. 
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Synaptic Function 
Reference No. Samples 
Brain 
Region Microarray platform Notable Findings 
 C S    
Mirnics et 
al., 
2000; 
Mirnics et 
al., 2001 
Two 
groups of 
6 and 5 S-
C pairs. 
BA9 UniGEM-V (high density cDNA) 
Decreased expression of 
genes involved in 
presynaptic function (PSYN), 
glutamate (GLUT) and GABA 
transmission.  
Significant downregulation of 
RGS4 in schizophrenia 
Vawter et 
al., 2002 15 15 BA9 NIA-Neuroarray 
Decreased expression of the 
same group of genes 
reported by Mirnics et al. 
(2000) 
Significant downregulation of 
HINT, UBE2N and GRIA2 
Hemby et 
al., 2002 9 8 EC Custom microarray 
Reduced levels of mRNA 
encoding for GRM3, GRIN1, 
synaptic vesicle amine 
transporter, synaptotagmin 
I and IV and SNAP 23 and 
SNAP 25 
Maycox et 
al., 2009 
23 28 BA10 Affymetrix GeneChip (CX cohort) 
49 transcripts commonly 
regulated in both cohorts: 
Genes implicated in synaptic 
vesicles recycling/secretion 
(ZnT3, VAMP2, SYT5), 
signal transduction 
(CACNB3, CACNG3, 
CAMKK2) and 
neurodevelopment (PHYHIP) 
27 16 BA9 MAS 5.0 (Harvard Cohort) 
Metabolic function 
Middleton 
et al., 2002 10 10 BA9 UniGEMV 
Five metabolic pathways 
downregulated in 
schizophrenia including 
mitochondrial malate shuttle 
system and ubiquitin 
metabolism 
Prabakaran 
et al., 2004 10 10 BA9 
HG-U133A GeneChip 
Affymetrix 
Downregulation of a group of 
genes implicated in 
glycolysis and upregulation 
of genes with a role in 
oxidative stress.  
Iwamoto et 
al., 2005 35 BA46 
HI-U133A GeneChip 
Affymetrix 
Reduced expression of 
mitochondria-related 
genes. 
Altar et al., 
2005 15 14 
Hippocampus 
(DG) 
Agilent Human 1 
(cDNA based) 
Downregulation in 
schizophrenia of genes 
including nicotinamide 
adenine dinucleotide (NADH) 
and mitochondrial ATPase 
Maycox et 
al., 2009 
23 28 BA10 Affymetrix GeneChip (CX cohort) 
MRPS28, SLC25A11 and 
SNN downregulated in 
schizophrenia 
27 16 BA9 MAS 5.0 (Harvard Cohort) 
 
 Table 1.3 Summary of notable Findings from microarray expression studies in 
schizophrenia. 
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Myelin and oligodendrocyte-related genes 
Reference No. Samples 
Brain 
Region Microarray platform Notable Findings 
 C S    
Hakak et 
al., 2001 12 12 BA46 
HuGene F1 
Affymetrix 
GeneChip 
Decreased expression in 
schizophrenia genes 
enriched in myelin-forming 
oligodendrocytes, including 
ErbB3, MAG and 
lymphocyte protein. 
Pongrac et 
al., 2002 10 10 PFC UniGEM-V Downregulation of PLP1  
Tkachev et 
al., 2003 15 15 BA9 Affymetrix GeneChip 
Downregulation of PLP1, 
MAG, CLDN11 and MOG (in 
the MHC chr. 6p21.3) 
Sugai et al., 
2004 6 6 DLPFC 
Clontech Atlas Human 
Neurobiology 
Clontech Atlas Human 
Cancer 
Downregulation of glia-
related protein genes 
including: 
MBP, MOBP, MAL and 
PEA15 
Aston et al., 
2004 14 12 
Temporal 
Cortex 
Affymetrix HgU95A 
GeneChip 
Downregulation of myelin-
related genes: 
MAG, PLLP, ERBB3 
Downregulation of TRAF4 
and HDAC3 
Upregulation of PER1 
Katsel et 
al., 2005 13 13 
BA 8, 10, 44, 
46, 23/31, 
24/32, 20, 21, 
22, 36/28, 7 
and 
17. 
Hippocampus, 
caudate 
nucleus, and 
putamen 
Affymetrix 
HG-U133 
GeneChip 
Downregulation of myelin-
related genes including: 
MAG, PLLP, MAL, ERBB3 
and MOG 
 
 
 Table 1.3 (Continued) 
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1.4 Epigenetic mechanisms in Schizophrenia 
The term epigenetics refers to a series of mechanisms that regulate gene expression 
through processes that do not involve the modification of DNA sequences. It has 
been proposed that epigenetic regulation may hold the key to the understanding of 
the interaction of genetic and environmental factors in the development of 
schizophrenia and other psychiatric disorders. Epigenetic mechanisms are not only 
dynamic partly in response to external input, they also are transmitted mitotically 
and in some cases epigenetic changes are able to remain even after gametogenesis 
and be transmitted across generations (Weaver et al., 2004; McLeod et al., 2007; 
Roth et al., 2009). Moreover, it has become increasingly evident that in the CNS 
epigenetic modifications can also occur as part of processes that play an important 
role in activity-dependent gene expression regulation in fully differentiated cells as a 
response to environmental factors in cognition and behaviour as well as learning and 
memory processes (Guan et al., 2002; Korzus et al., 2004; Tsankova et al., 2004; 
2006; Vecsey et al., 2007; Miller et al., 2007).  
Although there are number of epigenetic mechanisms that have been identified, the 
term has been most commonly used when referring to the modification of chromatin 
structure. Chromatin is the complex of DNA and proteins (histones and non-histones) 
that constitute the structure of chromosomes in the cell nucleus. The basic unit of 
chromatin is called a nucleosome and consists of ~147 DNA base pairs wrapping a 
histone octamer core (two copies of each of the four histones H1, H2, H3 and H4). 
There are two main conformations of chromatin that are relevant to gene expression, 
a condensed state known as heterochromatin and an extended state or euchromatin 
which in turn block or allow gene transcription respectively. In the cell nucleus 
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chromatin exists in a combination of these two states and remodelling of the 
conformation is possible through various processes such as covalent histone 
modifications and DNA methylation, which remain the two most extensively studied 
and best characterised in the brain (Jiang et al., 2008). Other epigenetic mechanisms 
include post-translational modification of mRNA transcripts by micro RNAs and other 
non-coding RNA molecules. The regulation of gene transcription through micro RNA-
mRNA interactions has become a topic of great interest as a possible regulator of 
functional pathways in the CNS.  
1.4.1 DNA methylation 
One of the most important and most extensively studied epigenetic processes is the 
covalent bonding of a methyl group to DNA in the side chain residues of cytosines 
that are immediately followed by a guanine known as CpGs. These dinucleotide 
sequences are much less frequent in the genome that would be expected by chance 
and the majority are methylated (Cooper et al., 1989). However, the promoter 
regions of genes usually contain areas with a high density of CpGs that are normally 
methylated to a lesser extend (Gardiner-Garden et al., 1987; Bird, 1986). It is in 
these CpG islands where regulation of gene expression by DNA methylation has been 
observed.  
The methylation reaction is carried out by transfer of a methyl group from S-
adenosine methyonine (SAM) and catalysed by a group of enzymes known as DNA 
methyltransferases (DNMTs), which are divided in two categories. The DNMT1 
isoform is a “maintenance” enzyme in charge of placing methyl groups in the 
complementary strands of already methylated cytosines after cell division. The 
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isoforms 3a and 3b are de novo DNMTs and they are responsible for new epigenetic 
changes (Okano et al., 1998). 
A basic model for repression of gene expression has been proposed whereby the 
methylation of CpGs is followed by the recruitment of methyl-DNA binding proteins. 
In addition to the methyl-DNA binding domain (MBD), these proteins also possess a 
transcription regulatory domain (TRD) that binds to scaffolding proteins and 
ultimately to histone deacetylases (HDACs). These in turn remove acetyl groups from 
the histone proteins, thus altering chromatin structure and inhibiting transcription 
(Thomson et al., 2010). Although DNA methylation is generally associated with 
inhibition of gene expression there are some reports of methylation resulting in 
increased expression, but the mechanism for this have not been determined 
(Chahrour et al., 2008; Cohen et al., 2008).  
There is some evidence that shows a correlation of the extent of methylation with 
gene inactivation, which is the basis for the “methylation density” model (Boyes and 
Bird, 1991; Cameron, et al., 1999). However, there have been reports of cases 
where there is only the need for methylation of one or few a cytosines located in 
trascription factor binding sites (Robertson et al., 1995; Pogribny et al., 2000). These 
studies later gave rise to the “critical site” model. 
The implication of epigenetic mechanisms in the aetiology of schizophrenia has been 
supported by studies that have reported high levels of enzymatic activity of DNMTs 
in mature CNS neurons (Brooks et al., 1996; Ravindran and Ticku, 2005) as well as a 
number of studies that have provided evidence for the involvement of DNA 
methylation in synaptic plasticity and memory formation (Levenson and Sweatt, 
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2005; Levenson et al., 2006; Miller et al., 2007; Lubin et al., 2008; Nelson et al., 
2008).  
Moreover, there have been reports of aberrant methylation patterns in genes 
identified as associated with risk for schizophrenia such as the human Reelin gene 
(RLN) and GAD1 (Impagnatiello et al., 1998; Guidotti et al., 2000; Knable et al., 
2004; Fatemi et al., 2005; Straub et al., 2007; Shifman et al., 2008; Liu et al, 2010). 
RLN encodes a glycoprotein that is secreted preferentially by GABA interneurons and 
is critical for neuronal migration during development and in supporting long-term 
potentiation in the adult CNS as well as regulating glutamate receptor homeostasis 
(Fatemi et al., 2005; Campo et al., 2009). The GAD1 gene in turn encodes the 
enzyme GAD67, which is responsible for the synthesis of GABA from glutamate. The 
important role of these genes in the GABAergic system makes them interesting 
candidates for the elucidation of the molecular basis of schizophrenia.  
From the initial discovery of DNA hypermethylation implicated in decreased 
expression of RELN and GAD67 in cortical and basal ganglia GABAergic interneurons 
of schizophrenic individuals (Chen et al., 2002; Costa et al., 2002) and the 
correlation of these findings with abnormal expression of DNA methyltransferase 1 
(DNMT1) (Veldic et al., 2004; 2005; Levenson et al., 2006; 2007; Ruzicka et al., 
2007), evidence has continued to accumulate in recent years pointing to the 
implication of aberrant epigenetic patterns in the promoter regions of these genes in 
the disorder. The majority of the studies performed thus far have attributed the 
decrease in protein levels to abnormal methylation patterns of CpG islands in the 
promoter regions of these genes (Abdolmaleky et al., 2005; Grayson et al., 2005; 
Benes et al., 2007; Huang HS et al., 2007).  
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Animal models have also been used in a number of studies in an attempt to elucidate 
whether these epigenetic modifications in RLN and GAD1 contribute to the 
schizophrenia phenotype. The heterozygote reeler mouse (HRM; Liu et al., 2001), 
characterised by reduced expression of reelin due to a single allele disruption, 
presents neuroanatomical and behavioural features similar to those observed in 
humans suffering from schizophrenia such as hippocampal-dependent learning deficit 
and impairment of hippocampal plasticity amongst others. The HRM has been used 
as a model for this and other disorders associated with cognitive impairment (Qiu et 
al., 2006). Moreover, treatment of mice with L-methionine (MET), necessary for 
DNMT catalytic activity, resulted in schizophrenic like behaviour in mice as well as 
replication of increased methylation of the RLN promoter and downregulation of both 
RLN and GAD1 genes in cortical interneurons (Dong et al., 2005). Additionally, the 
use of DNMT and HDAC inhibitors in neuronal progenitor cells has been shown to 
activate RLN and GAD1 expression (Kundakovic et al., 2009).  
Other schizophrenia candidate genes for which abnormal patterns of CpG island 
methylation have been reported include Brain-derived neurotrophic factor (BDNF) 
and catecholamine-O-methyltransferase (COMT). Two studies have reported changes 
in methylation status of COMT in schizophrenia. One such study showed methylation 
of the MB-COMT isoform of the gene to be reduced in schizophrenia and bipolar 
disorder cases, which yielded higher levels of expression of MB-COMT when 
compared to controls. Moreover, inverse correlation was observed between the MB-
COMT and dopamine D2 receptor gene (DRD2) expression. Finally, the authors 
reported an increase in the frequency of the 158-val allele of COMT in individuals 
presenting higher levels of methylation in MB-COMT (Abdolmaleky et al., 2006). The 
second report came from a microarray study (Mill et al., 2008) and although no 
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association of level of methylation with disease was reported, high levels of exonic 
methylation were consistently observed in individuals homozygous for the 158-val 
allele. 
In the case of BDNF there is evidence pointing to a specific temporal and spatial 
regulation of specific promoter regions in the gene in an activity-dependant manner 
(Lauterborn et al., 1996), in spite of the complex structure of the gene (Liu QR et al., 
2006; Aid et al., 2007; Pruunslid et al., 2007). In recent years a number of studies 
have made it evident that DNA methylation plays an important role in chromatin 
remodelling for learning-induced regulation of expression of BDNF (Martinowich et 
al., 2003; Lubin et al., 2008; Roth et al., 2009). However, only one study provided 
evidence for association of methylation status with genotype of SNP rs6265 
(val66met) located in the vicinity of the gene in tissue from frontal cortex of 
schizophrenia and bipolar disorder individuals (Mill et al., 2008).  
Genomewide epigenetic studies 
There is only one study to date that has taken a genomewide approach to the 
analysis of epigenetic mechanisms possibly implicated in psychosis. In their study, 
Mill et al. (2008) analysed post-mortem brain tissue from the frontal cortex of 35 
schizophrenia cases, 35 bipolar disorder cases and 35 matched controls from the 
Stanley Medical Research Institute. Using CpG island microarrays they identified a 
number of loci whose methylation status was associated with psychosis. Notably, 
they report disruption of loci relevant for glutamatergic and GABAergic 
neurotransmission, neurodevelopment and mitochondrial function and stress 
response. Amongst the most interesting findings from the study are the observed 
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downregulation of the vesicular glutamate transporter 1 (VGLU1) in schizophrenia 
cases, which correlated with hypermethylation of the promoter region of the gene in 
female schizophrenic individuals. The authors also reported increased expression of 
VGLU2 in the brains of schizophrenia cases, consistent with the reduced levels of 
methylation in the promoter region of this gene in female schizophrenia patients 
compared to controls. Other glutamate and GABA related genes highlighted in this 
study include Secretogranin II (SCG2) and MARLIN-1. The latter of these two is a 
RNA-binding protein known to have a role in regulation of the production of GABA 
receptors and was consistently hypermethylated in the three analysed groups 
(schizophrenia, bipolar disorder and major-psychosis). Finally, a significant 
correlation was observed in the methylation status of the gene encoding mitogen-
activated protein kinase kinase I (MEK1) with lifetime antipsychotic use in 
schizophrenia male subjects.  
1.4.2 Histone modifications 
Another major epigenetic mechanisms for chromatin structure modulation is the 
post-translational tagging of histone proteins. Covalent modifications to histones are 
various and they occur in specific sites of their N-terminal tail. To date, there are five 
post-translational modifications that have been thoroughly characterised: Acetylation 
and ubiquitination at lysine residues, methylation at lysine or arginine residues, 
phosphorylation at serine or threonine residues and ADP-ribosylation at glutamate 
residues.  
Acetylation of histones is perhaps the best characterised of these modifications in the 
CNS. The transfer of an acetyl group from acetyl-CoA to the -NH+ group of the lysine 
residue of the histones is catalysed by a group of enzymes known as histone 
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acetyltransferases (HATs) (Tanner et al., 1999, 2000; Lau et al., 2000). Acetylation is 
associated with increased gene activation with hyperacetylation generally thought to 
promote gene activity through chromatin decondensation. However acetylation is a 
reversible process and there is evidence that suggests that it is actually the dynamic 
combination of acetylation and deacetylation that regulates the activation of gene 
expression. The process of deacetylation is catalysed by a group of lysine 
deacetylases generally known as histone deacetylases (HDACs). These enzymes 
perform their function mainly through Zn2+-dependant charge-relay system (Finnin et 
al., 1999) or through nicotinamide adenine dinucleotide (NAD+)-dependent 
mechanism (Buck et al., 2004). Although the intracellular pathways that regulate 
histone acetylation in the CNS have not been well established, there are two 
signalling cascades that have been implicated thus far. The first one involves the 
mitogen-activated protein kinase (MAPK) super family. In this pathway the 
transcription factor cyclic AMP (cAMP)-response element binding protein (CREB) is 
phosphorylated through a series of signalling pathways that include cAMP, Ca+2 and 
extracellular-signal regulated kinase (ERK). Phosporylation in turn leads to activation 
of CREB and the recruitment of CREB binding protein (CBP), a transcriptional co-
activator with intrinsic HAT activity. The second identified pathway involved in the 
regulation of histone acetylation in the CNS is the nuclear factor κ (NFκB) 
signalling pathway. While it has been established that this regulation of NFκB 
depends on the action of the inhibitor of κB kinase (IKK), however the precise 
mechanism are yet to be defined (Yeh et al., 2004; Lubin and Sweatt, 2007). 
Following reports that HDACs inhibitors resulted in increased expression of REELIN in 
vitro (Chen et al., 2002), the first study to provide evidence of histone modification 
in schizophrenia was the one performed by Akbarian et al. (2005) who observed high 
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levels of histone methylation in prefrontal cortex (PC) of a subset of schizophrenia 
patients. Furthermore, they observed a correlation of this increased level of 
methylation with downregulation of four genes implicated in metabolic pathways. 
Following studies have found increased histone methylation correlating with 
decreased expression of GAD1 (Huang et al., 2007). Other findings include increased 
expression of histone deacetylase 1 (HDAC1) in prefrontal cortex of schizophrenic 
individuals (Sharma et al., 2008) but decreased HDAC3 in temporal cortex (Aston et 
al., 2004). 
Overall, while it is clear that epigenetic mechanisms have an important contribution 
to the schizophrenia phenotype, further analysis is still required in order to elucidate 
to which extent DNA and histone modifications might aroused as a response to 
stochastic events, environmental stimuli during development, maturation or aging or 
as a secondary effect of psychosis. Thus, perhaps one of the major challenges will be 
determining not only why these changes occur but also at which stage are they 
occurring in order to have a better understanding of their role in the development of 
the disease. 
1.4.3 Micro RNAs 
 The once common assumption that proteins are the primary regulator of cellular 
interactions in eukaryotic organisms has been challenged in recent years. In 
particular the revelation that the number of protein-coding genes was found to be 
much lower than expected in complex organisms and that the ratio of non-coding to 
protein-coding DNA increases proportionally to the complexity of each species 
(Mattick, 2001; Mattick and Makunin, 2005; Ambros, 2004; Zeng, 2009). Moreover, a 
growing body of evidence has led to the conclusion that RNA molecules generated 
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from non-coding DNA are implicated in regulatory processes much more complex 
than just cis-regulation of gene expression on the translational or transcriptional 
level, that include synapse regulation during development (Bicker and Schratt, 2008). 
A very particular group of these non-coding RNA molecules are micro RNAs 
(miRNAs). These are small endogenous RNA molecules that bind to mRNA in order to 
act as post-transcriptional negative regulators of gene expression (Lee, et al., 1993; 
Reinhart et al., 2000; Lee and Ambros, 2001; Lagos-Quintana et al., 2001).  
It is now known that miRNAs, along with other types of small RNAs, are implicated in 
the initiation of a complex and highly specific phenomenon known as RNA 
interference (RNAi) or gene silencing. This process involves the formation of an RNA-
protein complex known as miRISC that recognizes the mRNA target to start the gene 
silencing process by means of mRNA translation (Doench et a., 2003; 2004; Zeng et 
al., 2003) or destabilization that results in target mRNA degradation (Bagga et al., 
2005). In plants miRNAs commonly bind to target mRNAs with almost exact 
complementarity inducing mRNA cleavage (Rhoades et al., 2002). In contrast, 
perfect matching of metazoan miRNAs to their mRNA targets rarely occurs. The 
result of this type of interaction is not cleavage but repression of translation through 
mechanisms that are still a subject of intense investigation. Because of the imperfect 
pairing of miRISCs and mRNA, prediction target sequences has not been an easy 
task, however the efforts for the development of reliable genome-wide 
computational algorithms for the identification of these targets have been greatly 
aided by the use of microarray technology (Lewis et al., 2005; Nielsen et al., 2007).  
To date researches have agreed a series of important requirements for miRNAs 
target recognition and the successful repression of mRNA translation (Lewis et al., 
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2003; Bartel, 2009). Binding sites are in most cases located in the 3’ untranslated 
region (UTR) of the mRNA target. One of the most important factors identified so far 
for mRNA target recognition is the presence of a region complementary to the 
nucleotides 2-7 of the 5’ end of the miRNA, known as “seed region” and that the 
specificity of the pairing requires a perfect-matching sequence of at least 4 to 5 
nucleotides (Lewis et al., 2003; 2005). This finding was further supported by a study 
reporting that the ability of miRNA to repress translation of mRNA largely depends on 
the binding free energy between the target mRNA and the first 8 nucleotides at the 
5’ end of the miRNA (Doench and Sharp, 2004). This data suggests that each mRNA 
might target several mRNAs, an assumption consistent with recent microarray 
studies that have shown that miRNAs are able to downregulate many target mRNA 
containing sequences complementary to their “seed” regions (Lim et al., 2005). 
Recently it has been shown that miRNA can also exert their regulatory function when 
binding sites are artificially introduced to 5’ UTR or coding regions of mRNA targets 
although the extent of this effect has not been conclusively established yet (Lytle et 
al., 2007; Easow et al., 2007) 
Microarray analysis has also been used for identification and expression profiling of 
miRNAs in mammalian tissue samples (including human). Data collected from these 
studies shows that a significant proportion of the miRNAs identified so far are 
expressed in a tissue specific manner (Babak et al., 2004; Thomson et al., 2004; 
Sempere et al., 2004). Furthermore, these and other studies provided evidence to 
conclude that approximately 70% of the miRNAs detected so far are present in the 
brain and that they seem to be implicated in brain development (Krichevsky et al., 
2003; Miska et al., 2004; Thomson et al., 2004; Liu et al., 2004; Babak et al., 2004; 
Barad et al., 2004; Schratt et al., 2006; Kye et al., 2007; Bak et al., 2008). It is 
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therefore not surprising that miRNAs have become the focus of extensive 
investigation, in particular concerning their possible role in neurodevelopmental and 
psychiatric disorders.   
In a study using a mouse model of the human 22q11.2 microdeletions Stark et al. 
(2008) observed abnormal biogenesis of a number of miRNAs expressed in the brain 
due to disruption of the DiGeorge syndrome critical region gene-8 (DGCR8) resulting 
in the presence of the schizophrenia-like symptoms similar to those observed in 
individuals containing this chromosomal defect. Notably, an miRNA expression 
profiling study performed by Beveridge et al. (2010) in superior temporal gyrus and 
dorsolateral prefrontal cortex revealed a significant increase in global miRNA 
expression in schizophrenia that corresponded to an increase in DGCR8 and primary 
miRNA processing. This data supports previous findings of the expression of a 
number of miRNAs decreased in prefrontal cortex of schizophrenia patients (Perkins 
et al., 2007). An additional study in post-mortem samples from temporal cortex 
reported that miR-18 was significantly dysregulated in schizophrenia (Beveridge et 
al., 2008). Although evidence for the involvement of miRNAs in the aetiology of 
schizophrenia is still in an early stage, microarray analysis and other techniques have 
already proved to be a valuable resource in the identification and prediction of the 
effects of these molecules. Such is the case of miR-18 whose predicted mRNA 
targets include calcium sensor gene visinin-like1 (VSNL1) and the AMPA glutamate 
receptor subunit (GRIA2). These interactions were further confirmed by in vitro 
assays using HEK293 and SH-SY5Y cells. 
The identification miRNAs expressed in the brain and the constant improvement in 
methods of mRNA binding site prediction has also provided new possible approaches 
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in the investigation of miRNA implication in schizophrenia and other psychiatric 
disorders. One example of this is a single nucleotide polymorphism (SNPs) 
association study in schizophrenia cases and controls in which SNPs were selected, 
and all of them were located within +/- 100 bp from mature miRNA transcripts 
previously documented as exclusively expressed in the brain (Hansen et al., 2007). 
The study revealed that two SNPs (rs17578796 and rs17001) were significantly 
associated to disease status. Interestingly, it was observed that the two miRNAs 
harbouring these polymorphisms (miR-206 and miR-198) shared 15 common targets. 
A second example is the study performed by Zhu et al. (2009) in which they 
observed that a particular miRNA (miR-346) targeted susceptibility genes for 
schizophrenia (from Schizophrenia Gene database) twice as frequently as expected. 
They then identified that the gene encoding miR-346 was located within intron 2 of 
the glutamate receptor ionotropic delta 1 (GRID1) gene. Finally they went on to 
demonstrate that expression of both miR-346 and GRID1 was significantly reduced in 
dorsolateral prefrontal cortex of individuals with schizophrenia. It is noteworthy that 
GRID1 has been proposed from previous studies as a candidate gene for 
schizophrenia (Treutlein et al., 2009).  
Other studies have identified miRNAs implicated in processes that have long been 
regarded as associated to the pathology of schizophrenia. One such study showed 
that miR-219 was involved in NMDA receptor hypofunction in the prefrontal cortex of 
mice (Kocerha et al; 2009). These findings have encouraged further investigation to 
elucidate the precise role of miRNAs in the development of schizophrenia.  
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1.5 Rationale for this project 
The pathophysiology of schizophrenia is not well understood, but it is thought to 
have a strong genetic component with some environmental influences on aetiology. 
Despite the potential of GWAS studies to reveal genetic association of common 
alleles with schizophrenia, including the major histocompatibility complex region 
alleles (Stefansson et al 2009), the variants detected to date may account for as little 
as 4% of the risk of schizophrenia in a population (ISC et al., 2009). The fact 
remains that no marker or loci has reached genome-wide significance in any single 
study. There are a number of reasons that could account for these limitations, such 
as population stratification within a sample (SNPs varying in frequency across 
geographical regions) or inadequate coverage of common alleles within genes. In 
addition, in the majority of GWAS where 500,000 SNPs are routinely screened and p 
values of the order of 10-7 are necessary for an association to be deemed significant. 
Under these circumstances, larger case-control cohorts (from 2,000-4,000 
individuals), are being used in order to have the power to detect the small genetic 
effects expected from specific loci (Thomas et al., 2005). This has often led to the 
argument that “there are no genes of large effect in schizophrenia”. However, the 
GWAS approach for analysis of complex traits is based on single SNP associations 
and does not consider the underlying linkage disequilibrium (LD) patterns between 
loci. Data available from HapMap project has made evident that most of the human 
genome can be organized in haplotype blocks of SNPs in strong LD with each other. 
Indeed tag-SNPs used in GWAS do not represent all haplotype blocks and hence do 
not represent the true genetic variation present in the population (Morris, 2005).  
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To circumvent the limitations of GWAS, a number of alternative approaches have 
been proposed. One of them is to investigate associations with schizophrenia of 
specific candidate genes, selected on the basis of their strong biological plausibility. 
This approach has been used successfully by a number of studies, including three 
recent haplotype-block based analyses (Voisey et al 2010a; 2010b; Burdick et al., 
2010) where SNP association was assessed using smaller cohorts of controls and 
cases (total sample size from 310 to 410 individuals).  
The present study uses the above described candidate gene approach as the basis of 
its experimental design. Instead of making no assumptions about which genes are 
involved, candidate genes have been selected from those showing robust changes in 
expression in schizophrenia in brain regions implicated in functional abnormalities 
occurring in this condition from two previous microarray expression studies. 
Expression of over 30,000 mRNA transcripts was determined in post-mortem tissue 
from two brain regions associated with the pathophysiology of the disease 
(Brodmann Area 10: anterior prefrontal cortex and Broadmann Area 22: superior 
temporal cortex). Transcripts were screened in 28 schizophrenic and 23 control 
patients (Charing Cross Hospital Prospective Collection: CCHPC) The first publication 
reported the results from the prefrontal cortex, along with a direct comparison of 
microarray data between two large independent studies, the first comparison of this 
sort that has been made in schizophrenia. Furthermore, this is also the first 
microarray report comparing two demographically distinct cohorts - the Harvard 
Brain Bank (United States) and the CCHPP (United Kingdom) cohorts (Maycox et al., 
2009). This data has been validated and common candidate genes show the same 
direction and magnitude of effect in the Charing Cross Hospital prospective study 
and the Harvard Brain Bank.  
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To date, there has only been limited consistency between studies of small size but 
the data discussed above show that it is possible to detect significant and common 
changes in gene expression between independent cohorts. Moreover, the 
overlapping set comprises genes of relatively restricted function with significant 
enrichment in genes associated with synaptic function/ plasticity. Overall, 49 genes 
were identified that are differentially regulated in two independent schizophrenia 
cohorts. Interestingly, these genes cluster into a relatively small number of functional 
groups that are associated with synaptic function via synaptic vesicle regulation, 
signal transduction or cytoskeletal dynamics (Figure 1.1).  
The second publication concerns expression changes observed in BA22 region of 
schizophrenic subjects compared to controls and is being reviewed for publication 
(Barnes et al., 2011). Similarly to what was observed from candidate genes changed 
in BA10, specific pathways seem to be highlighted, particularly genes whose function 
seems to be crucial during neurodevelopmental stages.  
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Figure 1.1 Schematic representation of functional localization of schizophrenia 
candidate genes. (Maycox, et al., 2009). 
The study identified a number of genes implicated in synaptic function, signal transduction 
and cytoskeletal regulation that were differentially expressed in schizophrenia when 
compared to controls. In this figure, blue circles represent small synaptic vesicles, purple 
circles represent large dense cored vesicles while red hatching represent postsynaptic 
receptors and actin polymers are depicted as green small circles. 
The aim of the present project is to investigate whether the candidates identified 
in this gene expression study can provide insight into the aetiology of schizophrenia 
and potential susceptibility factors. A candidate gene based approach was therefore 
proposed for analysis of correlation of genetic variance with gene expression as well 
as analysis of possible association of selected candidate genes with disease. 
Candidate genes were selected not only on the basis of their differential expression 
in schizophrenia but also because they are implicated in one of two major functional 
categories: Genes implicated in synaptic processes and cellular communication and 
genes participating in the Wnt signalling pathway. A similar pathway-based approach 
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has been successfully used in a recent analysis of GWAS data that revealed 
association of genes related to glutamate metabolism, apoptosis and inflammation 
(Jia et al., 2010). These associations were not detected by the original single SNP 
GWAS analysis.  
Three main hypotheses were formulated for the present study: 
1. SNP variants/ haplotypes in genes whose expression is robustly altered 
in schizophrenia are associated with levels of gene expression and disease 
status. 
In this study, we will genotype SNPs in 6 candidate genes in 3 matched cohorts from 
the UK, including samples from the Charing Cross Hospital Prospective Collection, 
here designated Imperial College Prospective Study (ICPH) cohort. It is proposed to 
genotype up to 6 SNPS per candidate genes. SNP genotype data from the ICPS 
cohort will be used for associations with levels of expression. Factorial analysis of 
variance (ANOVA) will be used to identify significant correlations of expression with 
disease status, genotype/haplotype and interactions between variables. Bonferroni’s 
post-hoc tests will be used to correct for multiple testing. 
A subsequent association study will be carried out in a case-control cohort from East 
UK (East Anglia and East Yorkshire) with a total sample size of 321 individuals, a 
similar cohort size to the one used successfully by other association studies (Burdick 
et al., 2010). Golden Helix© software will be used for determination of allele and 
genotype frequencies between controls and schizophrenia subjects to determine 
their association with the disease. A logistic regression model and the χ2 test will be 
used for identification of allelic associations and genotypic associations. In addition, 
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logistic regression will be used to test three other genetic models to evaluate the 
increase in risk for disease conferred by genotypes containing the associated allele 
(‘D’) to the genotype with only the wild-type allele (‘d’).  
A moving-window analysis of association of haplotype with disease will be performed 
using Golden Helix©, while Haploview (Barrett, 2005; 2009) software will be used to 
determine LD patterns across SNP. PHASE program (Stephens et al., 2001; Stephens 
and Scheet, 2005) will be used for estimation of diplotypes for each individual. SNP 
and haplotype frequencies will also be correlated with age at onset as a clinical 
marker. To address the problem of multiple testing, p values were corrected using 
false discovery rate (FDR) values, following the Benjamini-Hochberg method 
(Benjamini and Hochberg, 1995; Benjamini and Yekutieli, 2001). This is a similar 
analytical approach used by Voisey et al. (2010a: 2010b) in their studies of similar 
cohort size (160 schizophrenia cases and 250 controls).  
In addition, correlation of SNP genotypes with other endophenotypes (such as age at 
onset) was considered for the present study. However, this information was not 
available for all individuals across the two main cohorts used: East UK and ICPS.  
2. Epistatic interactions may be detected between genes involved in 
common pathways. 
In recent years attention has been turned to gene-gene interactions, also known as 
epistasis, and their contribution to complex disorders (Carlborg and Haley, 2004; 
Daly and Altshuler, 2005; Marchini et al., 2005; Moore, 2005). In a simplified 
manner, if we consider an interaction between two loci, epistasis refers to a situation 
where the effect of the first gene on a particular phenotype depends on the 
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genotype of the second one. This could also be the case for interactions between 
several genes. It has been suggested that interactions between loci as well as 
environmental factors account for the non-linear correlation between genotype and 
phenotype observed in complex disorders, such as schizophrenia, and that these 
interactions have a more substantial effect in the risk for disease.  
Evidence of epistasis between candidate genes in schizophrenia has been reported 
from a number of studies, although very few of them involving interactions between 
genes within specific pathways (Straub et al., 2007; Nicodemus et al., 2007; 2010). 
In order to determine the possible association of defined functional pathways with 
disease, gene-gene interactions will be analysed in both groups of genes using an 
online application, GAIA (Macgregor and Khan, 2006), that allows testing for additive 
and dominant interaction gene-gene effects using case-control data for SNP 
genotypes.  
3. Epigenetic factors may be responsible for changes in expression of 
candidate genes. 
In order to explore this possibility, the promoter region of the DKK3 gene will be 
analysed in controls and cases under the assumption that, if present, CpG island 
methylation of this region would be associated with lower levels of expression and or 
disease status.  
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CHAPTER 2 Materials and Methods 
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2.1 Population samples description  
DNA samples from three independent cohorts of European ancestry were used for 
this study. Tissue samples collected as part of prospective programme at Imperial 
College (ICPS), used in previous expression studies, were included in the study for 
correlation of genetic variants with expression. In addition, blood samples from 
unrelated schizophrenia patients and controls were collected from East Anglia (EA) 
and East Yorkshire (EY) regions and constitute our two larger cohorts. Informed 
written consent was obtained from all subjects, with agreement of nearest relative or 
authorised representative, for use of tissue obtained post-mortem for research.  
2.1.1 Tissue samples from the Imperial College prospective 
collection 
The Imperial College Prospective Study (ICPS) cohort was comprised of 38 
schizophrenia cases and 37 controls collected from Charing Cross Hospital, London. 
These included 28 post-mortem tissue samples from BA10 of schizophrenic 
individuals (19 male and 9 female) and 23 controls (13 male and 10 female) included 
in the expression study performed by Maycox et al. (2009; Table 2.1). Schizophrenia 
samples consisted of a group of elderly patients whose condition in many cases had 
started before the introduction of antipsychotic medication and who had remained in 
psychiatric nursing facilities over long periods. Diagnosis of these patients was 
performed prospectively based on DSM-III criteria, using the available clinical data 
and through scrutiny of medical notes. All cases were diagnosed with residual 
schizophrenia and presented pronounced negative symptoms and intellectual 
dysfunction. Mean age of onset for patients in this cohort was 26 years old and the 
mean period between onset and death was 48 years. Thirteen patients were never 
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discharged after admission while only five had more than four periods of discharge 
between first admission and death in hospital. Eleven patients had been treated by 
electroconvulsive therapy and most of them were treated with neuroleptic drugs 
when they became available. The mean duration of treatment amongst patients was 
33 years although one patient was drug naïve at the time of death. Histological 
screening was performed in tissue from cases and those with evidence of Alzheimer’s 
disease, Parkinson’s disease or multiple sclerosis were excluded. 
Controls were recruited from Charing Cross Hospital and local nursing homes. All of 
these samples were collected from mentally normal tissue donors. Causes of death 
were similar in controls and cases with bronchopneumonia being the most common 
cause, followed by carcinoma (lung, bowel, prostate, bladder, oesophagus) and to a 
lesser extent ischemic heart disease and coronary artery occlusion. Autopsy revealed 
no major atrophy of brains. Controls and cases were collected over the same period 
and stored under the identical conditions.  
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Table 2.1 Summary of demographics of samples from ICPS cohort used in 
microarray study (Maycox et al., 2009) 
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2.1.2 Sample composition of the East UK cohort 
The East UK cohort used for analysis of genetic association of the proposed 
candidate genes with disease, consisted of blood samples from schizophrenia 
patients and matched controls, collected from the East Anglia and East Yorkshire 
regions in England. All controls and cases were of European ancestry. Eighty-five 
schizophrenia patients (46 males and 39 females) were recruited from the 
rehabilitation and acute services at Fulbourn Hospital in Cambridge, East Anglia. 
Forty-nine patients were taking clozapine at the time that the blood samples were 
collected and were categorised as responding or non-responding to this 
antipsychotic. Patients were diagnosed according to the DSM-III-R criteria. From the 
group of schizophrenics (SEA) one female of Afro-Caribbean descent and one male of 
Arabic descent were excluded. Seventy-nine controls (39 males and 40 females) of 
matched age and gender distribution were recruited from the oral surgery and 
ophthalmology clinics in Addenbrooke’s Hospital, Cambridge and were included in 
this cohort. From controls (CEA), one male of Asian descent and another male with a 
family history of schizophrenia were excluded. None of the remaining controls had 
any family history of major depression, bipolar disorder, schizophrenia or 
schizoaffective disorder (Table 2.2).  
The population sample collected from the East Yorkshire region contains a large 
proportion of individuals whose families may have been settled in this area for many 
generations with limited immigration. Seventy-two blood samples form schizophrenic 
patients (40 males and 29 females and 3 for whom information regarding sex was 
not provided) were collected from the psychiatric outpatient clinic based at De La 
Pole Hospital in Hull, EY. Six patients were treated with clozapine from which three 
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responded positively and one showed moderate improvement. The patients were 
diagnosed using the DSM-IV criteria, through which 38 patients were diagnosed with 
paranoid schizophrenia, 15 with disorganised type, 1 with catatonic type, 5 with 
undifferentiated type. Although no endophenotype data was available for this cohort, 
the mean age of onset was known and registered as 19.75 with the earliest onset 
observed at 9 years old and the latest at 47 years. Eighty-five control subjects (38 
males and 41 females plus 6 for whom information regarding sex was not provided) 
were recruited from the Hull Royal Infirmary. None presented with a family history of 
major depression, bipolar disorder, schizophrenia or schizoaffective disorder. Mean 
age of controls was matched to that of cases, as well as gender distribution (Table 
2.2). 
 
Disease 
Status 
Geographic Region- 
UK n 
Age-at -
Ascertainment Gender  
   Mean S.D. Male Female 
Controls 
East  Anglia 79 38.7 18.9 
39 
(49.4%) 
40 
(50.6%) 
East Yorkshire 
79 
(85) 36.9 10.2 
38 
(48.1%) 
41 
(51.9%) 
Schizophrenics 
East  Anglia 85 44.6 15.1 
46 
(54.1%) 
39 
(45.9%) 
East Yorkshire 
69 
(72) 48.2 17.5 
40 
(58.0%) 
29 
(42.0%) 
Total 
312 
(321)     
 
Table 2.2 Summary of demographics of samples from East UK cohort. 
Mean age at ascertainment and gender distribution for the East UK cohort are presented in 
the table. The 9 samples for which no information regarding sex was available (collected 
from the EY region) were not used in the gender proportion calculation but are included in 
the total number of samples (321).  
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2.2 Analysis of DNA 
2.2.1 DNA extractions and purification 
Extractions of DNA from blood and tissue samples were performed using the BACC 
Nucleon genomic extraction kit (Tepnel Life Sciences) according to the supplier 
instructions. After ethanol precipitation and washing (with 70% ethanol) DNA was 
resuspended in 0.1 ml of deionised water (SIGMA-ALDRICH) and subsequently 
diluted to a final concentration of 20 µg/µl for use as template for PCR amplification. 
Stock DNA samples were placed at -20º C for long-term storage while dilutions were 
kept at 4º C while genotyping of SNPs. 
DNA purification was performed using SureClean (Bioline) or QIAquick PCR 
Purification Kit (QIAGEN) following the procedure recommended by the 
manufacturers. Purity of DNA was assessed by determination of the UV light 
absorbance ratio at 260 nm and 280 nm using a NanoDrop Analyser (Thermo 
Scientific), an absorbance ratio (A260/280) of 1.6-1.8 being obtained for pure DNA. 
Concentration of DNA was also determined based on the optical density (OD) values 
measured at a wavelength of 260 nm based on the assumption that an OD value of 
1 corresponds to a concentration of 50 µg/ml for double-stranded DNA (Sambrook 
and Russell, 2001).  
2.2.2 DNA amplification with polymerase chain reaction (PCR) 
Standard PCR reactions were carried out using a mixture containing 60 to 100 ng of 
DNA template, 1x PCR buffer, 1.5mM MgCl2, 0.2mM dNTP mix, forward and reverse 
primers to a final concentration of 0.5µM and one unit of Platinum® Taq polymerase 
(Invitrogen) or GoTaq® polymerase (Promega) using pure deionised water to make a 
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total reaction volume of 30 µl. PCR amplification was performed using a Px2 
Thermohybaid® thermocycler as follows: 95 ºC for 3.5 minutes, 1 cycle followed by 
38 cycles of 30s at 95 ºC, 30 s at the optimized annealing temperature (generally 50-
64 ºC) and 1 min at 72° C and a final cycle of 6 min at 72 ºC. 
2.2.3 Agarose gel electrophoresis 
Agarose gel electrophoresis was used in order separate DNA fragments according to 
their size, after amplification or digestion. In some cases, it was also used as an 
intermediate step for purification of DNA for cloning or sequencing. Gels were 
prepared using agarose ‘Electran’ (BDH) in a 0.5x TBE Buffer (43.75 mM of Tris 
base, 44.48 mM of boric acid and 1mM of EDTA pH8.0). Agarose gel concentrations 
varied from 0.7 to 1.5% depending on the resolution required and the size 
differences between the DNA fragments that were being separated. A 0.5 µg/ml 
solution of ethidium bromide (SIGMA) was used for detection of DNA under UV light. 
Two markers were used: ΦX174 DNA/BsuRI (Hae III) marker 9 (Fermentas) and 
HypperLadder IITM (Bioline) for different fragment size identification. 
2.2.4 DNA sequencing 
For each sample, a sequencing mixture was prepared containing either 600 ng of 
purified DNA plasmid or 100 ng/Kb of PCR product, along with 3.2 pmole of 
sequencing primer adding distilled water (SIGMA) to give a total volume of 10 µl. 
DNA sequencing was then performed by the MRC CSC Genomics Core Laboratory, 
Imperial College London.  
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2.3 Molecular biology techniques 
2.3.1 Preparation of DNA constructs 
Plasmid DNA constructs were prepared using PCR for cloning of desired sequence 
with further agarose gel electrophoresis for identification and separation of bands. 
DNA fragments were later excised from the gel and purified using QIAquick gel 
extraction kit (QIAGEN). Ligations were performed using one unit of Taq DNA ligase 
(NEB) with 1X reaction buffer and an insert to vector ratio of 1:3. 25 ng of vector 
plasmid DNA were used for each reaction and volume was adjusted to 10 µl using 
molecular biology rate water (SIGMA). The reaction mix was maintained at 16ºC 
overnight in order to ensure successful ligation. 5 µl of the ligation product were 
subsequently transformed into 50 µl of One Shot TOP10 chemically competent E. Coli 
cells (Invitrogen) by incubating at 4 ºC for 30 minutes followed by a 30 seconds heat 
shock at 42 ºC and finally recovery at 4 ºC for 2 minutes.  After transformation 
bacteria were left to grow in SOC medium at 37 ºC and shaking at 200 rpm for one 
hour before spreading onto agar plates containing 100 µg/ml of ampicillin or 50 
µg/ml of kanamycin.  
2.3.2 Selection and screening of positive colonies 
For constructs containing a Lac Z site, positive colonies were selected using blue 
white screening method (Sambrook and Russell, 2001). After transformation 
bacterial solution was spread across agar plates containing 50 µg/ml of ampicillin 
(Sigma-Aldrich) and 40 µl of a 2% X-gal (Calbiochem) solution combined with 7 µl of 
a 20% isopropyl-β-D-thio-galactoside (IPTG; Calbiochem). The presence of the insert 
was later confirmed by PCR. For constructs without the Lac Z site, at least 10 to 20 
colonies were harvested and screened for the insert using PCR. For expression 
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constructs orientation of the insert was confirmed by enzyme digestion. Positive 
colonies were then cultured in order to extract DNA plasmid using QIAprep mini prep 
kits (QIAGEN) for sequencing.  
2.3.3 Cell culture and transfection 
N2a and COS7 cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) 
containing10% FBS (Dubelco) at 37 °C and 5% CO2. Transfections were performed 
using Lipofectamine 2000 (Invitrogen) according to manufacturers directions. Cells 
were allowed to achieve 90% confluence before transfection.  For activation of Wnt 
signalling pathway, cells were treated with a 5µM solution of the GSK-3β VIII (EMD 
Calbiochem) inhibitor overnight before fixing. 
2.3.4 Immunocytofluorescence  
Cells used for analysis of protein subcellular localization and immunofluorescent 
staining were seeded in 24-well plates on round cover slips coated with 0.01% poly-
lysine slips. In the case of transfections with fluorescent constructs and Wnt3A 
construct were fixed 48 hours after transfection using a 4% paraformaldehyde (PFA) 
solution in phosphate buffer saline (pH 7.3), for 20 minutes at room temperature. 
Permeabilisation of cells was performed using a 0.5% solution of Triton-X (Sigma-
Aldrich) in PBS, for 15 minutes, followed by at least three PBS washes (of 5 minutes 
each) before counterstaining by incubation with a 0.5 µg/ml DAPI solution in PBS 
buffer for 10 minutes. Cover slips were finally mounted onto slides using Fluorosave 
reagent (Calbiochem) 
Immunostaining of endogenous β-catenin was performed by plating cells as 
described above and allowing them to grow for 24 hours before fixing them with 4% 
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PFA solution. After permeabilisation of the cells with 0.5% Triton, and three PBS 
washes, cover slips were incubated with a 10% FBS/PBS solution for an hour at 
room temperature for blocking. Cells were then incubated with rabbit anti-β-catenin 
(1:2000) at 4ºC overnight followed by secondary anti-rabbit Alexa Fluor 594 antibody 
(1:1,000;Molecular Probes) and DAPI counterstaining and mounting. 
2.3.5 Western Blot 
For Western Blot analysis cells were seeded in 6-well plates and transfected as 
previously described. Cells were lysed, 48 hours after transfection, in 20mM Tris·HCl 
(pH 8), 137 mM NaCl, 10% glycerol, 1% Nonidet P-40, 2mMEDTAcontaining 
1mMPMSF, 1mMsodium orthovanadate, 5mMsodiumfluoride, and a mixture of 
protease inhibitors (Roche). Protein concentrations were determined using a 
Bradford protein assay kit (Bio-Rad). Samples were separated by 10% SDS/PAGE gel 
electrophoresis using a Mini-PROTEAN Tetra Cell (Bio-Rad) and a Precision Plus 
Protein All Blue Standards (Bio-Rad) as protein size marker. Bands were then 
transferred to a nitrocellulose membrane (Amersham Hybond™ ECL™, GE 
Healthcare) using a, Semi-Phor semi-dry transfer system (Hoefer Scientific 
Instruments). Membranes were blocked in 5% nonfat milk/PBS-Tween (0.1%) and 
incubated with primary antibody at 4ºC overnight.  
For analysis of β-catenin we used polyclonal rabbit anti-β-catenin (1:4000; Sigma-
Aldrich) while analysis of DKK3 was performed by incubation with rabbit polyclonal 
anti-GFP antibody (1:10000; Abcam). Primary antibody incubation were followed by 
three washes using PBS-Tween buffer before a second incubation with an anti-rabbit 
HRP (1:3000; Vector) for 1 hour at room temperature and then developed using the 
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Immun-Star HRP chemiluminescent kit (Bio-Rad) and Amersham Hyperfilm ECL (GE 
Healthcare). 
Western blotting of secreted DKK3 was carried out by replacing medium of GFP-
DKK3 transfected cells with serum free DMEM, 24 hours after transfection. Cells were 
harvested and lysed as specified above after additional 24 hours and the medium 
collected for protein precipitation. Precipitation was carried out by adding an equal 
volume of a 20% trichloroacetic acid (TCA) solution to medium samples (for a final 
TCA concentration of 10%) and incubating them at 4º C for 45 minutes. Precipitated 
was recovered by centrifugation at 13000 rpm at 4º C for 30 minutes. The pellet 
obtained was washed with a 90% cold acetone solution followed by a second wash 
with cold acetone (100%). Protein was re-suspended in 2X SDS buffer for Western 
blot analysis.  
2.3.6 Luciferase Assays 
N2a cells were seeded in 96-well plates and allowed to achieve 90% confluence 
before being transfected with the luciferase reporter TOPFlash or FOPFlash (A gift 
from Dr. Magdalena Sastre from Imperial College London), renilla luciferase pRL-CMV 
vector (PROMEGA) as a transfection control, RFP-β-catenin and GFP-DKK3 or GFP 
empty vector. In addition, cells transfected with either TOPF or FOPFlash, renilla 
pRL-CMV vector, and GFP and RFP empty vectors were used as controls. Three wells 
containing N2a cells were then transfected with each of the six combinations of DNA 
constructs for luciferase activity measurement. A Dual-Luciferase Reporter assay 
system from Promega was used for this purpose. Cells were harvested 48 hours after 
transfection and lysed by adding 70 µl of 1X passive lysis buffer (PLB) provided with 
the kit to each well and incubating at room temperature for 15 minutes on a rocking 
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platform. Luciferase activity was measured immediately after completion of lysis 
using a FluoroSkan Ascent microplate reader (Thermo Scientific). Firefly luciferase 
activity of TOPFlash and FOPFlash was measured initially by adding 50 µl of 
luciferase assay reagent II (LARII) to 50 µl of cell lysates. Once this reaction was 
complete, renilla luciferase activity of the transfection control vector was measured 
by adding 50 µl of 1X Stop & Glo reagent to the lysate and LARII mix. 
The procedure described above was repeated at least three times for N2a and COS7 
cells for optimisation of transfection conditions and to minimise variation in 
measurement of luciferase activities. For experiments performed to determine the 
effect of DKK3 on Wnt signalling activation, optimised DNA ratios of reporter 
constructs with respect to the RFP-β-catenin construct were defined as 1:1. Similarly, 
DNA ratio of GFP-DKK3, or GFP empty vector, with respect to RFP-β-catenin was 
maintained as 1:1. Finally, 1.4 ng of pRL-CMV vector were used for each 
transfection. The total amount of DNA was constant throughout all experiments and 
was set as 200 ng per well. For the case of ‘reporter only’ transfections GFP and RFP 
empty vectors were used as controls. 
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CHAPTER 3 Correlation of gene expression with 
genotype and genotype with schizophrenia of 
genes involved in synaptic processes and 
intracellular signalling. 
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3.1 Introduction 
The involvement of synaptic dysfunction and deficient connectivity in the aetiology of 
schizophrenia has been supported by evidence from a variety of studies. Findings 
from structural and neurochemical studies point to a contribution of deficient 
neurotransmitter function underlying the pathophysiology of the disorder (e.g. 
Carlsson and Carlsson, 1990; Akil et al., 1999; Beasley et al., 2002b; Reynolds et al., 
2002; Bitanihirwe et al., 2009). In addition, linkage, association and expression 
studies have also provided a number of candidate genes with important roles in 
synaptic and memory formation processes (e.g. Numakawa et al., 2004; Talbot et 
al., 2004; Corfas et al., 2004; Roy et al., 2007; Buxbaum et al., 2008).  
The present study has its basis in data collected from microarray mRNA expression 
studies in post-mortem brain samples from Brodmann areas 10 and 22 (BA 10 and 
BA22) of schizophrenia cases and controls (Maycox et al., 2009; Barnes et al., 2011). 
In this section we present results from the analysis of three candidate genes selected 
for their involvement in synaptic processes, neurotransmitter release and cell-cell 
communication pathways. The analysis consists of two parts; the first one involves 
the correlation of genotype with levels of expression while the second part of the 
study was the analysis of association of genotype with disease. 
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3.1.1 Overview 
3.1.1.1 Correlation of genotype with levels of expression 
The aim for the first part of the analysis was to identify significant correlations 
between genetic variation and mRNA levels of the candidate genes. In order to do 
so, a number of SNPs were selected in regions (within, proximal and distal) 
containing each of our candidate genes. Genotypes from these SNPs in controls and 
cases from the ICPS cohort (Section 2.1.1) were then used to explore correlations 
with expression levels. Using the data-set reported by previous microarray studies 
(Maycox et al., 2009; Barnes et al., 2011) SNP genotypes of all candidate genes 
were then correlated with expression data of controls anda cases. Three-way 
analysis of variance (ANOVA) was used to evaluate the effect of all variables on 
levels of expression of each candidate genes, as well as the interactions between 
these variables. For analysis of single SNPs, disease status and genotype were 
considered as independent variables. Multilocus associations were assessed by 
grouping haplotypes according to their likely evolution, based on regions of strong 
LD across SNPs. The software Haploview (Barrett, 2009) was used to estimate LD 
values. PHASE v. 2.1 (Stephens et al., 2001; Marchini et al., 2006) was used to 
predict both haplotype pairs for each individual (diplotype). Correlation of diplotype 
with expression levels was then performed using a two-way ANOVA. Following these 
analyses, post-hoc Bonferroni-corrected individual comparisons were performed to 
correct for multiple testing. 
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3.1.1.2 Analysis of association of genotype with schizophrenia 
For the second part of this analysis we tested the hypothesis that these variants 
might also be associated with schizophrenia. For this purpose, SNP genotype data 
was collected for an additional larger group of schizophrenia cases and unrelated 
matched controls, the East UK cohort (Sections 2.1.2). This cohort comprised 
controls and cases of European ancestry from East Anglia and East Yorkshire regions 
in England. These cohorts were combined in view of the expected similarities 
between them and the low levels of population stratification in England compared to 
those across Europe (Wilson et al., 2001; Capelli et al., 2003; O’Dushlaine et al., 
2010). The software G*power (Faul et al., 2007; 2009) was used to calculate size 
effects (w) for particular changes in minor allele frequencies (MAF) between controls 
and cases. These ‘w’ values were subsequently used to estimate the power of a 
case-control study to detect significant SNP effects (α= 0.05), using the East UK 
cohort (n=321). From this calculation, it was determined that the analysis had 
sufficient power (1-β= 0.8 to 1, where β represents type II error) to detect 
significant effects of SNPs with a difference in MAF of 8% or greater in cases 
compared to controls. This was true for all the MAF values of controls used for the 
power calculation (Table 3.1).  
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 Increase of MAF in Cases 
Control MAF 7% 8% 10% 
50% 0.14 0.16 0.2 
40% 0.142887 0.163299 0.204124 
30% 0.152753 0.174574 0.218218 
20% 0.175 0.2 0.25 
10% 0.233333 0.266667 0.333333 
    
Power 70-78% 
Power ≥ 80% 
Power ≥ 88% 
Power ≥ 95% 
Table 3.1 Power calculation for the East UK cohort.  
Power heat map calculated using the software G*Power. Effect size (w-values) are 
represented in the table, for different Case/Control MAFs at α=0.05, considering the East UK 
cohort, with a total sample size of 321 individuals.  
The genotype data collected from the East UK cohort was then used to perform a 
candidate gene based genetic association study. Deviations from Hardy-Weinberg 
equilibrium and LD values were calculated using the software Haploview in controls 
and cases. Golden Helix© SNP and Variation Suite 7 (SVS7) software version 7.3.0 
(Golden Helix, Inc., Bozeman, Montana) was used for application of a logistic 
regression to assess allele associations while χ2 test was applied to analyse genotypic 
associations. In addition, three models of disease penetrance were tested in order to 
compare the effect of genotypes containing the disease associated allele ‘D’ to those 
containing the wild-type allele ‘d’’. All p-values were corrected for multiple testing 
using the in-built feature of the software, which calculates false discovery rate (FDR) 
values based on the Benjamini-Hochberg method (Benjamini and Hochberg, 1995; 
Benjamini and Yekutieli, 2001; Storey and Tibshirani, 2003). This method has been 
used in a number of candidate gene association studies with similar sample sizes to 
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the East UK cohort (Voisey et al., 2010a; 2010b; Jia et al., 2010) and it is considered 
more appropriate for SNP association studies compared to Bonferroni’s for a number 
of reasons. It has been the subject of debate that Bonferroni-type corrections can be 
extremely conservative and might decrease power when statistical tests are not 
independent, which is the case for SNPs in strong LD with each other (Macregor and 
Khan, 2006; Straub et al., 2007; Evans, 2008).  
Analysis of the effect of haplotypes on risk of schizophrenia was performed using two 
methods. The first one of these was a moving window type analysis performed using 
Golden Helix©, where χ2 test was applied to compare haplotype frequencies between 
controls and cases from the East UK cohort. For this analysis, p values were 
corrected by calculating FDR values. The second method for analysis of haplotype 
association with disease consisted in defining groups of similar haplotypes and 
comparing their frequencies in controls and cases using Fisher’s exact test. This 
approach has the advantage that it reduces the degrees of freedom for the analysis 
and avoids grouping together rare haplotypes of large and small effect (Morris, 2005; 
2008).  
Haplotype analysis is commonly regarded to be a more powerful tool to detect 
genetic association with disease when compared to the single SNP approach. This is 
due to the fact that a haplotype approach considers LD patterns between loci, which 
provides an advantage since it has been observed that much of common variation 
can be structured in haplotype blocks of SNPs in strong LD with one another 
(International HapMap consortium, 2005). Another important consideration 
supporting haplotype analysis is that protein function is determined by the linear 
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DNA sequence corresponding to each copy of the coding gene and therefore will be 
affected by variation in the maternal or paternal haplotypes (Clark, 2004). 
Finally, a third hypothesis was considered that there might be gene-gene interactions 
potentially contributing to an increased risk of disease. In order to explore this idea, 
analysis of epistatic interaction was also performed between all pairs of genes using 
genotype data from controls and cases of the ICPS and the East UK cohorts. For this 
analysis, the online based application GAIA was used to calculate p values for 
interaction between loci as well as an overall p value for significance of association 
over and above SNP association (Macgregor et al., 2006; 
http://gump.qimr.edu.au/GAIA/gaia.html). For this analysis 1000 permutations were 
used to calculate empirical p values.  
3.1.2  Selected candidate genes 
Three candidate genes were selected for this part of the study. The first candidate, 
the solute carrier family 30 member A3 (SLC30A3) is also known as ZnT3 and is the 
third member of the family of proteins known as zinc transporters. ZnT3 has been 
identified as the only source of chelatable zinc (Zn+2) in synaptic vesicles of zinc 
secreting neurons (Palmiter et al., 1996; Wenzel et al., 1997; Cole et al., 1999; 
Salazar et al., 2004; Suh et al., 2005; Linkous et al., 2008; Chi et al., 2008). Release 
of Zn+2 from presynaptic buttons and its translocation to postsynaptic terminals 
results in important effects on the modulation of excitatory synapses through 
regulation of glutamate and γ aminobutiric acid (GABA) receptors (Xie et al., 1994; 
Palmiter et al., 1996; Jacob et al., 1998; Marin et al., 2000; Sheline et al., 2002). 
Along with these findings, the reported downregulation of ZnT3 in post-mortem 
cortical brain tissue from the BA10 region of schizophrenia cases (Maycox et al., 
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2009; Figure 3.1) provided strong support for selection of this gene as candidate for 
the present study. A significant decrease in gene expression was observed from 
microarray data in schizophrenia cases compared to controls (p=0.003). Validation of 
this data by qPCR later confirmed this result (p=0.009). 
 
Figure 3.1 Levels of expression of SLC30A3 (ZnT3) in BA10 post-mortem tissue 
from schizophrenia cases and controls (Maycox et al, 2009) 
Validation analysis of microarray study was carried out by QPCR and confirms a significant 
decrease in expression of SLC30A3 in schizophrenia (p=0.009). Data is obtained from 
Maycox et al (2009).  
The second candidate gene considered was the voltage dependent, R-type, α1E 
subunit or calcium channel CaV2.3 (CACNA1E). In the central nervous system (CNS) 
calcium channels play and important role in neurotransmitter release, neuronal 
excitability and other calcium dependent processes. In the brain at least five genes 
coding for alpha 1 subunits of these channels have been identified, namely alpha 1A 
to 1E. The expression of each one of these subunits regulates the properties of 
specific calcium channels. The 1E subunit, particularly, has been associated with high 
voltage R-type currents in rat and human brain (Ellinor et al., 1993; Williams et al., 
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1994). R-type voltage-gated calcium channels (α1E) are expressed primarily in 
neurons, particularly in dentate granule, entorhinal cortex and hippocampal CA3 
pyramidal neurons (Day et al., 1996). In presynaptic terminals the main function of 
these channels is to trigger fast neurotransmitter release whilst those located in cell 
bodies and dendrites, they elicit depolarization. In hippocampus, R-type channels are 
particularly important in long-term potentiation (LTP) and therefore have a major 
role in synaptic plasticity, learning and memory processes (Breustedt et al., 2003). 
The biology of R-type calcium channels has not been clearly elucidated. However, 
inhibition of R-type currents by activation of glutamate and GABA receptors in a G-
protein dependent manner has been reported (Wu et al., 1998; Yu and Shinnick-
Gallagher, 1998; Toro-Castillo et al., 2007; Meza et al., 2007). 
The functional relevance of voltage-gated calcium channels in neurological processes 
has guaranteed their extensive investigation in relation to a variety of neurological 
disorders including association of R-type channels with neuropathic pain (Greenberg, 
1997; Matthews et al., 2007; Benarroch, 2010). In addition, evidence for association 
of a SNP in the CACNA1C (CaV1.2) gene with bipolar disorder has been identified 
(Ferreira et al., 2008) and more recent reports provide evidence of association of this 
polymorphism with major depression and schizophrenia (Green et al., 2010; 
Nyegaard et al., 2010). CACNA1E was initially selected for the present study because 
it was one of the transcripts most significantly changed in BA22 in schizophrenia, 
from a previous microarray expression study using samples from the ICPS cohort 
(Appendix A: Barnes et al., 2011). After validation, a significant increase (1.24 fold, 
p=0.003) in mRNA levels of CACNA1E was confirmed in affected individuals when 
compared to controls. 
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The third candidate gene selected was the S100 calcium binding protein A8 
(S100A8), also known as myeloid-related protein 8 (MRP8) and calgranulin A. This 
gene is part of a family of EF-hand Ca2+ binding proteins involved in regulation of a 
variety of cell processes including differentiation, survival and proliferation (Fritz et 
al., 2010). Together with the S100A9 protein (MRP14, calgranulinB), S100A8 has 
been found to be particularly abundant in neurotrophils in the form of a heterodimer 
known as calprotectin (Hessian et al., 1993; Stroncek et al., 2005). Calprotectin has 
a high affinity for arachidonic acid and binding of this lipid has been observed to 
have an effect on activation of the NADPH oxidase complex in phagocytes (Bouzidi et 
al., 2004). The role of calprotectin in chronic inflammation has been well 
documented (Lügering et al., 1995; Foell et al., 2004; McCormick et al., 2005). In 
addition, this heterocomplex is known to have chemotactic, antimicrobial, apoptotic 
and growth-regulating properties (Rammes et al., 1997; Murao et al., 1999; Ghavami 
et al., 2010). However, little is known about the function of S100A8 in the CNS. 
The relevance of S100A8 as a candidate gene for schizophrenia is strengthened 
when considering that it is located in chromosome 1q25-31, a region associated with 
schizophrenia from previous linkage studies (Hovatta et al., 1999; Brzustowicz et al., 
2000; Ekelund et al., 2001), and also contains the CACNA1E (Figure 3.2). Like 
CACNA1E, S100A8 was also found to be significantly upregulated in BA22 (Appendix 
A, Barnes et al., 2011) and BA10 (Maycox et al, 2009) of schizophrenia cases 
compared to controls from the ICPS cohort (Appendix B).  
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Figure 3.2 Schematic representation of the localization of schizophrenia 
candidate genes in chromosome 1q21-q31.  
With the exception of RGS4, expression mRNA levels of all these genes were identified from 
the ICPS as significantly increased in post-mortem tissue from PFC of schizophrenia 
compared to controls (Appendix B, Barnes et al., 2011). RGS4 has been identified as a 
candidate gene for schizophrenia from a number of studies (Mirnics et al., 2000; 2001; 
Chowdari et al., 2002).  
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3.2 Methodology 
3.2.1 Selection of single nucleotide polymorphisms (SNPs) 
The selection of SNPs of interest was performed by using data from the open access 
HapMap database (http://hapmap.ncbi.nlm.nih.gov), following a series of well 
established guidelines that enhance the power of the study (Pettersson et al., 2009). 
Initially, known polymorphisms within the gene region for which genotype data was 
available were selected. SNPs within coding regions, preferably non-synonymous or 
located in regulatory regions of the gene were given priority for selection. Proximity 
of the selected SNPs to regions identified in GWAS as being associated with 
schizophrenia was also considered as high priority. Additionally, in order to avoid the 
difficulties associated with the interpretation of frequency differences from SNPs with 
low minor allele frequencies (MAFs), polymorphisms with a MAF of between 20%-
30% in samples of European ancestry were preferred (Table 3.2). Finally, two more 
important criteria and, in some cases, the deciding factor for SNP selection were 
considered: the characteristics of the sequence that might make the SNP difficult to 
genotype and the availability of restriction enzymes that could be used to distinguish 
between the two alleles.  
For the analysis of association of genetic variants in ZnT3 with schizophrenia, four 
SNPs were selected within a 14.1 Mb region in chromosome 2. SNP 1 (rs6547521) is 
located in the 5’ end of the gene at 4.7 Kb upstream from the ATG start codon. The 
second SNP (rs11126936) is located in intron 1, while SNPs 3 (rs2083363) and 4 
(rs11126931) are both located in the 3’ flanking region at a distance of 1.9 Kb and 
2.9 Kb, respectively, from the end of the gene. Although none of the selected SNPs 
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are located in coding regions of ZnT3, they are located in, or close to, regions with 
potential for regulation of gene expression (Chen et al., 2006). 
For analysis of the CACNA1E gene, five genes were selected. SNP1 (rs17743547) was 
selected for its location in a splice site, while SNPs 3 (rs35737760) and 5 (rs704326) 
were selected as they are non-synonymous variants and cause a change in the 
amino-acid residue of the protein. Two more polymorphisms, SNP 2 (rs2280865) in 
intron 22 and SNP 4 (rs4652678) in exon 32 were also included in the analysis. 
Although the latter is located in a coding region of the gene, the base change does 
not result in a change of amino acid residue as is therefore deemed as a 
synonymous change.  
Finally, although genotype information for SNPs in the S100A8 gene region was 
limited, two polymorphisms in this gene were used in this study, one located in an 
intronic region (rs3795391; intron 1) and the other one (rs3006488) located in the 
untranslated region (UTR) at the 3’ end of the gene.  
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ZnT3     Frequency (%) 
 
SNP Location 
 
n 
 
G/G G/C C/C  C 
rs6547521 5’  65  52.3 40.0 7.7  27.7 
     G/G G/T T/T  T 
rs11126936 Intron 1  113  61.1 34.5 4.4  21.7 
     G/G G/C C/C  C 
rs2083363 3’  61  54.1 41.0 4.9  25.4 
     C/C C/T T/T  T 
rs11126931 3’  65  56.9 38.5 4.6  23.8 
          
CACNA1E          
     G/G G/A A/A  A 
rs17743547* 
Intron 10 
(splice site) 
 23  78.3 21.7 0.0  10.9 
     T/T T/C C/C  C 
rs2280865 Intron 22  120  28.3 38.3 33.3  47.5 
     T/T T/A A/A  A 
rs35737760 
Exon 23 
[D⇒E] 
 
37 
 
N.A N.A N.A 
 
5.6 
     T/T T/C C/C 
 
C 
rs4652678 Exon 32 (syn)  112  53.1 38.1 8.8  27.9 
     G/G G/A A/A 
 
A 
rs704326 
Exon 47 
[A⇒T] 
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28.6 45.5 25.6 
 
48.7 
          
S100A8          
     A/A A/G G/G 
 
G 
rs3795391 Intron 1  113  83.2 15.9 9.0  8.8 
     T/T T/C C/C 
 
C 
rs3006488 3’ UTR  113  83.2 15.9 9.0  8.8 
 
Table 3.2 HapMap database frequency data of SNPs selected in ZnT3, CACNA1E 
and S100A8 
Frequency data available from the HapMap database for all SNPs in genes involved in 
synaptic processes and cell communication. The data shown in this table above corresponds 
to the HapMap CEU cohort, composed of unrelated individuals of European ancestry from 
the CEPH collection. Genotype data for SNP rs17743547 (*) corresponds to the AFD-EUR-
PANEL, which comprises 23 unrelated individuals of European ancestry from the CEPH 
collection.  
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3.2.2 Genotyping 
Genotyping was performed by polymerase chain reaction (PCR) amplification of the 
gene fragment containing the SNP of interest, followed by restriction enzyme 
digestion for determination of genotype frequencies (Figure 3.3).  
Primer pairs for SNP genotyping were designed with the aid of Primer 3 v. 0.4.0 
(http://frodo.wi.mit.edu) so that the CG content was not higher than 55% 
(Supplementary Table 2; Appendix B). Theoretical Tm values for the primer pairs 
were calculated and used as a guideline for optimization of PCR conditions. 
Annealing temperature gradients, modification of template concentrations, increase 
of Taq polymerase units and/or addition of an enhancing solution (Invitrogen) were 
necessary for optimization of amplification conditions of some SNPs.  
Restriction enzymes suitable for each polymorphism were selected using a web-
based tool (http://tools.neb.com/NEBcutter2/index.php) from New England Biolabs. 
This application provides a list of all the commercially available enzymes that have 
recognition sites matching one or several points of a given sequence. In order to 
ensure a complete digestion, 1 unit of enzyme was used for each digestion and the 
reactions were carried out for 16 h under mineral oil at the recommended 
temperature for each enzyme (normally 37º C). Once the digestion was completed 
digestion products were analysed by agarose gel electrophoresis. Gels were prepared 
using 1.7 to 2.0 % (by weight) of agarose (depending on the size of the bands 
analysed) in TBE buffer (ph= 8) stained with 1% ethidium bromide. Band sizes were 
determined by comparison φX174 DNA/Bsru (HaeIII) marker 9 (Fermentas).  
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Figure 3.3 Example of genotyping of one of the SNPs in the CACNA1E gene. 
An example of the method used for determination of genotypes by restriction enzyme 
digestion and agarose gel electrophoresis analysis. For this SNP, one restriction site is 
present for the BspHI (NEB) restriction enzyme when the ‘T’ allele is present but not for the 
‘C’ allele. This means that two bands can be observed after digestion only when the ‘T’ allele 
is present while the intact 599 pb fragment is obtained for ‘C’. A φX174 DNA/Bsru (HaeIII) 
marker 9 (Fermentas) DNA ladder was used to determine the size of the bands.  
3.2.3 Analysis of the correlation of genetic variation with gene 
expression 
Correlation of genetic variation with gene expression was performed using genotype 
data from cases and controls from the ICPS cohort. Expression data for the same 
cohort was obtained from previous microarray studies (Maycox et al., 2009; Barnes 
et al., 2011). Genotypic associations with mRNA levels of single SNPs for all 
candidate genes were tested by analysis of variance (ANOVA). Deviation from 
normality of the data was assessed by in-built Prism tests such as the D’Agostino and 
Pearson and Kolmogorov-Smirnov normality tests. For each gene an initial three-way 
ANOVA was performed using the application Rweb module 
(http://www.biostatisticien.eu/cgi-bin/Rweb/buildModules.cgi; ©J. Banfield; Montana 
State University). For this analysis three independent variables were defined; disease 
status, genotype and SNP ID with expression as the outcome variable. Further two-
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way ANOVA was then performed using Prism v. 5 software (Graph Pad), with only 
disease status and genotype as independent variables and expression as the 
outcome. Due to the low numbers of rare allele homozygotes for most SNPs, two 
genotype groups were considered, one containing individuals carrying both copies of 
the common allele (1/1) and a second one containing individuals carrying one or two 
copies of the rare allele (1/2+2/2). Post-hoc comparisons between controls and 
cases were performed for each genotype group and Bonferroni corrected p values 
were obtained.  
In addition to single SNP analysis, analysis of haplotype effects on gene expression 
was performed. Because both gene copies represent the genetic make up of each 
individual, correlations with levels of expression were performed considering 
diplotypes using a similar approach to the one used for correlations with genotypes 
of single SNPs. Due to the presence of rare alleles of very low frequency and in order 
to reduce the dimensionality of the analysis, haplotypes were grouped together 
according to their similarity and LD across haplotypes. Similarity was based on the 
abundance of alleles shared by haplotypes within a group. LD values were calculated 
using the Haploview software from the Daly Lab at Broad Institute, MIT (Barrett, 
2009;http://www.broadinstitute.org/scientific-community/science/programs/medical-
and-population-genetics/haploview/haploview). For analysis of the effect of 
haplotypes on the levels of expression of candidate genes, PHASE software v2.1 
(http://stephenslab.uchicago.edu/software.html) was used to calculate haplotype 
frequencies and to predict diplotypes for each individual in the ICPS cohort. PHASE 
has been demonstrated to infer haplotype phase with a 95% accuracy in previous 
studies based on data from unrelated individuals (Stephens et al., 2001; Marchini et 
al., 2006). For all three candidate genes two groups of similar haplotypes were 
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defined: A and B. Individuals containing diplotypes composed of two haplotypes from 
group A were subsequently compared to diplotypes comprising one or two copies of 
haplotypes in group B.  
3.2.4 Analysis of SNP association with disease status.  
Analysis of association of candidate genes with schizophrenia was performed using 
schizophrenia samples and matched controls within the East UK cohort (Section 
2.1.2). Previous to SNP association analysis, deviations from Hardy-Weinberg 
equilibrium in all cohorts were assessed for all SNPs using the χ2 goodness-of-fit test 
determined with Prism v.5, comparing observed with expected values. These results 
were later confirmed by analysis using the Haploview software.  
Allelic and genotypic associations with disease were assessed using the Golden 
Helix© software. Initially, a logistic regression model was applied in order to estimate 
odds ratio and p value for allele associations, while genotypic associations were 
evaluated using a χ2 test. In addition, a logistic regression model was also applied to 
the analysis in order to incorporate models for disease penetrance. Three basic 
models were used, comparing the effect of genotypes carrying the disease 
associated allele ‘D’ to those containing the wild type allele ‘d’. The first model 
considered was the additive model where risk for disease is increased by γ (γ>1) for 
genotype d/D and of 2γ for genotype D/D relative to genotype d/d. The parameter γ 
refers to a measurement of genetic penetrance and is often calculated as odds ratio 
(OR). The second model tested was the common recessive, in which risk of disease 
only increases when both copies of the ‘D’ allele are present. Finally, the common 
dominant model was tested where it is assumed that only one copy of the associated 
allele is sufficient to produce an increase in risk of disease of γ. Additionally, the 
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multiplicative model of disease is commonly used, although it has not been 
considered in the present study. According to this model the risk for disease 
increases by γ with each copy of the A allele present (Morris, 2008; Clarke et al., 
2011; Table 3.3).  
 
 Penetrance  Relative Risk 
Disease model d/d d/D D/D  d/D D/D 
Additive ƒ0 ƒ0γ 2ƒ0γ  γ 2γ 
Common recessive ƒ0 ƒ0 ƒ0γ  1 γ 
Common dominant ƒ0 ƒ0γ ƒ0γ  γ γ 
Multiplicative ƒ0 ƒ0γ ƒ0γ
2  γ γ2 
 
Table 3.3 Disease penetrance models from Clarke et al., 2011. 
Shown in the table (modified from Clarke et al., 2011) are disease penetrance functions of 
genotypes d/d, d/D and D/D with baseline disease penetrance ƒ0 for the non-associated 
genotype d/d. Relative risk of disease are represented as well for genotypes d/D and D/D 
compared to wild type genotype d/d, where the genetic penetrance parameter is γ>1.  
To address the problem of multiple testing, false discovery rate (FDR) values were 
calculated according to the Benjamini-Hochberg method of correction for multiple 
comparisons (Benjamini and Hochberg, 1995; Benjamini and Yekutieli, 2001; Storey 
and Tibshirani, 2003). This method has increasingly been used for other association 
studies as an alternative to Bonferroni-type corrections, often regarded as overly 
conservative since they do not take into account LD patterns between markers 
(Voisey et al., 2010a; 2010b; Jia et al., 2010). FDR values are calculated as part of 
the analysis performed by the Golden Helix© software. The Benjamini-Hochberg 
correction is also included as an in-build option in PLINK (Purcell et al., 2007; 
http://pngu.mgh.harvard.edu/~purcell/plink/), and other software packages widely 
used for whole-genome genetic association studies. An additional method for 
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multiple testing corrections used in the present study is the calculation of empirical p 
values by permutation testing (Evans, 2008). Although this approach is 
computationally demanding, most of the software packages available for analysis of 
SNP association are able to perform it.  
Following assessment of single locus association with disease, haplotype analysis was 
performed. Haplotype analysis is commonly regarded to be a more powerful tool to 
detect genetic association with disease when compared to the single SNP approach. 
This is due to the fact that a haplotype approach considers LD patterns between loci. 
This is advantageous since it has been observed that much of common variation can 
be structured in haplotype blocks of SNPs in strong LD with one another 
(International HapMap consortium, 2005). Another important consideration 
supporting haplotype analysis is that protein function is determined by the sequence 
contained in each copy of the gene and therefore will be affected by variation in 
either maternal or paternal haplotypes (Clark, 2004). 
The Haploview software was used to estimate LD, represented as values of D’ where 
0.7<D’≤1 is considered as strong LD. The expectation maximisation (EM) was 
implemented within the Golden Helix software to calculate haplotype frequencies 
(Excoffier and Slatkin, 1995). Test for association was performed using a moving 
window approach in the Golden Helix© software. For this analysis the software 
generates haplotype blocks according to the settings specified by the user. For 
example, in an analysis comprising four SNPs, one might opt for a case/control 
comparison of two, three or four SNP haplotype frequencies. The number of markers 
selected defines the size of the ‘window’ that slides across the LD spine to generate 
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the haplotype blocks. A χ2 test is then used to identify significant differences in 
haplotype block frequencies between controls and cases.  
A second approach to the haplotype analysis was taken by comparing four SNP 
haplotype frequencies in controls and cases. In order to reduce the degrees of 
freedom and increase the power of the analysis, two haplotype groups were 
generated. These groups were defined by the likely evolution of the haplotypes and 
considering LD patterns across SNPs. Analysis was then carried out using a Fisher’s 
and χ2 test to compare haplotype and diplotype frequencies in controls and cases 
(analogous to the determination of allelic and genotypic associations). Once more, 
PHASE version 2.1, was used to predict haplotype pairs (diplotypes) for each 
individual.  
3.2.5 Analysis of epistatic interactions between candidate genes 
In accordance with the pathway approach of the present study, it was important to 
determine whether statistical epistasis between pairs of genes functionally related 
could be contributing to an increase in risk of disease. An exploratory analysis of 
statistical epistasis was performed using genotype data for the three candidate genes 
involved in synaptic and cellular communication processes from controls and cases of 
the East UK cohort, used for the association study. The selected tool for this analysis 
was, the web-based application GAIA (http://gump.qimr.edu.au/GAIA/gaia.html). 
This application allows the calculation of p values for interaction over and above any 
main effect (“interaction only” term). It also includes an “overall” p-value, which 
tests for significance of the joint main effects for both SNPs and the interaction effect 
over the mean effect. This results in a test with 3 degrees of freedom for an additive 
model. For the present study, the “interaction only” test was used because it has 
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been reported to be the most suitable of the two for candidate gene based analysis 
(Macgregor and Khan, 2006). Calculation of an empirical p value for the most 
significant interaction was carried out using 1000 permutations in each case. In 
addition, the Benjamini-Hochberg method was also applied in order to calculate 
corrected p-values for individual interaction values. 
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3.3 Results 
In this section the results from the analysis of SNP genotype and haplotype effect on 
mRNA levels and disease status of three genes implicated in synaptic function and 
cell-cell communication processes are described. The analysis of gene expression 
confirmed our previous reports of significant differences in regulation of these 
candidate genes in schizophrenia subjects compared to healthy controls. Although no 
significant effect of any individual SNP variant on levels of expression was observed 
for any of the polymorphisms in ZnT3 or S100A8, associations were detected for 
three SNPs in CACNA1E. Furthermore, an overall association was detected for the 
four SNPs in ZnT3 contributing to a significant interaction of disease status and 
genotype with respect to gene expression. 
In the second stage, carried out using the East UK cohort, four polymorphisms in the 
ZnT3 gene were found to be significantly associated with risk of schizophrenia. Allelic 
and genotypic associations obtained through the application of a logistic-regression 
model, remained significant for all four SNPs after multiple comparisons correction. 
Moreover, a moving-window analysis revealed a number of haplotypes significantly 
associated with disease status. A different approach for haplotype analysis later 
confirmed the significant association with disease of two groups of similar 
haplotypes.  
Finally, evidence for statistical epistasis was observed between SNP rs11126931 in 
the 3’ flanking region of ZnT3 and rs2280865 in intron 22 of CACNA1E. Additionally, 
SNP rs4652678, a synonymous polymorphism located in exon 23 of CACNA1E, was 
also found to significantly interact with both SNPs analysed in S100A8: rs3795391 
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and rs3006488. Although these interactions were not maintained after correction for 
multiple testing, the indication of epistatic interaction between genes that are so 
closely related in function makes it an interesting subject for further exploration.  
3.3.1 ZnT3: Analysis of SNP genotype effect on expression levels 
and study of association with disease 
3.3.1.1 Correlation of SNP genotypes and haplotypes with mRNA levels in the 
ICPS cohort 
Genotype data for four SNPs in ZnT3 in controls and cases of the ICPS cohort was 
used for correlation with validated gene expression data of this gene in BA10 
(Supplementary Table 4; Appendix C). As it has been discussed previously, ZnT3 was 
previously reported as significantly downregulated in the BA10 region in 
schizophrenia (Maycox et al., 2009). Initial three-way ANOVA was performed 
considering disease status, genotype and SNP ID as independent variables with 
mRNA levels as the outcome variable. This analysis resulted in a significant 
association of disease status with levels of expression (p= 5.33 x 10-4). Although no 
significant effect of either genotype or SNP ID was identified, the analysis yielded a 
significant p value for interaction between disease status and genotype (p= 
0.029756). In order to further explore this interaction a two-way ANOVA analysis 
was carried out using only disease status and genotype as independent variables. 
For this analysis genotype groups (1/1 or 1/2+1/2) for each SNP were considered as 
levels of the variable ‘genotype’. This analysis confirmed the significant association of 
disease status with expression levels (p=3.0 x 10-4), although no significant 
interaction of disease status with genotype was observed. Finally, post-hoc 
Bonferroni comparisons made between controls and cases across all genotypes did 
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not result in significant p-values. However, it was interesting to observe that the 
most substantial differences in ZnT3 mRNA levels between controls and cases were 
observed in individuals with the 1/1 genotype across all four SNPs (Figure 3.4).  
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Figure 3.4 Analysis of SNP and disease status effect on ZnT3 mRNA levels. 
Levels of expression of ZnT3 in BA10 are presented in this figure for controls and 
schizophrenia cases. For comparison, mRNA levels of ZnT3 for individuals homozygous of the 
major allele (1/1), of the four SNPs analysed, are presented in a separate histogram to those 
corresponding to subjects carrying at least one copy of the minor allele (1/2 + 2/2). Three 
and two-way ANOVA were performed by comparing all genotypes in controls and cases (1/1: 
controls n=8-9; cases n=12-17 with 1/2+2/2: controls n=13-15; cases n=9-10) across all 
SNPs.  
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In order to further explore possible SNP pair interactions, analysis of two SNP 
haplotypes was performed using phased data predicted from PHASE v. 2.1. For each 
SNP pair, expression data for individuals carrying both common haplotypes (Common 
diplotype: 1-1/1-1) was compared to expression data of those carrying at least one 
copy of the rare haplotypes (Rare diplotypes: any diplotype formed by at least one 
copy of haplotypes 1-2, 2-1 and 2-2). Using a similar analysis of the effect of 
individual SNPs on expression of ZnT3, a factorial ANOVA was performed initially 
considering three independent variables: disease status, diplotype and SNP pair. This 
approach revealed a significant effect of disease status (p=3.1 x 10-5) but no effect 
of either diplotype or SNP pair. However, a significant interaction was observed 
between disease status and diplotype with respect to gene expression (p=7.1x 10-4), 
which is even more striking than for the individual SNPs. In order to evaluate these 
effects in more detail, a two-way ANOVA was then performed using only disease 
status and diplotypes as independent variables, where diplotype groups for each SNP 
pair were considered levels of the variable ‘diplotype’ and the outcome variable was 
gene expression. From this analysis, a significant effect of disease status on mRNA 
levels was confirmed (p< 1.0 x 10-4) but no significant direct effect between disease 
status and diplotype was observed. Bonferroni post-tests were used once more for 
comparison of ZnT3 levels of expression between controls and cases for all 
diplotypes. Although these comparisons did not yield any significant p values, once 
again it was interesting to observe that consistent with the results from analysis of 
single SNP genotypes, the differences in levels of expression between controls and 
cases were greater for individuals carrying both copies of the most common 
haplotype (1-1), across all SNP pairs. (Figure 3.5). 
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Figure 3.5 Analysis of the effect of two SNP diplotypes of ZnT3 on mRNA levels in 
controls and cases of the ICPS cohort.  
Levels of expression of ZnT3 in BA10 are presented in this figure for controls and 
schizophrenia cases across all SNP pairs. mRNA levels of ZnT3 are presented in two separate 
histograms for purposes of clarity: One for individuals carrying both copies of the most 
common haplotype (1-1/1-1) and a second histogram for those carrying at least one copy of 
haplotypes 1-2, 2-1 or 2-2. Three and two-way ANOVA was performed by comparing both 
diplotype groups (1-1/1-1: controls n=7-9; cases n=9-16 or diplotypes containing one copy 
of 1-2, 2-1 or 2-2: controls n=12-16; cases n=10-17) across all SNP pairs.  
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Although no significant effects of any individual SNP genotype or 2 SNP diplotype on 
expression levels was observed thus far, the fact that the largest differences in ZnT3 
mRNA levels are observed between controls and cases carrying two copies of the 
common alleles (for either one or two SNPs) prompted the analysis of the effect of 
four SNP haplotypes. In order to address the problem posed by the presence of very 
rare haplotypes and in order to increase the power of the analysis by reducing the 
degrees of freedom, two groups of haplotypes were defined using a method 
described by A. Morris (2005; 2008). Instead of grouping haplotypes according to 
their frequency, which may lead to a lack of power for identifying the effect of rare 
haplotypes, categories were defined according to likely evolution (Table 3.4). For this 
study, similarity between haplotypes was determined by the frequency of alleles they 
shared and considering the strong LD patterns observed in ICPS cohort across all 
four SNPs but particularly for SNPs 2, 3 and 4. A two-way ANOVA was performed in 
order to compare mRNA levels of ZnT3 between controls and cases carrying two 
copies of any combination of haplotypes in group A (A,A) with those carrying at least 
one haplotype from group B (A,B; B,B). No significant effect of disease status or 
diplotype on the expression of ZnT3 was observed, nor any significant interaction 
between these factors was identified (Figure 3.6).  
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 Haplotype Frequency (%) 
  Controls  Cases 
Group A 1-1-1-1 58.81  56.18 
 1-1-2-1 2.89  0.11 
 2-1-1-1 5.77  18.68 
 1-2-1-1 0.01  1.43 
Group B 1-2-2-2 1.08  10.93 
 2-2-1-1 0.04  0.61 
 2-2-1-2 1.36  0.59 
 2-2-2-2 29.76  11.25 
 
Table 3.4 Haplotype blocks defined for correlation with ZnT3 expression. 
The table presents two haplotype groups defined according to frequency of alleles shared 
and considering strong LD patterns of all four SNPs in the ICPS cohort. 
 
 
 
Figure 3.6 Analysis of the effect of four SNP diplotypes of ZnT3 on mRNA levels in 
controls and cases of the ICPS cohort. 
For this analysis haplotypes were grouped according to their likely evolution in two groups 
(described in section 3.2.3). Both haplotype copies were considered for each individual, 
analogous to the analysis of individual SNPs genotypes. Two-way ANOVA was performed to 
compare frequencies of controls and cases carrying both haplotypes belonging to group A 
(controls n=10; cases n=16) with those carrying at least one of the haplotypes from group B 
(controls n=10; cases n=13). No significant effect of disease status or diplotype was 
observed nor a significant interaction between variables. 
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3.3.1.2 Analysis of association of SNPs and haplotypes in ZnT3 with 
schizophrenia in the East UK cohort 
Analysis of SNP association with disease status was performed by genotyping the 
four selected SNPs in the ZnT3 gene (Figure 3.7) in the East UK cohort of controls 
(n=164) and cases (n=157) collected from the East Anglia (EA) and East Yorkshire 
(EY) regions in England (Section 2.1.2). Prior to the association study, deviations 
from Hardy-Weinberg equilibrium were assessed for all SNPs in controls and cases 
using Haploview software. No significant deviations were observed for any of the 
SNPs. Application of the χ2 test to the analysis, using Golden Helix© resulted in 
significant allelic association of all four SNPs with schizophrenia. These associations 
remained significant after correction using FDR values (Table 3.5). In addition, the χ2 
test for genotypic association also revealed significant associations of genotype with 
disease for SNP 3 as well as SNP 4, and these associations remained significant after 
correction (Table 3.6). Further examination of the genotype data suggested that 
disease penetrance for all four variants could be consistent with a dominant model. 
This was evident when comparing odds ratio (OR) values of genotypes containing 
the minor allele ‘D’ (d/D and D/D) with the major allele genotype (d/d). Indeed, 
application of a dominant model to a logistic regression analysis (with a χ2 
distribution and one degree of freedom) resulted in an increased power for detecting 
genotypic associations with disease for all four SNPs. These values remained 
significant after correction using FDR values (Table 3.6).  
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Frequency 
(%) 
 
  
False 
Discovery 
Rate 
East UK Samples n 
Minor 
Allele 
 
p value OR CI 95%  p value 
SNP 1 
rs6547521: 5’ 
 
      
  C       
Schizophrenia 258 36.1  0.023* 1.59 1.07-2.37  0.045* Controls 210 26.2  
SNP 2  
rs11126936: Intron 1  
       
  T       
Schizophrenia 274 33.2  0.028* 1.57 1.05-2.35  0.037* Controls 212 24.1  
SNP3  
rs2083363: 3’ 
       
  C       
Schizophrenia 266 31.2  0.002** 2.00 1.29-3.11  0.008** Controls 200 19.0  
SNP4  
rs11126931: 3’ 
       
  T       
Schizophrenia 266 29.3  0.033* 1.58 1.04-2.42  0.033* Controls 212 20.8  
 
Table 3.5 Summary of statistical analysis for allelic association of SNPs of ZnT3 in 
the East UK cohort.  
Minor alleles of all four SNPs in the ZnT3 gene were found to significantly contribute to the 
risk for disease. All p values and FDR values were calculated using Golden Helix© software. 
Significant p values are indicated by * when p<0.05 and by ** when p<0.01. 
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    Genotype   
 
 
  χ
2 Test  
Dominant Model  
Logistic regression 
East UK 
Samples n Frequency (%)  
p value 
(FDR)  
p value 
(FDR) 
Odds Ratio 
(CI95%) 
SNP 1  
rs6547521: 5’ 
 
 
  G/G G/C C/C    
 Schizophrenia 129 41.9 44.2 14.0  0.079 
(0.11) 
 0.028* 
(0.038)* 
1.78 
(1.06-2.99)*  Controls 105 56.2 35.2 8.6   
SNP 2  
rs11126936: Intron 1  
 
 
  G/G G/T T/T    
 Schizophrenia 137 47.4 38.7 13.9  0.096 
(0.096) 
 0.031* 
(0.031)* 
1.75 
(1.05-2.94)*  Controls 106 61.3 29.2 9.4   
SNP3  
rs2083363: 3’ 
 
 
  G/G G/C C/C    
 Schizophrenia 133 48.1 41.4 11.0  0.008** 
(0.035)* 
 0.002** 
(0.009)** 
2.29 
(1.33-3.93)**  Controls 100 67.0 28.0 5.0   
SNP4  
rs11126931: 3’ 
 
 
  C/C C/T T/T    
 Schizophrenia 133 50.4 40.6 9.0  0.046* 
(0.093) 
 0.015* 
(0.029)* 
1.91 
(1.13-3.24)*  Controls 106 66.0 26.4 7.5   
 
Table 3.6 Summary of statistical analysis of genotypic associations of SNPs in 
ZnT3 in the East UK cohort. 
The P-values and FDRs presented in the table were calculated using Golden Helix© from the 
application of a χ2 to identify genotype associations with disease. In addition, a logistic 
regression model was applied as a trend test in which three genetic models were tested, 
comparing the effect of genotypes containing the disease allele ‘D’ to those with the wildtype 
allele ‘d’: (1) Additive, where DD >Dd> dd. (2) Dominant, where (DD, Dd)>dd. (3) 
Recessive, where DD>(dd,Dd). Significant p-values are indicated by * when p<0.05 and ** 
when p<0.01. The association of schizophrenia with the SNP alleles, when adjusted for the 
FDR, retained significance for all SNPs and this corresponded to the dominant model of 
genotype association (See Appendix D; Supplementary Table 5 for best fit of data with 
disease penetrance models). 
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In order to assess a possible contribution of one or more haplotypes to the risk of 
schizophrenia, a moving-window analysis was performed using Golden Helix©. 
Linkage disequilibrium (LD) for all SNPs in controls and cases was also estimated 
using the HaploView platform and represented as percentage values of D’  (Figure 
3.8). Overall, higher LD values were seen in controls compared to cases from the 
East UK cohort across all polymorphisms. These differences in LD structure observed 
between controls and cases are interesting because they might indicate significant 
differences in haplotype distribution. Lower LD values in schizophrenia indicate a 
greater degree of chromosomal crossover between these SNPs, leading to an 
increase in haplotype classes that are found in schizophrenia (Figure 3.9). 
This suggestion was later confirmed by the results from the haplotype analysis 
performed using Golden Helix©. Significant associations with disease were obtained 
for a number of haplotypes. In particular, it was interesting that two and four SNP 
haplotypes containing the common alleles of all SNPs had a protective effect while 
those formed entirely from minor alleles significantly increased the risk of disease 
(Table 3.7). Notably all common allele haplotype associations remained significant 
after multiple testing corrections. In addition, association of the two SNP haplotype 
constructed from the minor alleles of SNPs 3 and 4 also remained significant after 
correction.  
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Figure 3.8 Linkage disequilibrium values for four SNPs of ZnT3 in the East UK 
cohort.  
Linkage disequilibrium (LD) diagram obtained from analysis using Haploview for the East UK 
cohort. LD values are represented as D’. Although strong LD was observed across SNPs in 
both controls and cases (denoted by D’ values rank from 0.8 to 1), LD appeared stronger in 
controls with a very well defined haplotype block of SNPs rs11126936, rs2083363 and 
rs11126931. 
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In order to obtain an overall p-value for association of four SNP haplotypes, data 
collected from the analysis from Golden Helix analysis was used to calculate an 
empirical p-value through a Monte Carlo method using the CLUMP software (Sham 
and Curtis, 1995). A significant overall p-value was obtained from this analysis 
(p=0.036). Moreover, the differences in frequencies of haplotypes GGGC (1111) and 
CTCT (2222) between controls and cases confirmed the significant effects observed 
from the previous analysis (Figure 3.9). 
Finally, an additional haplotype analysis was performed using the approach described 
by Morris (2008). In an attempt to increase the power of the analysis by reducing 
degrees of freedom, haplotypes were grouped into two categories. Instead of 
defining these categories according to haplotype frequency, they were defined by 
haplotype similarity. This approach takes into account LD patterns across SNPs and it 
was preferred because it avoids pooling together rare haplotypes with large and 
small effect, which may result in false negative association with disease (Morris, 
2006; 2008). For the analysis two groups of similar haplotypes were defined and 
Fisher’s exact test was used to assess association with disease (Table 3.8). A 
significant difference was observed when comparing the frequencies of these 
haplotype groups between controls and cases (p=0.009), with an increase in the 
frequency of haplotypes of group B from 21% in cases to 31% in schizophrenia. 
Additionally, diplotypes were estimated using PHASE v. 2.1 and a χ2 test was used 
for the analysis, analogous to the one carried out to detect genotypic associations. A 
significant association of diplotypes with disease status was also observed 
(p=0.0145; Figure 3.10).  
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Figure 3.9 Four SNP haplotypes of ZnT3 in controls and cases from the East UK 
cohort.  
Frequencies for four SNP haplotypes in controls and cases are presented. A significant 
overall p-value (p=0.036) was obtained from permutation test using the Monte Carlo based 
CLUMP software. The increased representation of the haplotype conformed by all common 
alleles (1111), as well as the decrease in frequency of the one formed by the rare alleles 
(2222), in controls compared to cases is consistent with results from the moving window 
analysis. 
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 Haplotype Frequency (%) 
  Controls  Cases 
Group A 1-1-1-1 70.06  59.94 
 1-1-2-1 0.00  0.71 
 1-2-1-1 4.07  3.81 
 2-1-1-1 4.84  4.34 
Group B 1-2-2-2 0.01  3.50 
 2-1-2-2 0.08  1.53 
 2-2-1-2 1.36  0.59 
 2-2-2-1 0.87  0.83 
 2-2-2-2 18.72  26.77 
 
Table 3.8 Haplotype groups defined for ZnT3 in the East UK cohort. 
Considering LD patterns observed in controls and cases of the East UK cohort, two haplotype 
groups were defined based on haplotype similarity for association with disease status. For 
this purpose, data obtained from PHASE was used in order to predict both haplotypes in 
each individual and to calculate haplotype frequencies in controls and cases. 
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Figure 3.10 Frequencies of two haplotype groups of SNPs in ZnT3 in East UK 
cohort.  
Two groups of similar haplotypes were defined. Frequencies of haplotypes in Group A were 
compared to those in Group B in controls and cases using Fisher’s exact test (A). A 
significant association was obtained for haplotype with disease due to an increase in 
frequencies of haplotypes in group B in schizophrenia compared to controls (p=0.009). In 
addition, phased data was used to perform a comparison of diplotype frequencies using the 
χ2 test (B). This also resulted in significant association with disease status (p=0.0145).  
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3.3.2 CACNA1E: Analysis of SNP association with expression levels 
and disease status 
3.3.2.1 Correlation of SNP genotypes and haplotypes with mRNA levels in the 
ICPS cohort 
Five SNPs in the CACNA1E gene were genotyped in controls and cases from the ICPS 
cohort for correlation with expression data for this gene in BA22 (Supplementary 
Table 4; Appendix C). CACNA1E was found to be upregulated in BA22 of 
schizophrenia subjects when compared to healthy controls from the ICPS cohort 
(Appendix A: Barnes et al., 2011). Initial factorial ANOVA performed using three 
variables, resulted in a significant association of disease status with levels of 
expression (p=0.0017). No significant association of either genotype or SNP ID on 
expression was observed and no significant interactions between variables were 
found. A subsequent two-way ANOVA performed by considering only disease status 
and genotype as independent variables confirmed the significant effect of disease 
status (p<1.0x10-3). Subsequent Bonferroni post-hoc comparisons between controls 
and cases across all genotypes revealed significant differences for major allele 
homozygotes of SNP1 and 3 as well as minor allele carriers of SNP 2 with respect to 
gene expression (Figure 3.11). 
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Figure 3.11 Analysis of SNP and disease status effect on CACNA1E mRNA levels. 
Levels of expression for five SNPs of CACNA1E in BA22 are presented in this figure for 
controls and schizophrenia cases of the ICPS cohort. For clarity purposes, mRNA levels for 
individuals homozygous for the major allele (1/1), of the five SNPs analysed, are presented 
in a separate histogram to those corresponding to subjects carrying at least one copy of the 
minor allele (1/2 + 2/2). However, three and two-way ANOVA was performed by comparing 
both genotype classes in controls and cases (1/1: controls n=5-18; cases n=6-20 with 
1/2+2/2: controls n=2-16; cases n=4-19) across all SNPs.  
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In order to determine haplotype effects on levels of expression a two SNP haplotype 
analysis analogous to the one performed for ZnT3 was carried out. Expression levels 
of CACNA1E were compared between controls and cases carrying either two copies 
of the common haplotype (1-1/1-1) or at least one copy of a rare haplotype (1-2, 2-1 
or 2-2), using a two-way ANOVA. Two SNP pairs, SNP 2 and 5 and SNPs 4 and 5 
could not be included due to insufficient number of samples in one of the diplotype 
groups (Figure 3.12). The analysis confirmed a significant effect of disease status 
(p=3x10-4) but no effect of diplotype and no significant interactions between these 
variables. Bonferroni post-hoc comparisons between controls and cases across 
diplotype groups resulted in significant p-values for diplotypes of the major alleles (1-
1/1-1) of SNP pairs 1,3, 1,4 and 3,4. In additon, significant differences in mRNA 
levels of CACNA1E between controls and cases carrying at least one copy of the less 
common haplotypes (1-2, 2-1 or 2-2) was observed for SNP pairs 1 and 2 and 2 and 
4.  
Analysis of the five-SNP haplotype effect on mRNA levels of CACNA1E was performed 
next using the approach described previously for ZnT3. Haplotypes were group into 
two categories according to their of similarity, defined by the alleles they shared 
(Table 3.9). Diplotypes for each individual were estimated using PHASE v 2.1 in order 
to compare mRNA levels of CACNA1E between controls and cases carrying two 
copies of any combination of haplotypes in group A (A,A) with those carrying at least 
one haplotype from group B (A,B and B,B). A two-way ANOVA revealed a border-line 
but not significant effect (p=0.0561) of disease status on levels of expression but no 
effect of diplotype and no significant interactions between variables either (Figure 
3.13). 
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Figure 3.12 Analysis of the effect of two SNP diplotypes of CACNA1E on mRNA 
levels in controls and cases of the ICPS cohort. 
Levels of expression of CACNA1E in BA22 are presented in this figure for controls and 
schizophrenia cases across SNP pairs. Haplotypes of SNPs 2 and 5 and SNPs 4 and 5 were 
not included due to limited number of samples in one of the diplotype groups. Two-way 
ANOVA was performed in order to compare expression levels in controls and cases for both 
diplotype groups (1-1/1-1: controls n=7-9; cases n=9-16 or diplotypes containing one copy 
of 1-2, 2-1 or 2-2: controls n=12-16; cases n=10-17) across all SNP pairs. In this figure 
mRNA levels of CACNA1E are presented in two separate histograms for clarity purposes.  
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 Haplotype Frequency (%) 
  Controls  Cases 
Group A 1-1-1-1-1 12.44  11.82 
 1-1-1-1-2 42.96  40.51 
 1-1-1-2-1 2.02  3.40 
 1-1-2-1-2 0.14  2.85 
 1-2-1-1-1 10.37  16.02 
 1-2-1-1-2 2.04  1.82 
 1-2-1-2-1 4.85  3.87 
 2-1-1-1-2 1.66  3.67 
Group B 1-2-2-2-1 10.14  2.17 
 1-2-2-2-2 1.36  0.58 
 2-2-1-1-2 1.10  0.33 
 2-2-1-2-1 3.40  0.62 
 
Table 3.9 Haplotype blocks defined for correlation with CACNA1E expression. 
Haplotypes were grouped according to their similarity into two blocks. Grouping was 
performed considering the shared alleles and LD values, particularly across SNPs 1 to 4. 
 144
 
Figure 3.13 Analysis of the effect of five SNP diplotypes of CACNA1E on mRNA 
levels in controls and cases of the ICPS cohort. 
For this analysis haplotypes were grouped according to their likely evolution in two groups 
(described in section 3.2.3). Both haplotype copies were considered for each individual, 
analogous to the analysis of individual SNPs genotypes. Two-way ANOVA revealed no 
significant effect of disease status, genotype or interactions. Post-hoc Bonferroni’s corrected 
t-test comparisons were made between controls and cases carrying either two copies of 
haplotypes in Group A (controls n=14; cases n=17) or those carrying at least one of the 
haplotypes from Group B (controls n=6; cases n=8). No significant differences were 
observed in CACNA1E expression levels between controls and cases for any of the diplotype 
groups.  
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3.3.2.2 Analysis of association of SNPs and haplotypes in CACNA1E with 
disease status in the East UK cohort 
Considering SNP frequencies in the ICPS cohort (Supplementary Table 4; Appendix 
C) and taking into account the power calculation previously performed (Section 
3.2.4) only three SNPs in CACNA1E were considered for further study. Analysis of 
SNP 2 (rs2280865), SNP 4 (rs4652678) and SNP 5 (rs704326) in CACNA1E was 
performed using controls and cases from the East UK cohort. Even though the two 
alleles in SNP5 have very similar frequencies, the fact that this variant is non-
synonymous was a decisive factor for the inclusion of the polymorphism in this 
analysis (Figure 3.14). 
Previous to analysis of genetic association with disease, Hardy-Weinberg equilibrium 
was assessed for each group with no significant deviations observed. From analysis 
using a χ2 test no allelic association with disease were observed (Table 3.10). 
Genotype contribution to risk of disease was also assessed using Golden Helix© to 
perform a χ2 test, with no significant associations observed. In addition logistic 
regression analysis was performed applying the three models for disease penetrance 
(additive, dominant and recessive) with no significant associations detected. (Table 
3.11).  
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  Frequency 
(%) 
 
 
East UK Samples n 
Minor 
Allele 
 
p value OR CI 95% 
SNP 2  
rs2280865: Intron 22 
 
    
  C     
Schizophrenia 214 42.1  0.381 0.83 0.58-1.25 Controls 172 46.5  
SNP 4  
rs4652678: Exon 32  
     
  C     
Schizophrenia 260 27.7  0.858 1.04 0.68-1.59 Controls 182 26.9  
SNP5 
rs704326: Exon 47 [T/A] 
     
  A     
Schizophrenia 270 46.3  0.831 0.96 0.66-1.40 Controls 186 47.3  
 
Table 3.10 Summary of statistics for allelelic association of SNPs in CACNA1E in 
the East UK cohort. 
Results form the analysis of allelic associations of three SNPs in CACNA1E with 
schizophrenia. Summarised in the table are p-values and odds ratio (OR) obtained from 
application of the χ2 test using Golden Helix©.  
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    Genotype 
    χ2 Test 
East UK Samples n Frequency (%)  p value  
SNP 2  
rs2280865: Intron 22 
 
  T/T T/C C/C   
Schizophrenia 107 29.9 56.1 14.0  0.325 
Controls 86 29.1 48.8 22.1  
SNP 4  
rs4652678: Exon 32   
 
  T/T T/C C/C   
Schizophrenia 130 50.8 43.1 6.1  0.308 
Controls 91 56.0 34.1 9.9  
SNP5 
rs704326: Exon 47 [T/A] 
 
  G/G G/A A/A   
Schizophrenia 135 22.2 48.2 29.6  0.720 
Controls 93 25.8 43.0 31.2  
 
Table 3.11 Summary of statistics for analysis of genotypic association of SNPs in 
CACNA1E in the East UK cohort. 
Analysis of genotype effect on risk for schizophrenia of three SNPs in CACNA1E was 
performed using the χ2 test. No significant associations were observed. 
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In order to identify possible haplotype associations with disease, the same two 
methods as those used for ZnT3 were applied for CACNA1E. The first approach was 
a moving-window analysis using Golden Helix© while the second one involved 
grouping haplotypes according to their similarity in order to decrease the degrees of 
freedom for the analysis. Linkage disequilibrium across the three SNPs in CACNA1E 
was estimated using Haploview with genotype data from controls and cases from the 
East UK cohort and represented as D’. Values of D’ were similar between controls 
and cases with strong LD observed particularly between SNPs 1 and 2 in both groups 
(Figure 3.15).  
Moving-window analysis did not reveal significant association of haplotypes with 
schizophrenia. Haplotype frequencies were very similar for controls and 
schizophrenia cases except for a difference observed in the most common 3-SNP 
haplotypes containing the major alleles for SNPs 2 and 4 and the minor allele of SNP 
5 (112; Figure 3.16). A second haplotype analysis was performed by defining two 
groups of similar haplotypes (Table 3.12) Fisher’s exact test was used to compare 
frequencies of haplotypes in group A and group B between controls and cases. 
Additionally, diplotypes were estimated for all individuals in the East UK cohort using 
PHASE v. 2.1. Subsequently, χ2 test was used to compare haplotype frequencies 
between controls and cases carrying both haplotypes belonging to either of the two 
groups (A,A or B,B) or one haplotype from each group (A,B). No significant 
association of haplotype with disease were identified from this analysis (Figure 3.17). 
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Figure 3.15 Linkage disequilibrium values for three SNPs in CACNA1E in the East 
UK cohort. 
Linkage disequilibrium (LD) values for three SNPs in CACNA1E calculated with Haploview, 
using genotyping data from controls and cases of the East UK cohort. Strong LD is observed 
across these three SNPs in both groups with D’ values between 0.67 and 0.92. 
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Figure 3.16 Frequencies of CACNA1E haplotypes in controls and cases of the East 
UK cohort. 
Frequencies of 3-SNP haplotypes of SNPs 2 (rs2280865), SNP 4 (rs4652678) and SNP 5 
(rs704326) in CACNA1E, in controls and cases from East UK.  
 
 152
 
 Haplotype Frequency (%) 
  Controls  Cases 
Group A 1-1-1 15.62  15.21 
 1-1-2 36.67  40.42 
 1-2-1 1.56  1.37 
Group B 2-1-1 17.88  13.85 
 2-1-2 4.10  3.05 
 2-2-1 21.13  22.69 
 2-2-2 2.68  3.27 
 
Table 3.12 Haplotype groups defined for CACNA1E in the East UK cohort. 
Two haplotype groups for CACNA1E were defined for the analysis of their contribution to risk 
for schizophrenia in the East UK cohort. Shared alleles and LD across markers was 
considered, especially between SNPs 2 and 4. No significant association was observed. 
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Figure 3.17 Frequencies of two haplotype groups of SNPs in CACNA1E in East UK 
cohort.  
Two groups of similar 3-SNP haplotypes were defined for CACNA1E. Frequencies of 
haplotypes in Group A were compared to those in Group B in controls and cases using 
Fisher’s exact test (A). Phased data was also used to compare diplotype frequencies in 
controls and cases using χ2 test (B). No significant associations of haplotype with disease 
were identified from this approach. 
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3.3.3 S100A8: Analysis of SNP genotype effect on gene expression 
and study of association with disease 
3.3.3.1 Correlation of SNP genotypes and haplotypes with mRNA levels in the 
ICPS cohort 
Allelic and genotypic effects of two SNPs in S100A8 with levels of expression of the 
gene were explored using RT-PCR validated data from BA10 region of controls and 
cases from the ICPS cohort. Genotype data of these SNPs is available in 
Supplementary Table 4 (Appendix C). Analysis was performed as described above for 
the other two genes, an initial factorial ANOVA was performed with three 
independent variables defined as disease status, genotype and SNP ID. The analysis 
revealed a significant effect of disease status on mRNA levels (p= 0.0083) but no 
effect of genotype. There was no significant interaction between these variables was 
found either (Figure 3.18). Bonferroni post-tests were performed in order to compare 
expression levels of each genoytpe between controls and cases with no significant 
differences observed.  
Finally, haplotype effects on gene expression were analysed. For this analysis, two 
haplotype groups were defined with the most common haplotype (1-1) in Group A, 
while the rare haplotypes (1-2, 2-1 and 2-2) were in Group B. Following the same 
methodology as the one used for the previous two genes, values of gene expression 
were correlated with genotype information for each individual, taking into account 
both haplotype pairs (diplotypes). Two-way ANOVA was performed to compare 
S100A8 mRNA levels in controls and cases either carrying both common haplotypes 
(A,A) or one or both haplotypes from group B (A,B and B,B). No significant effect of 
either disease status or diplotype was observed. Also, no significant interaction 
between these variables was found (Figure 3.19).  
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Figure 3.18 Correlation of genotype of two SNPs in S100A8 with expression levels 
in controls and cases of the ICPS cohort. 
The figure presents S100 mRNA levels of controls and cases according to the genotype of 
two SNPs in this gene. For clarity purposes the figure presents expression levels of 
individuals carrying two copies of the major allele separate to those with at least one copy of 
the minor allele. For three and two-way ANOVA values of expression were compared 
between controls and cases across all genotypes.  
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Figure 3.19 Analysis of the effect of two SNP diplotypes of S100A8 on mRNA 
levels in controls and cases of the ICPS cohort. 
For this analysis haplotypes were grouped in two groups (described above). Both haplotype 
copies (diplotypes) were considered for each individual. Two-way ANOVA was performed in 
order to compare S100A8 mRNA levels between controls and cases carrying either two 
copies of haplotypes in group A (controls n=18; cases n=20) or those carrying at least one 
of the haplotypes from group B (controls n=5; cases n=7). The analysis did not reveal any 
significant effect of disease status, genotype or interactions between these factors.  
 
 
 
 
 
 
 157
3.3.3.2 Analysis of association of SNPs and haplotypes in S100A8 with disease 
status in the East UK cohort 
Analysis of allelic and genotypic association of S100A8 with schizophrenia was carried 
out using genotype data for the two selected SNPs, in controls and cases from the 
East UK cohort. Both polymorphisms selected are located in potentially regulatory 
regions of the gene (Chen et al., 2006; Lomelin et al., 2010; Figure 3.20). Although 
none of them was identified as significantly correlated with levels of expression of 
the gene the possibility that they might contribute to risk of disease was interesting 
to explore. A χ2 test was applied in order to determine the contribution of alleles to 
risk of schizophrenia was assessed using Golden Helix©. No significant association 
resulted from this analysis for any of the two polymorphisms (Table 3.13). Analysis 
of genotype contribution to risk of disease was carried out using χ2 test and disease 
penetrance models (Additive, dominant and recessive) were tested using a logistic 
regression analysis. No significant associations of genotype with disease were 
observed by any of these two analyses (Table 3.14).  
Finally, in order to identify possible pairwise associations of the two SNPs in S100A8 
with schizophrenia, haplotype analysis was also performed using Golden Helix©. 
Haplotype frequencies between controls and cases were compared using χ2 test.  No 
significant associations were observed from this analysis.  
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  Frequency 
(%) 
 
 
East UK Samples n 
Minor 
Allele 
 
p value OR CI 95% 
SNP1 
rs3795391: Intron 1 
 
    
  G     
Schizophrenia 264 12.9  0.274 1.40 0.76-2.56 Controls 188 9.6  
SNP2  
rs3006488: 3’ UTR 
     
  C     
Schizophrenia 294 14.6  0.129 1.52 0.88-2.66 Controls 208 10.1  
 
Table 3.13 Summary of statistical analysis for allelelic association of SNPs in 
S100A8 in the East UK cohort. 
Allele frequencies were calculated from Golden Helix© analysis. OR and p values for 
association with schizophrenia were obtained using a χ2 test. No significant association with 
disease was observed for any of the two SNPs in East UK cohort. 
 
 
 
 
 
    Genotype 
    χ2 Test 
East UK Samples n Frequency (%)  p value  
SNP1 
rs3795391: Intron 1 
 
  A/A A/G G/G   
Schizophrenia 132 76.5 21.2 2.3  0.478 
Controls 94 83.0 14.9 2.1  
SNP2  
rs3006488: 3’ UTR 
 
  T/T T/C C/C   
Schizophrenia 147 74.1 22.5 3.4  0.305 
Controls 104 80.8 18.3 0.9  
 
Table 3.14 Summary of statistical analysis of genotypic associations of SNPs in 
S100A8 in controls and cases of the East UK cohort. 
Analysis of genotypic association of two SNPs in S100A8 with disease was performed using a 
χ2 test.  
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3.3.4 Analysis of epistatic interaction between genes involved in 
synaptic processes and intracellular signalling  
Analysis of gene-gene interactions was performed using the online application GAIA 
(http://gump.qimr.edu.au/GAIA/gaia.html). For this analysis, genotype data from 
controls and cases of the East UK cohort was used. Individual SNP associations 
observed for ZnT3 were confirmed by GAIA analysis. In addition a significant 
interaction was observed between SNP 4 (rs2083363) in ZnT3 and SNP 2 
(rs2280865) in CACNA1E (p=0.025). Moreover, interaction between SNP 4 
(rs4652678) of CACNA1E and both SNPs in S100A8 (p=0.0193: rs3795391 and 
p=0.0476: rs3006488) were also observed to increase the risk for disease (Figure 
3.21).  
Multiple testing was addressed by performing a permutation test (in-built in GAIA) in 
order to calculate an empirical p value. As discussed previously, this method was 
preferred over the Bonferroni’s correction because the latter is considered as too 
conservative since it does not take into account underlying LD patterns across 
markers. Although none of these interactions remained significant after correction 
using 1000 permutations, the interactions suggested by this analysis and the 
function of the three candidate genes suggest that gene-gene interactions within this 
group should be explored using a larger sample size and functional studies. 
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Figure 3.21 Analysis of epistatic interactions between ZnT3, CACNAIE and 
S100A8. 
Gene-Gene interactions observed between SNP4 in ZnT3 and SNP 2 in CACNA1E. Significant 
interactions were also observed between SNP 4 in CACNA1E and both SNPs in S100A8. 
However, none of the empirical p values were significant after 1000 permutations. 
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3.4 Discussion 
3.4.1 Analysis of SNP genotype effect on expression levels of ZnT3, 
CACN1E and S100A8 confirmed significant differences 
between controls and cases 
In the present study four SNPs in ZnT3, five SNPs in CACNA1E and two SNPs in 
S100A8 were selected in order to explore possible genotype effects on levels of 
expression of these candidate genes. For this purpose, validated expression data 
resulting from two previous expression profiles in BA10 and BA22 (Maycox et al., 
2002; Barnes et al., 2011) was used. From these studies expression of ZnT3 was 
reported as significantly decreased, while S100A8 was upregulated in BA10 of 
schizophrenic individuals when compared to controls from the ICPS cohort. Both 
CACNA1E and S100A8 were reported as upregulated in BA22 of schizophrenia cases 
of the ICPS cohort when compared to controls. RT-PCR data was available for 
expression of ZnT3 and S100A8 in BA10, as well as for expression of CACNA1E in 
BA22 of controls and cases from the ICPS cohort.  
A significant association of disease status with levels of expression of the three 
candidate genes analysed in this section was confirmed. The differences in mRNA 
levels between controls and cases of the ICPS cohort observed across all genotypes 
were consistent with the direction of the changes reported from microarray studies 
for each one of the three candidate genes. Particularly interesting was the case of 
ZnT3 where the analysis revealed a significant genotype by disease status 
interaction. Although Bonferroni post-hoc comparisons did not result in significant p 
values for any of the genotypes, it was remarkable that the differences that could 
account for the significant effect of disease status on expression of the gene were 
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observed only between controls and cases with the most common genotype (1/1) for 
all four SNPs. Furthermore, a significant interaction of disease status and diplotype 
was also observed from the analysis of the effect of two SNP haplotypes on ZnT3 
expression in controls and cases. As seen in single SNP genotype analysis, the 
greatest differences in expression levels between controls and cases were observed 
almost exclusively in individuals carrying both copies of the most common haplotype 
(1-1) for all SNP pairs. 
In contrast to what was observed for ZnT3, where the significant interaction of 
genotype and disease status with respect to gene expression reflected an overall 
genotype effect, in the case of CACNA1E there was no overall effect however, 
significant associations of individual genotypes were observed. Bonferroni post-hoc 
comparisons revealed significant differences in levels of expression of CACNA1E 
between controls and cases with the common genotype (1/1) of SNP 1 (rs17743547) 
and SNP 3 (rs35737760) and controls and cases with at least one copy of the rare 
genotypes (1/2 and 2/2) of SNP 2 (rs2280865). Additionally, significant differences in 
levels of expression were observed between controls and cases with at least one 
copy of the rare haplotypes (1-2, 2-1 and 2-2) of SNP pairs 1,2 and 2,4. The fact 
that no significant association of genotype with levels of expression was observed for 
SNP 4 (rs4652678) individually, affirms the importance of a haplotype-based 
approach that might reflect the underlying LD patterns across variants. These results 
are noteworthy in spite of the absence of an overall effect that could contribute to a 
significant interaction between disease status and genotype with respect to gene 
expression.  
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The results described above suggest that the four SNPs in ZnT3 contributing to an 
overall association of genotype with expression, and the four SNPs in CACNA1E 
whose genotype was significantly associated with expression levels, could be in 
strong LD with polymorphisms with regulatory properties. SNP rs6547521 is located 
in the 5’ region of ZnT3, which is interesting in the particular case of zinc transporter 
proteins since there is evidence of transcriptional regulation through zinc induced 
binding of metal-regulatory transcription factor 1 (MTF1) to metal-response elements 
(MREs) in target genes usually located in the 5’ UTR (Zheng et al., 2008). In 
addition, SNP rs11126936, in ZnT3 and SNPs rs17743547 and rs2280865 in 
CACNA1E are all located in intronic regions of the genes. It is currently a widely 
accepted that intronic DNA plays and important role in regulation of gene expression, 
although the precise mechanisms through which this regulation takes place are not 
yet clear and are the subject of extensive investigation (Lomelin et al., 2010). Thus it 
remains a possibility that these variants might be in strong linkage with other 
variants directly affecting gene expression. 
3.4.2 Significant association of single SNPs and haplotypes of ZnT3 
with schizophrenia 
Analysis of four SNPs in ZnT3 revealed significant allelic associations with 
schizophrenia for all markers when comparing controls and cases from the East UK. 
All of these associations remained significant after correction using FDR values. 
Moreover, genotypic association was also observed for SNP 3 (rs2083363) located in 
the 3’ flanking area of the gene. Interestingly, when a dominant model for disease 
penetrance was applied, all four polymorphisms were found to be associated with 
disease and these associations remained significant after correction for multiple 
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testing. Logistic regression models are a common method used in association studies 
because they are more flexible than traditional tests (Clarke et al., 2011). This 
approach has increasingly been used in recent years for GWAS and candidate gene-
base studies of association (Le Hellard et al., 2010; Bae et al, 2011). 
Finally, a moving-window haplotype analysis revealed significant association with 
disease of two-SNP haplotypes and four-SNP haplotypes containing either major 
alleles for all SNPs (1-1 or 1111) or minor alleles of all SNPs (2-2 or 2222). It was 
seen that those associated haplotypes containing only major alleles had a protective 
effect, while associated haplotypes with only minor alleles, significantly increased the 
risk of disease. These results are consistent with associations with schizophrenia 
observed from analysis of single SNPs and with the strong LD patterns observed 
across all four polymorphisms in controls and cases of the East UK cohort. In 
addition, four-SNP haplotype analysis revealed a significant association with disease 
when common and rare haplotypes were grouped, according to their evolutionary 
similarity, into two categories and their frequencies were compared between controls 
and cases. 
In summary, these findings suggest that ZnT3 may be an important candidate gene 
for schizophrenia, further to the previously reported downregulation of ZnT3 in BA10 
of patients compared to controls, which was confirmed in two independent cohorts 
(Maycox et al., 2009). The identification of ZnT3 as sole transporter of the 
presynaptic chelatable zinc makes it the more functionally relevant in relation to 
schizophrenia. Although knock out of the gene in mouse and rat models had failed to 
produce a strong recognisable phenotype except for a relatively increased 
susceptibility to induced seizure (Cole et al., 1999; 2000; 2001), a recent study has 
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reported a seemingly age dependent cognitive phenotype in ZnT3 knock out mice at 
6 months but not at 3 months of age. These findings were supported by significantly 
reduced expression of proteins implicated in memory and learning in older mice, 
including NMDAR2A/R2B subunits and AMPAR (Adlard et al., 2010). These data are 
consistent with previous findings of the effects of dietary zinc deficiency in age-
dependant cognitive impairment in rats (Keller et al., 2001) as well as observations 
that deficiency of maternal dietary zinc affects expression of NMDAR subunits in 
pups, which persists until adult life (Chowanadisai et al., 2005). 
3.4.3 No significant association of SNP or haplotypes of CACNA1E 
or S100A8 with schizophrenia 
Although no significant differences were observed for single SNPs or haplotypes in 
either CACNA1E or S100A8 with disease status, these genes remain worthy of 
consideration not only due to the previously reported upregulation of these genes in 
BA22 (and of S100A8 in BA10) but also because of their location in chromosome 
1q21, a region previously linked with schizophrenia (Brzustowicz et al., 2000; 
Hovatta et al., 1999; Ekelund et al., 2001). A number of factors could account for the 
lack of genetic association reported in the present study of CACNA1E or S100A8 
with schizophrenia in a case-controls sample of European background. Amongst the 
drawback encountered in the present study it is perhaps important to consider the 
limited availability of characterised markers within the S100A8 region, as well as the 
fact that some of the polymorphisms analysed in CACANA1E turned out to be 
uninformative.  
Other reports provide additional support for the study of these genes in the context of 
schizophrenia. Knock out mouse models of CACNA1E (-/- CaV2.3) have been 
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generated with a variety of phenotypes. Notably, alterations in pain perception 
(Saegusa et al., 2000; 2002), response and tolerance to morphine and cocaine (Han 
et al., 2002; Yokoyama et al., 2004; Osanai et al., 2006), impaired spatial memory 
(Kubota et al., 2001) as well as behavioural changes including increased anxiety and 
fear (Lee et al., 2002). Other phenotypes observed in the -/- CaV2.3 models include 
low seizure susceptibility (Weiergraber et al., 2007; 2008). In addition, there has 
been a suggestion of an important role of S100A8 in embryogenesis (Passey et al., 
1999) and cell differentiation (Siegenthaler et al., 1997). 
An interesting possibility to be explored is that the increased expression of 
CACNA1E and S100A8 in schizophrenia might be indicative of disturbances in the 
inflammatory response. In recent years there has been an increasing interest in the 
investigation of inflammatory processes in the context of schizophrenia 
pathophysiology. One reason for this is the apparent close relation between chronic 
inflammation and metabolic syndrome (Monteiro and Azevedo, 2010) and the high 
incidence of antipsychotic-induced lipid abnormalities and disturbed glucose 
metabolism (Arranz et al. 2004; McEvoy et al., 2005) in schizophrenia patients. 
These findings are particularly interesting when considering the growing evidence of 
metabolic disturbance in schizophrenia patients, as well as reports of increased risk 
of type-2 diabetes in schizophrenia patients across different populations (Sugawara 
et al., 2010; Lin and Shuldiger, 2010). Decreased glucose tolerance and insulin 
secretion have also been reported in mouse models of CaV2.3 deficiency (Matsuda et 
al., 2001; Pereverzev et al., 2002; Jing et al., 2005), consistent with recent evidence 
of SNP associations in the CACNA1E gene with type 2 diabetes (Holmkvist et al., 
2007). Furthermore, there have been reports of increased expression of another 
 168
member of the S100 family of proteins, S100B in schizophrenia, a gene that has 
been associated with insulin resistance (Steiner et al., 2010). 
Moreover, recent studies have reported increased expression of inflammation-related 
genes such as interferon gamma (IFN-γ) and tumour necrosis factor alpha (TNF-α) in 
schizophrenia cases compared to controls, even in drug-naïve patients (Saetre et al., 
2007; Reale et al., 2011). Interestingly, a number of reports have proposed that one 
of the mechanisms of regulation of the S100A8 gene occurs through TNF, INF-γ and 
interleukin-10 (IL-10) in macrophages (Xu and Geczy, 200; Xu et al., 2001). The 
latter is a type of activation that has been also observed in and colon cancer cells in 
a process that involves activation of the MAPK and JNK/p38 pathways (Ichikawa et 
al., 2011).  
3.4.4 Evidence of modest epistatic interaction between two SNPs in 
ZnT3 and CACNA1E and four SNPs in S100A8 and CACNA1E 
In a simplified manner, if we consider an interaction between two loci, epistasis 
refers to a situation where the effect of the first gene on a particular phenotype 
depends on the genotype of the second one. This phenomenon has increasingly 
been investigated in relation to diseases susceptibility in relation to complex 
disorders and particularly to schizophrenia (Carlborg and Haley, 2004; Daly and 
Altshuler, 2005; Moore, 2005). Indeed, evidence of epistasis between candidate 
genes in schizophrenia has been reported in a number of studies, particularly 
involving the COMT, NRG1, the gene coding for AKT1 protein, RGS4, DAOA and the 
disrupted in schizophrenia 1 (DISC1) genes (Straub et al., 2007; Nicodemus et al., 
2007; 2010; Sei et al., 2010). Epistatic interactions of COMT with the aldehyde 
dehydrogenase 3B1 (ALDH3B1) gene have also been reported (Wang et al., 2009).  
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The exploratory analysis of gene-gene interactions performed using GAIA with 
genotype data from the East UK cohorts revealed significant nominal p values for 
interactions between SNP rs4652678 in ZnT3 and SNP rs2280865 in CACNA1E and 
between SNP rs4652678 in CACNA1E with both SNPs in S100A8 (rs3795391 and 
rs3006488). The analysis also confirmed the significant association of the four SNPs 
analysed in ZnT3 with schizophrenia. Although empirical p values calculated by 1000 
permutations in GAIA for these effects did not remain significant, the indication of 
epistatic interactions among these genes, contributing to risk of schizophrenia is 
worthy of further exploration. Particularly interesting are gene-gene interactions 
between CACNA1E and S100A8 for their close functional relation and possible 
implication to metabolic syndrome in schizophrenia.  
3.4.5 Conclusion 
The results presented in this section provide evidence for association of four SNPs in 
ZnT3 with schizophrenia in the East UK cohort of controls and cases of European 
descent. In addition, significant haplotype associations with disease were also 
observed when grouping haplotypes by their similarity, in order to avoid comparisons 
between rare and common haplotypes (Morris, 2008). Considering the LD patterns of 
the four analysed SNPs in ZnT3, these findings are consistent with previous studies 
in which the use of a haplotype-based approach resulted in an increased power to 
detect associations of candidate genes with schizophrenia (Petterson et al., 2010; 
Vosey et al., 2010a; 2010b; Burdick et al., 2010) Moreover, the results further 
support the implication of ZnT3 in schizophrenia pathophysiology suggested from a 
previous microarray study (Maycox et al., 2009) from which the gene was found to 
be significantly downregulated in BA10 of schizophrenia subjects in two independent 
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cohorts. Even though analysis of the effect of SNP genotype on levels of expression 
of ZnT3 did not result in any significant correlations, it is possible that the associated 
markers might be in strong LD with another SNP with a regulatory effect on 
transcription.  
ZnT3 is a strong candidate gene for schizophrenia due the specific localization of the 
gene in synaptic vesicles of different neuronal populations (Palmiter et al., 1996; 
Wenzel et al., 1997; Paoletti et al., 2009). Although the specific function of metallic 
zinc and of the ZnT3 regulation in synaptic processes has not been clearly 
established, there are some clues that point to its role in a number of processes, 
including memory and learning (Frederickson et al., 1990; Whittle et al., 2009). As 
an example, it has been established that zinc-releasing neurons are also 
glutamatergic and that their somata are mainly located in cerebral cortex and limbic 
structures (Sindreu et al., 2003; Frederickson et al., 2005; Paoletti et al., 2009), 
indicating a role in telencephalic information processing (Slomianka et al., 1990). 
Furthermore, it has been shown that endogenous zinc has a role in modulation of 
synaptic plasticity through inhibition of NMDA receptors in different brain regions 
(Vogt et al., 2000; Low et al., 2000; Coughenour and Barr, 2001; Sindreu et al., 
2003; Izumi et al., 2006; Madry et al., 2007; Gielen et al, 2009; Takeda et al., 2010). 
Finally, association of other zinc-related genes with schizophrenia has been 
previously reported. Perhaps the most notable case being the SNP rs13447006 in the 
gene for zinc finger protein 804A (ZNF804A) identified and further replicated from 
two GWAS (O’Donnovan et al., 2008; ISC, 2009).  
Finally, although no association of either CACNA1E or S100A8 with disease status 
was observed, significant epistatic interactions between these two genes were 
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suggested by an exploratory analysis. This was also the case for CACNA1E and ZnT3. 
The evidently complex regulation of the calcium channels and the numerous 
processes in which they are implicated makes the elucidation of their implication in 
schizophrenia more of a challenge. In addition it is important to consider the 
possibility that the observed changes in regulation of the gene are part of either a 
compensatory mechanism or related to co-morbidity of the disorder. An example of 
this could be a possible relation between the observed association of CACNA1E with 
glucose metabolism and insulin release (Matsuda et al., 2001; Jing et al., 2005) and 
the metabolic syndrome observed in patients under antipsychotic treatment.   
 
 
 
 
 
 
 
 
 
 
 172
 
 
 
 
CHAPTER 4 Correlation of gene expression with 
genotype and genotype with disease status of 
genes involved in Wnt signalling pathway. 
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4.1 Introduction 
Wnt signalling refers to intracellular processes initiated by activation of cysteine-rich 
secreted ligands known as Wnt proteins. Wnt proteins have been shown to control a 
variety of mechanisms through different pathways. Perhaps the most extensively 
studied of these is the canonical Wnt signalling pathway, which is characterised by 
the activation of target genes through the translocation of the protein β-catenin to 
the cell nucleus. In addition, two other non-canonical pathways have been 
recognised: The planar cell polarity pathway and the calcium (Ca2+) pathway (Figure 
4.1 from Rao and Kühl, 2010).  
 
 
Figure 4.1 Simplified representation of Wnt signalling pathways. 
The three types of Wnt signalling are represented from left to right: The canonical Wnt 
signalling pathway, which involves regulation of β-catenin; the calcium Wnt pathway, 
characterised by mediation of calcineurin (CaCN) and finally the planar cell polarity pathway, 
which involves jun N-terminal kinase (JNK) induced cytoskeletal rearrangements (From Rao 
and Kühl, 2010) 
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While the important role of Wnt signalling in processes such as cell proliferation, cell 
fate specification and cell migration during developmental stages has been well 
established over the past twenty years (Gavin et al., 1990; Moon et al., 1997; 2004; 
Wodarz and Nusse, 1998; Dale, 1998; Miller, 2002; Logan and Nusse, 2004), it was 
only recently recognised that Wnt pathways are also involved in the modulation of 
synaptic function and memory consolidation in adult CNS in mammals (Sokol et al., 
1991; Ahmad-Annuar et al., 2006; Lucas and Salinas, 1997; Hirabayashi et al., 2004; 
Chen et al., 2006; Beaumont et al., 2007; Maguschak and Ressler, 2008; Wexler et 
al., 2008; Salinas and Zou, 2008; Avila et al., 2010). These findings have suggested 
that disruptions in Wnt signalling, or related proteins, might be implicated in the 
pathophysiology of schizophrenia and other neurological disorders. Increased 
immunoreactivity of Wnt-1 has been observed in pyramidal neurons of CA3 and CA4 
regions in brains of schizophrenic subjects when compared to unaffected individuals 
(Miyaoka et al., 1999). The opposite was observed for β-catenin and γ-catenin whose 
expression was reduced in hippocampus of schizophrenia cases (Cotter et al., 1998). 
In addition, downregulation of the glycogen synthase kinase 3 beta (GSK-3β) has 
been demonstrated in frontal cortex of schizophrenia cases (Kozlovsky et al., 2000; 
2004; Beasley et al., 2001). Finally, it was recently suggested that some atypical 
antipsychotics contribute to activation of canonical Wnt signalling in a dishevelled-3 
dependant manner via D2 dopamine receptors (Sutton et al., 2007).  
It has been proposed that interactions between genetic and environmental factors 
during the early stages of neurodevelopment could account for the abnormalities in 
morphology and connectivity observed in the schizophrenic brain (Harrison, 1999; 
Gregorio et al., 2009; Kobayashi et al., 2010). The potential involvement of a 
disruption in Wnt signalling in the pathophysiology of schizophrenia is consistent with 
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this neurodevelopmental hypothesis and represents an intriguing subject for 
investigation.  
4.1.1 Overview 
4.1.1.1 Correlation of genotype with levels of expression 
In the second part of the analysis, three genes involved in the canonical Wnt 
signalling pathway whose expression was significantly changed in schizophrenia from 
previous studies (Ftouh et al., 2005; Maycox et al., 2009; Barnes et al., 2011) were 
selected. Polymorphisms in each gene were genotyped in controls and cases from 
the ICPS cohort. Expression data provided from the previously described microarray 
studies (Maycox et al., 2009; Barnes et al., 2011) was then used to determine the 
effect of genotype/haplotype on levels of expression, as described in section 3.1.1.1. 
Haplotype associations with gene expression were analysed by grouping haplotypes 
according to their ancestral similarities, taking into account LD patterns across SNPs. 
Haploview was used to estimate LD values while diplotypes for each individual were 
estimated using PHASE v. 2.1. Correlation of diplotype with expression levels was 
then performed using a two-way ANOVA.  
4.1.1.2 Analysis of association of genotype with schizophrenia 
Further analysis of association with disease was carried out using the East UK cohort. 
A logistic regression model was applied for identification of significant allelic effect on 
risk of schizophrenia. Genotypic associations were tested using χ2 test and logistic 
regression was used for testing three other genetic models where the effects of 
genotypes containing the associated allele ‘D’ are compared to those carrying the 
wild-type allele only ‘d’: An additive model where risk of disease is DD>Dd>dd, a 
dominant model where (DD,Dd>dd) and a recessive model where DD>(Dd,dd) were 
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tested. All tests were applied using Golden Helix© software. Analysis of association of 
haplotypes with disease was performed using the same two approaches used for 
previously described candidate genes. Initially a moving-window haplotype analysis 
was performed using Golden Helix©. A second analysis was later performed by 
grouping similar haplotypes and comparing their frequencies in controls and cases 
using Fisher’s χ2 test. Additionally, PHASE v. 2.1 was used to estimate diplotypes for 
each individual and compare their frequencies in controls and cases, using a χ2, as it 
has been previously described.  
Finally, we considered the possibility of an interaction between polymorphisms 
located in different genes associated with Wnt signalling on the risk of schizophrenia. 
For this reason, statistical epistasis between pairs of genes was tested as well, in the 
East UK cohort, using GAIA. 
4.1.2 Selected candidate genes 
For this part of the study, three candidate genes were selected for their involvement 
in the Wnt signalling pathway. Polymorphisms in the secreted Frizzled–related 
protein 3 (SFRP3 or FRZB), the Wnt1 inducible signalling pathway protein 3 (WISP3) 
and the third member of the Dickkopf family of proteins (DKK3) were genotyped for 
analysis of association with gene expression and disease status. 
The first candidate gene, SFRP3 or FRZB belongs to a family of Wnt modulators of 
Wnt signalling. These proteins were initially considered to be Wnt antagonists due to 
the fact that they possess a cysteine rich domain (CRD) homologous to the Wnt 
binding domain of the Frizzled proteins. Several studies confirmed this interaction 
(Wang et al., 1997a; Lin et al., 1997; Bafico et al., 1999) however, data collected 
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from other studies suggest the existence of alternative mechanisms of interaction of 
SFRP3 with Wnt and Frizzled proteins that in some cases could also lead to activation 
of Wnt signalling (Wang et al., 1997b; Yoshino et al., 2001; Bovolenta et al., 2008; 
Kress et al., 2009; Mii and Taira, 2009; von Marschall and Fischer, 2010). 
A number of studies have provided evidence suggesting that FRZB and other SFRPs 
might have an important role in regulation of cell proliferation (Bi et al., 2009) and as 
a tumour suppressor in various types of cancer (Zi et al., 2005; Veeck et al., 2006; 
2008a; Dahl et al., 2007; Guo et al., 2008; Qu et al., 2008; Berndt et al., 2009; 
Kongkham et al., 2010). We selected FRZB for analysis of genetic association with 
schizophrenia based on the highly significant reduction in FRZB mRNA levels in BA10 
in schizophrenia patients when compared to controls (Figure 4.2; Maycox et al., 
2009). From the microarray data analysis a 1.6 fold decrease in mRNA levels of FRZB 
was observed in patients when compared to controls (p=0.003). Validation of this 
data using qPCR, later confirmed the significant downregulation of FRZB in 
schizophrenia (p=0.008). To our knowledge, no other reports of the involvement of 
FRZB in psychiatric disorders have been made previously.  
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Figure 4.2 Significant difference in levels of expression of FRZB (SFRP3) in BA10 
post-mortem tissue between schizophrenia cases and controls (Maycox et al., 
2009) 
Data from the microarray performed by Maycox et al., (2009) using two independent assays, 
one of which includes samples from the ICPS cohort. A 1.6 fold decrease in the expression of 
FRZB was observed in schizophrenia subjects when compared to controls (p=0.003). Further 
validation by QPCR confirmed this result (p=0.008). 
The second candidate gene selected for this section was the Wnt1 inducible 
signalling pathway protein 3 (WISP3). Along with WISP1 and WISP2, WISP3 is a 
member of the CCN family of secreted growth factors, which also contains (and owes 
its name to) connective tissue growth factor (Ctgf), cysteine-rich protein 61 (Cyr61) 
and nephroblastoma over-expressed (Nov). CCN proteins have been recognised as 
important extracellular matrix (ECM) modulators of cellular response to 
environmental input. CCN proteins have been shown to participate in the regulation 
of embryonic development and in adult organisms they have been found to be 
important in inflammatory responses and injury repair. Moreover, there is evidence 
for the involvement of CCN factors in tumour cells proliferation, apoptosis and 
haematopoietic stem cells self-renewal processes (Chen et al., 2009). 
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Investigation of WISP3 has mainly focused on mutations that cause progressive 
pseudorheumathoid dysplasia (PPD), an autosomal recessive disorder characterised 
by progressive degeneration of the cartilage. The onset of the disease is typically 
between three and eight years of age and with no extraskeletal symptoms reported 
to date in PPD patients (Hurvitz et al., 1999, Nakamura Y et al., 2007). These 
findings led to the conclusion that human WISP3 acts mainly as a modulator of 
skeletal growth and homeostasis. However, reports of differential expression of 
WISP3 in colon cancer cells, compared to normal cells, have opened up a second line 
of research for the elucidation of the functional roles of this gene. From these first 
reports, several studies have been carried out to explore the mechanisms through 
which WISP3 contributes to tumorigenesis in colon and other types of cancer. These 
mechanisms seem to be closely related to the role of WISP3 in Wnt signalling 
processes and have been extensively explored within this context (Pennica et al., 
1998; Kleer et al., 2002; 2004; 2007; Cervello et al., 2004; Zhang et al., 2005; 
Huang et al., 2010; Frank et al., 2010). 
Although up until now, there are no reports of the involvement of WISP3 in 
schizophrenia aetiology, a significant increase in the mRNA levels of WISP3 in 
schizophrenia patients compared to controls was found in a microarray study of BA22 
described previously (Appendix A; Barnes et al., 2011). Moreover, further validation 
of these findings in controls and cases of the ICPS cohort using qPCR confirmed the 
up-regulation of the gene in schizophrenia (p=0.03). 
The third gene considered for this part of the study was a member of the Dickkopf 
family of proteins (DKK3). Dickkopf proteins are secreted glycoproteins particularly 
known for their role in regulation of the Wnt signalling pathway. The family of 
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human Dickkopf proteins consists of DKK1, 2, 3 and 4 and is characterized by two 
highly conserved cysteine-rich domains (Cys-1 and Cys-2). An additional fifth 
member, soggy, has been identified and seems to be structurally related to DKK3 but 
lacks the cysteine domains (Krupnick et al., 1999). From the five members of this 
family, DKK1 is the most studied as it was identified as a potent inhibitor of the Wnt 
signalling pathway during head induction in Xenopus embryos (Glinka et al., 1998).  
DKK3 has been extensively investigated in the context of cancer due to the observed 
down-regulation of the gene in immortalized cells when compared to normal cells 
(Tsuji et al., 2000; 2001). For this reason the gene is also known as REIC (reduced 
expression in immortalised cells). Down-regulation of DKK3 has also been reported in 
a variety of cancer cell lines and tumour tissue samples, in many cases due to 
epigenetic mechanisms (Nozaki et al., 2001; Kobayashi et al., 2002; Abarzua et al., 
2005; 2007; Edamura et al., 2007; Roman-Gomez et al., 2004; 2007; Untergasser et 
al., 2008; Lee EJ et al., 2009; Veeck et al., 2008b; Chim et al., 2008; Yue et al., 
2008).  
Although DKK3 has been mainly regarded as a tumour suppressor there are a few 
reports that suggest a possible involvement of this gene in the pathophysiology of 
schizophrenia. The present work extends previous findings from a post-mortem 
study of tissue samples from BA22 of controls and schizophrenia cases carried out by 
Ftouh et al. (2005). Using suppression subtractive hybridization, the authors 
identified a sequence whose expression was reduced in schizophrenia. The sequence 
was later recognised to be part of the DKK3 gene. Further validation of these results 
by slot blot hybridization revealed that expression of DKK3 in schizophrenia was 
reduced by 35% compared to mRNA levels in controls (p<0.026). Moreover, 
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quantitative PCR (RT-PCR) confirmed these findings with a significant reduction of 
mRNA levels of DKK3 in cases (p<0.012). Additional support for the implication of 
DKK proteins in the aetiology of schizophrenia has been provided by a recent report 
of an association of a SNP in DKK4 (rs2073665) with the disease from both family 
and case/control studies (Proitsi et al., 2008). 
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4.2 Methodology 
4.2.1 Selection of polymorphisms 
The selection of SNPs of interest was performed as described in section 3.2.1 using 
data from the open access HapMap database (http://hapmap.ncbi.nlm.nih.gov; Table 
4.1). Four SNPs were selected in the FRZB gene: SNP 1 (rs10206992) and SNP 2 
(rs7607737) are both located in intron 1, SNP 3 (rs288329) is located in intron 3 and 
finally SNP 4 (rs16823799) is located in the 3’ untranslated region (UTR) of the gene. 
These four SNPs were of interest due to their location in regions with potential for 
regulation of gene expression (Chen JM et al., 2006; Lomelin et al., 2010). For 
analysis of WISP3 only three SNPs were selected: SNP 1 (rs2280153) and SNP 2 
(rs1230348) are both located in intron 2 while SNP 3 (rs130345) is a coding variant 
located in exon 3 resulting in a change in the amino acid residue of the protein from 
glutamine (Q) to histidine (H). Finally, three more SNPs were selected for analysis of 
DKK3. SNP 1 (rs2291599) located in intron 5, SNP 2 (rs7480026) and SNP 3 
(rs3206824) in exon 8. The latter is also a non-synonymous variant resulting in a 
change in amino acid from arginine (R) to glycine (G). All three SNPs are present in 
the two identified isoforms of the DKK3 gene. 
 
 
 
 
 
 183
 
FRZB     Frequency (%) 
 
SNP Location 
 
n 
 
T/T T/G G/G  G 
rs10206992 Intron 1  113  54.9 38.1 7.1  26.1 
     C/C C/T T/T  T 
rs7607737 Intron 1  113  75.2 23.0 1.8  13.3 
     C/C C/T T/T  T 
rs288329 Intron 3   62  72.6 21.0 6.5  16.9 
     G/G G/A A/A  A 
rs16823799 3’   113  88.5 8.8 2.7  7.1 
          
WISP3          
     G/G G/A A/A  A 
rs2280153 Intron 2  113  60.2 36.3 3.5  21.7 
     G/G G/A A/A  A 
rs1230348 Intron 2  113  43.4 44.2 12.4  34.5 
     G/G G/T T/T  T 
rs1230345 
Exon 23 
[Q⇒H] 
 
113 
 
58.4 37.2 4.4 
 
23.0 
DKK3          
     G/G G/A A/A 
 
A 
rs2291599 Intron 5  62  61.3 35.5 3.2  21.0 
     C/C C/T T/T 
 
T 
rs7480026 Intron 6  113  87.6 12.4 0.0  6.2 
     G/G G/A A/A 
 
A 
rs3206824 
Exon 8 
[R⇒G] 
 
113  54.9 41.6 3.5  23.3 
 
Table 4.1 HapMap frequency data of SNPs selected in FRZB, WISP and DKK3 
Frequency data available from the HapMap database for all SNPs in genes involved in Wnt 
signalling pathway. The data shown in the table above corresponds to the HapMap CEU 
cohort, composed of unrelated individuals of European ancestry from the CEPH collection.  
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4.2.2 Genotyping 
Genotyping was performed by polymerase chain reaction (PCR) amplification of the 
gene fragment containing the SNP of interest, followed by restriction enzyme 
digestion for determination of genotype frequencies, as described in section 3.2.2. 
Primer pairs for SNP genotyping were designed so that the CG content was not 
higher than 55% (Supplementary Table 3; Appendix B).  
4.2.3 Analysis of correlation of genetic variation with gene 
expression 
Correlation of genetic variation with gene expression was performed using genotype 
data from cases and controls from the ICPS cohort using the methodology described 
in section 3.2.3. . Genotypic associations with mRNA levels of single SNPs for all 
candidate genes were tested by analysis of variance (ANOVA) using Prism v. 5 
software (Graph Pad). Deviation from normality of the data was assessed by in-built 
Prism tests such as the D’Agostino and Pearson and Kolmogorov-Smirnov normality 
tests. For each gene an initial three-way ANOVA was performed using disease status, 
genotype and SNP ID as three independent variables with expression as the 
outcome. Further two-way ANOVA was then used to compare expression levels 
between controls and cases and across genotypes.  
Analysis of the effect of haplotypes on gene expression was performed using both 
haplotype copies for each individual (diplotypes) as described in section 3.2.3. For 
each candidate gene two groups of haplotypes were defined according to their 
ancestral similarity: A and B. Individuals containing diplotypes composed of two 
haplotypes from group A were then compared to diplotypes comprising one or two 
copies of haplotypes in group B.  
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4.2.4 Analysis of SNP association with disease status 
Analysis of association with schizophrenia of the three candidate genes involved in 
Wnt signalling pathway was also performed using schizophrenia samples and 
controls from the East UK cohort. The analysis was carried out using the same 
procedure described in section 3.2.4.  
For estimation of allelic association with disease, a logistic regression model was 
applied in order to estimate odds ratio and p values using Golden Helix©. Genotypic 
associations were evaluated using a χ2 test and logistic regression in order to 
incorporate the three models for disease penetrance previously described. 
Corrections for multiple testing were performed by calculating false discovery rate 
(FDR) values using Golden Helix© SVS7.  
Haplotype analysis was performed using a moving window approach in the Golden 
Helix© software as well as a second analysis performed by comparing frequencies in 
controls and cases of diplotype, as described in section 3.2.4.  
4.2.5 Analysis of epistatic interactions between candidate genes 
For the participation of these candidate genes in the Wnt signalling pathway, it was 
considered of great interest to explore the possible statistical epistasis within this 
group contributing to an increased risk of schizophrenia. This analysis was carried 
out using genotype data for FRZB, WISP3 and DKK3 in controls and cases from the 
East UK cohort. For this analysis, the web-based application GAIA was used for 
calculation of p values for interaction (as it has been discussed in section 3.2.5).  
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4.3 Results 
In this section, the analysis of the correlation of genotype with mRNA levels and 
disease status of FRZB, WISP3 and DKK3, three genes implicated in Wnt signalling 
pathway, are described. The effect of genotype on gene expression in the ICPS 
cohort supported the significant differences in expression of these candidate genes in 
schizophrenia subjects compared to healthy controls previously reported from the 
microarray study. Significant association of genotype with gene expression was 
observed for four SNPs in FRZB. Moreover, significant associations between mRNA 
levels were detected for individual diplotypes of FRZB using ANOVA to compare gene 
expression levels of controls and cases with two-SNP haplotypes (1-1/1-1) or at least 
one copy of the rare haplotypes (1-2, 2-1 and 2-2).  
The results of genotype association with schizophrenia using the East London cohort 
are also described in this chapter. Although not maintained after correction for 
multiple testing, a nominal significant association with disease was identified for the 
minor allele of SNP 2 (rs7480026) in DKK3, using a χ2 test. In addition a significant 
effect of genotype of the same SNP 2 on disease status was identified when using 
logistic regression for application of an additive model of disease penetrance. This 
association however, was not maintained after correction for multiple testing using 
FDR values. 
Analysis of the effect of haplotype on disease status was performed using a moving-
window approach with the Golden Helix© software. This analysis resulted in 
significant association with disease of three haplotypes in WISP3 and four haplotypes 
in DKK3. In order to correct for multiple testing, FDR values were calculated based 
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on the Benjamini-Hochberg method. After this procedure, none of the haplotypes 
identified remained significantly associated with schizophrenia, in spite of the notable 
differences in LD patterns between controls and cases for all three genes.  
Finally, an exploratory analysis of gene-gene interactions between the three 
candidate genes analysed in this chapter, resulted in modest evidence for statistical 
epistasis between SNP 1 (rs10206992) in FRZB and SNP 2 (rs1230348) in WISP3. 
Once more, correction for multiple testing resulted in a loss of significance for this 
interaction so further investigation of statistical epistasis between these two genes is 
necessary.  
4.3.1 FRZB: Analysis of SNP genotype effect on expression levels 
and study of association with disease 
4.3.1.1 Correlation of SNP genotypes and haplotypes with mRNA levels in the 
ICPS cohort 
Four SNPs in FRZB were genotyped in controls and cases of the ICPS cohort 
(Supplementary Table 4; Appendix C) for correlation with mRNA data from BA10. 
FRZB was reported from a previously discussed microarray study as significantly 
downregulated in schizophrenia compared to controls in BA10 (Maycox et al., 2009). 
An initial three-way ANOVA revealed a significant association of disease status with 
expression  (p= 6.49 x 10-11). No significant effect of genotype or SNP ID was 
identified and no interactions between variables were observed. Further two-way 
ANOVA confirmed the significant effect of disease status on levels of expression 
(p<0.0001). Furthermore significant associations of individual SNPs with expression 
levels were obtained after Bonferroni post-hoc comparisons. Significant differences in 
mRNA levels of FRZB were seen between controls and cases with the common 
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genotype (1/1) of SNP 2 (p<0.05), SNP 3 (p< 0.01) and SNP 4 (p< 0.05), as well as 
those with at least one copy of the minor allele (genotypes: 1/2 and 2/2) of SNP 1 
(p< 0.01; Figure 4.3).
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Figure 4.3 Analysis of SNP genotype and disease status effect on mRNA levels of 
FRZB. 
Levels of expression of FRZB in BA10 are presented in this figure for controls and 
schizophrenia cases of the ICPS cohort. For comparison, two separate histograms are 
shown, for of individuals homozygous for the major allele (1/1), for the four SNPs analysed, 
and mRNA and for subjects with at least one copy of the minor allele (1/2 + 2/2). Three and 
two-way ANOVA was performed by comparing all genotypes in controls and cases across all 
SNPs. 
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Following single SNP analysis, the effect of two-SNP haplotypes on levels of 
expression was assessed. Two-way ANOVA was used to compare mRNA levels of 
controls and cases for subjects with two copies of the common haplotype (1-1/1-1) 
and subjects with at least one copy of the minor allele haplotypes (1-2, 2-1 and 2-2). 
Association of individual diplotypes with gene expression was identified from 
Bonferroni post-tests, that resulted in significant differences in expression levels for 
individuals with at least one copy of haplotypes 1-2, 2-1 or 2-2 of SNPs 1 and 2 (p< 
0.0001), SNPs 1 and 3 (p< 0.01), SNPs 1 and 4 (p< 0.01) and SNPs 2 and 4 (p< 
0.05) as well as for individuals with both copies of the most common haplotype of 
SNPs 2 and 3 (p< 0.05; Figure 4.4).  
Finally, four-SNP haplotypes were correlated with levels of expression by grouping 
haplotypes into two groups according to their likely evolution. Phased data was 
obtained for controls and cases of the ICPS cohort, using PHASE v. 2.1 and 
Haploview was used to determine LD patterns across the four polymorphisms. Since 
linkage disequilibrium values for controls and cases were highest between SNP 1 and 
SNP 2 (D’=1), haplotype groups were defined as those containing the major allele for 
SNP 1 in Group A and those carrying the minor allele for SNP 2 in Group B (Table 
4.2). Once these groups were defined, expression levels were compared between 
controls and cases carrying both copies of haplotypes in Group A (A,A) with those 
having at least one copy of haplotypes in Group B (A,B and B,B). Two-way ANOVA 
yielded a significant effect of disease status (p= 7.0 x 10-4) and a significant 
interaction of disease status with diplotype (0.0143). Furthermore, Bonferroni post-
tests revealed a significant difference in mRNA levels for FRZB of controls compared 
to cases carrying at least one of the haplotypes in Group B (Figure 4.5). These 
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results further confirmed the significant association of defined diplotypes with levels 
of expression, which was also evident from the previous analysis of two-SNP 
haplotypes. 
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Figure 4.4 Analysis of the effect of two-SNP diplotypes of FRZB on mRNA levels in 
controls and cases of the ICPS cohort.  
Levels of expression of FRZB in BA10 are shown in this figure for controls and schizophrenia 
cases across all SNP pairs. mRNA levels are presented in two separate histograms for clarity: 
one for individuals carrying both copies of the most common haplotype (1-1/1-1) and a 
second histogram for those carrying at least one copy of haplotypes 1-2, 2-1 or 2-2. Three 
and two-way ANOVAs were performed by comparing both diplotype groups.  
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 Haplotype Frequency (%) 
  Controls  Cases 
Group A 1-1-1-1 58.93  42.37 
 1-1-1-2 1.22  1.29 
 1-1-2-1 5.91  11.79 
 1-2-1-1 1.27  5,14 
 1-2-1-2 2.31  2.81 
 1-2-2-1 2.41  9.48 
Group B 2-1-1-1 22.97  18.48 
 2-1-1-2 4.27  4.05 
 2-1-2-1 0.66  2.35 
 
Table 4.2 Haplotype groups defined for FRZB in the ICPS cohort. 
This table presents two haplotype groups defined according to LD patterns across SNPs in 
the ICPS cohort. Major and minor alleles of SNP1 were used to determine haplotypes in each 
group. 
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Figure 4.5 Analysis of the effect of four SNP diplotypes of FRZB on mRNA levels in 
controls and cases of the ICPS cohort. 
For this analysis haplotypes were grouped according to their likely evolution in two groups 
(described above). Both haplotype copies were considered for each individual, analogous to 
the analysis of individual SNPs genotypes. Two-way ANOVA was performed to compare 
mRNA levels of controls and cases carrying both haplotypes belonging to Group A (controls 
n=12; cases n=13) with those carrying at least one of the haplotypes from Group B (controls 
n=10; cases n=14).  
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4.3.1.2 Analysis of association of SNPs and haplotypes in FRZB with disease 
status in the East UK cohort 
The four SNPs used above (Figure 4.6) were genotyped in the East UK cohort of 
controls and cases (total n=321) for analysis of SNP association with disease status. 
No deviations from Hardy-Weinberg equilibrium were observed for any SNPs using 
Haploview software. Application of a logistic regression model to the analysis, using 
Golden Helix© did not result in significant allelic associations (Table 4.3). Also, no 
significant genotype effect on disease status resulted from the χ2 test. Finally, 
application of logistic regression to test disease penetrance models did not result in 
significant association of genotype with disease (Table 4.4).  
Even though no SNP associations with disease were obtained, haplotype associations 
were explored because analysis of LD patterns across polymorphisms provides a 
powerful approach in detecting significant association of candidate genes with 
disease status. Initially, LD values were calculated using Haploview in the East UK 
cohort. Variations in LD patterns were observed between controls and cases, which 
indicates possible significant differences in haplotype distribution (Figure 4.7). 
Moving-window haplotype analysis did not result in significant associations for two, 
three or four-SNP haplotypes, consistent with the similar frequencies of four-SNP 
haplotypes in controls and cases of the East UK cohort (Figure 4.8).  
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  Frequency 
(%) 
 
 
East UK Samples n 
Minor 
Allele 
 
p value OR CI 95% 
SNP 1 
rs10206992: Intron 1 
 
    
  G     
Schizophrenia 288 20.8  03532 0.82 0.54-1.25 Controls 218 24.3  
SNP 2  
rs7607737: Intron 1  
     
  T     
Schizophrenia 266 12.4  0.4554 0.82 0.48-1.39 Controls 210 14.8  
SNP3  
rs288329: Intron 3 
     
  T     
Schizophrenia 266 15.4  0.8666 1.04 0.73-1.74 Controls 202 14.9  
SNP4  
rs16823799: 3’ UTR 
     
  A     
Schizophrenia 264 7.2  0.8386 0.93 0.47-1.86 Controls 208 7.7  
 
Table 4.3 Summary of statistics for allele association of SNPs in FRZB in the East 
UK cohort.  
No significant associations were seen from application of a logistic regression model to 
calculate p values and odds ratio (OR) using Golden Helix©.  
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    Genotype 
    χ2 Test 
East UK 
Samples n Frequency (%)  p value  
SNP 1 
rs10206992: Intron 1 
 
  T/T T/G G/G   
 Schizophrenia 144 61.1 36.1 2.8  0.2389 
 Controls 109 58.7 34.0 7.3  
SNP 2  
rs7607737: Intron 1 
 
  G/G G/A A/A   
 Schizophrenia 133 75.9 23.3 0.8  0.2614 
 Controls 105 61.3 29.2 9.4  
SNP3  
rs288329: Intron 3 
 
  G/G G/A A/A   
 Schizophrenia 133 70.7 27.8 1.5  0.9099 
 Controls 101 72.3 25.7 2.0  
SNP4  
rs16823799: 3’ UTR 
 
  C/C C/T T/T   
 Schizophrenia 132 85.6 14.4 0.0  0.8316 
 Controls 104 84.6 15.4 0.0  
 
Table 4.4 Summary of statistics for analysis of genotypic associations of SNPs of 
FRZB in the East UK cohort. 
P-values are presented in this table following the application of χ2 to test for genotype 
associations with disease using Golden Helix©. No significant associations were observed 
for any one of four polymorphisms analysed.  
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Figure 4.7 LD values for four SNPs of FRZB in the East UK cohort.  
Linkage disequilibrium (LD) diagram obtained using Haploview for controls and cases of the 
East UK cohort. Although strong LD was observed for SNP 1 with all other polymorphisms in 
controls (D’ values rank from 0.85 to 1), clear differences in this pattern were observed in 
schizophrenia cases. 
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Figure 4.8 Frequencies of four-SNP haplotypes of FRZB in East UK cohort. 
Frequencies of four-SNP haplotypes of FRZB as calculated by Golden Helix©. No haplotype 
associations with disease were observed from moving-window analysis. 
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A second approach was used for haplotype analysis was taken by defining two 
groups of haplotypes using SNP 1 as reference for definition of haplotype groups 
following the procedure described above. PHASE v. 2.1 was used to calculate 
haplotype frequencies and to estimate diplotypes for each individual in the East UK 
cohort. Haplotypes containing the major allele for this variant were present in Group 
A and those containing the minor allele were classified as Group B (Table 4.5). 
Fisher’s exact test was used to compare frequencies of haplotype groups in controls 
and cases. In addition, phased data was used to compare diplotype frequencies in 
controls and cases using χ2 test (Figure 4.9). There were no significant associations 
with schizophrenia resulted from this approach. 
 
 Haplotype Frequency (%) 
  Controls  Cases 
Group A 1-1-1-1 54.66  57.39 
 1-1-1-2 2.32  2.50 
 1-1-2-1 4.88  7.26 
 1-2-1-1 1.90  1.10 
 1-2-1-2 2.13  2.64 
 1-2-2-1 9.22  7.74 
Group B 2-1-1-1 21.47  18.72 
 2-1-1-2 2.03  1.88 
 2-2-1-1 0.15  0.49 
 
Table 4.5 Haplotype groups defined for FRZB in the East UK cohort. 
Two groups of haplotypes were defined for SNPs in FRZB considering LD patterns calculated 
from Haploview. Haplotype frequencies in controls and cases for this analysis were 
calculated from PHASE v 2.1. 
 
 
 202
 
Figure 4.9 Frequencies of two haplotype groups of SNPs in FRZB in East UK 
cohort.  
Two groups of similar haplotypes were defined. Frequencies of haplotypes in Group A were 
compared to those in Group B in controls and cases using Fisher’s exact test (A). Phased 
data was also used to perform a comparison of diplotype frequencies using χ2 test (B). No 
significant associations were observed from this analysis. 
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4.3.2 WISP3: Analysis of SNP association with expression levels and 
disease status 
4.3.2.1 Correlation of SNP genotype with mRNA levels of WISP3 in the ICPS 
cohort 
Correlation of genotypes for three SNPs in WISP3 with levels of expression of the 
gene was performed using data from the ICPS cohort (Supplementary Table 4; 
Appendix C). WISP3 mRNA levels in BA22 were significantly upregulated in 
schizophrenia (Barnes et al., 2011; Appendix A). Three-way ANOVA analysis using 
three independent variables (disease status, genotype and SNP ID) with gene 
expression as the outcome, revealed a significant effect of diseases status 
(p=0.00033) but no effect of genotype or SNP ID. There were no significant 
interactions between variables. Further two-way ANOVA confirmed these findings 
with a significant effect of disease status on mRNA levels (p=0.0004) but no effect of 
genotype and no interactions between factors (Figure 4.10).  
Two-SNP haplotype analysis was not performed because of very low numbers of 
individuals in either one of the haplotype groups: subjects carrying both copies of the 
common haplotype (1-1/1-1) or those carrying at least one copy of the less common 
haplotypes (1-2, 2-1 or 2-2). Three-SNP haplotype analysis was performed by 
defining two groups of similar haplotypes (Table 4.6). Diplotypes were estimated 
using Phase v. 2.1 and two-way ANOVA was used to compare mRNA levels between 
controls and cases with either two copies of haplotypes from group A or at least one 
copy of any haplotypes from group B (Figure 4.11). This analysis did not result in 
any significant effect of haplotypes on WISP3 expression, although the effect of 
disease status showed border-line significance (p=0.054). 
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Figure 4.10 Analysis of SNP genotype and disease status effect on mRNA levels of 
WISP3. 
Levels of expression of WISP3 in BA22 for controls and schizophrenia cases of the ICPS 
cohort are shown for major and minor allele genotypes. Two separate histograms are shown 
for clarity, one for individuals homozygous for the major allele (1/1) in the three SNPs 
analysed, and a second one for mRNA values of subjects with at least one copy of the minor 
allele (1/2 + 2/2). Three and two-way ANOVA was performed by comparing all genotypes in 
controls and cases across all SNPs. 
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 Haplotype Frequency (%) 
  Controls  Cases 
Group A 1-1-1 39.86  39.41 
 1-1-2 0.06  1.55 
 1-2-1 29.77  25.70 
Group B 2-1-1 1.02  0.00 
 2-1-2 28.76  33.29 
 
Table 4.6 Haplotype groups defined for WISP3 in the ICPS cohort. 
The table presents two groups of similar haplotypes defined for analysis of haplotype effect 
on gene expression levels.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11 Analysis of the effect of three-SNP diplotypes of WISP3 on mRNA 
levels in ICPS cohort. 
Haplotypes were grouped according to their likely evolution into two groups (described 
above). Both haplotype copies for each individual were analysed using two-way ANOVA, in 
order to compare frequencies of controls and cases carrying both haplotypes belonging to 
Group A (controls n=7; cases n=5) with those carrying at least one of the haplotypes from 
Group B (controls n=10; cases n=11). 
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4.3.2.2 Analysis of the association of SNPs and haplotypes in WISP3 with 
disease status in the East UK cohort 
The three WISP3 SNPs selected for correlation with tissue expression in the ICPS 
cohort were used for analysis of association with disease in the East UK cohort 
(Figure 4.12). No significant allelic associations were obtained from application of a 
logistic regression model using SVS7 Golden Helix© (Table 4.7). Similarly, no 
significant association of genotype with disease were seen using the χ2 test (Table 
4.8). In addition, the application of three other genetic models (additive, dominant 
and recessive) using logistic regression did not result in significant associations.  
Although no associations were seen from single SNP analysis, a moving-window 
haplotype analysis revealed a significant protective effect of two-SNP haplotypes 
containing both major alleles for SNP 1 and SNP 2 and for SNP 2 and SNP 3. A 
significant protective effect of the haplotype containing all major alleles for the three 
SNPs was found (Table 4.9). The difference in frequencies of haplotype 1-1-1 (C-C-
G) between controls and cases was the largest observed across all three-SNP 
haplotypes (Figure 4.13). A second analysis was performed by grouping haplotypes 
according to their evolutionary similarity and LD patterns. Haploview was used to 
calculate D’ values across all SNPs. Both controls and cases showed strong LD (D’ 
from 0.82-1.0) although some differences in the pattern across SNPs were observed 
between groups (Figure 4.14). Haplotype groups were defined (Table 4.10) and 
frequencies were compared between controls and cases using the Fisher’s exact test. 
Phase v.2.1 was also used to predict haplotype pairs for each individual, in order to 
compare diplotype frequencies between controls and cases using a χ2 test (Figure 
4.15). No significant differences in frequencies in either haplotype or diplotypes were 
observed. 
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  Frequency 
(%) 
 
 
East UK Samples n 
Minor 
Allele 
 
p value OR CI 95% 
SNP 1 
rs2280153: Intron 1 
 
    
  T     
Schizophrenia 278 28.4  0.668 1.09 0.73-1.63 Controls 210 26.7  
SNP 2  
rs1230348: Intron 1  
     
  T     
Schizophrenia 258 32.6  0.074 1.43 0.96-2.13 Controls 202 36.0  
SNP3  
rs1230345: Exon 3 [Q/H] 
     
  T     
Schizophrenia 264 27.6  0.445 1.18 0.77-1.80 Controls 196 24.5  
 
Table 4.7 Summary of statistics for allele association of SNPs in WISP3 in the East 
UK cohort.  
Summarised in this table are p values and odds ratio (OR) calculated by applying a logistic 
regression model using Golden Helix©.  
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    Genotype 
    χ2 Test 
East UK Samples n Frequency (%)  p value  
SNP 1 
rs2280153: Intron 1 
 
  C/C C/T T/T   
 Schizophrenia 139 50.4 42.4 7.2  0.0579 
 Controls 105 59.0 28.6 12.4  
SNP 2  
rs1230348: Intron 1 
 
  C/C C/T T/T   
 Schizophrenia 129 41.1 45.7 13.2  0.2037 
 Controls 101 52.5 38.6 8.9  
SNP3  
rs1230345: Exon 3 [Q/H] 
 
  G/G G/T T/T   
 Schizophrenia 132 53.0 38.6 8.4  0.2805 
 Controls 98 61.2 28.6 10.2  
 
Table 4.8 Summary of statistics for analysis of genotypic associations of SNPs of 
WISP3 in the East UK cohort. 
The table presents p-values for genotype associations with disease using a χ2 and Golden 
Helix©. No significant associations were observed for any one of three polymorphisms 
analysed. 
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Figure 4.13 Frequencies of three-SNP haplotypes for WISP3 in the East UK 
cohort. 
Frequencies of three-SNP haplotypes of WISP3 as calculated by Golden Helix©. No haplotype 
associations with disease were observed from moving-window analysis following FDR 
correction. 
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Figure 4.14 LD values for four SNPs of WISP3 in the East UK cohort.  
Linkage disequilibrium (LD) maps for three SNPs in WISP3 in controls and cases of the East 
UK cohort. D’ values calculated using Haploview indicated strong LD across all SNPs in both 
groups (D’ values rank from 0.82 to 1).  
 
 
 
 
 
 
 
 
 
 
 
 
 Haplotype Frequency (%) 
  Controls  Cases 
Group A 1-1-1 45.22  33.28 
 1-1-2 1.64  2.35 
 1-2-1 26.00  35.09 
 1-2-2 0.54  0.73 
Group B 2-1-2 23.18  24.87 
 2-1-1 2.85  3.44 
 2-2-2 0.53  0.19 
 
Table 4.10 Haplotype groups defined for WISP3 in the East UK cohort. 
Haplotype frequencies in controls and cases calculated using PHASE v 2.1 for two groups of 
haplotypes of SNPs in WISP3 considering LD patterns calculated from Haploview.  
 
 213
 
Figure 4.15 Frequencies of two haplotype groups of SNPs in WISP3 in the East UK 
cohort.  
Two groups of similar haplotypes were defined. Frequencies of haplotypes in Group A were 
compared to those in Group B in controls and cases using Fisher’s exact test (A). Phased 
data was also used to perform a comparison of diplotype frequencies using χ2 test (B). No 
significant associations were observed from this analysis. 
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4.3.3 DKK3: Analysis of SNP genotype effect on expression levels 
and study of association with disease 
4.3.3.1 Correlation of SNPs and haplotypes of DKK3 with mRNA levels in the 
ICPS cohort 
Correlation of genotypes and haplotypes of DKK3 SNPs with levels of expression was 
performed with data available from RT-PCR analysis using samples from BA22 of 
subjects from the ICPS cohort. Expression of this gene was not identified as 
significantly changed in schizophrenia from previously described microarray studies 
(Maycox et al., 2009; Barnes et al., 2011). However, a previous study identified 
expression of DKK3 as being reduced by 35% in BA22 in schizophrenic post-mortem 
samples from the BA22 by 35% compared to healthy controls, using suppression 
subtractive hybridization as well as slot blot hybridization and RT-PCR for validation 
(Ftouh et al., 2005).  
Three SNPs were genotyped in the ICPS cohort (Supplementary Table 4; Appendix 
C). Correlation of genotype with levels of expression for three DKK3 SNPs in controls 
and cases were performed using ANOVA. Factorial analysis with disease status, 
genotype and SNP ID as independent variables did not result in any significant 
effects of any of these factors or interactions between them. A two-way ANOVA 
confirmed this result. Expression levels of controls and cases were similar for all 
genotypes and all SNPs (Figure 4.16).   
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Figure 4.16 Analysis of DKK3 SNP genotype and disease status effect on mRNA 
levels. 
Levels of expression of DKK3 in BA22 for different genotypes are presented in this figure for 
controls and schizophrenia cases of the ICPS cohort. Two separate histograms are shown for 
clarity, one for individuals homozygous for the major allele (1/1) in the four SNPs analysed, 
and another for subjects with at least one copy of the minor allele (1/2 + 2/2). Three and 
two-way ANOVA was performed by comparing all genotypes in controls and cases across all 
SNPs. No significant effects of either disease status or genotype observed. 
 
 
 216
The effect of DKK3 haplotypes on mRNA levels was assessed as previously described. 
Initially two-SNP haplotypes were analysed using two-way ANOVA with no significant 
effect of either disease status or diplotype observed and no significant interactions 
between variables. Once more, levels of expression between controls and cases were 
very similar for both diplotype groups across all SNP pairs (Figure 4.17). In order to 
analyse the effect of three-SNP haplotypes on levels of expression, data obtained 
from PHASE analysis was used to define two groups of similar haplotypes (Table 
4.11). Levels of expression of controls and cases from both diplotype groups were 
compared using a two-way ANOVA with no significant differences resulting from the 
analysis (Figure 4.18).  
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Figure 4.17 Analysis of the effect of two-SNP diplotypes in DKK3 on mRNA levels 
the ICPS cohort.  
Levels of expression of DKK3 in BA22 shown for major and minor allele diplotypes in controls 
and schizophrenia cases of the ICPS cohort for all SNP pairs. For clarity purposes, mRNA 
levels are presented in two separate histograms, one for individuals carrying both copies of 
the most common haplotype (1-1/1-1) and a second histogram for individuals with at least 
one copy of haplotypes 1-2, 2-1 or 2-2. Three and two-way ANOVA was performed by 
comparing both diplotype groups. No significant differences in expression levels were 
observed between controls and cases for any diplotype.  
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 Haplotype Frequency (%) 
  Controls  Cases 
Group A 1-1-1 62.80  76.35 
 1-1-2 12.87  5.69 
 1-2-1 5.40  6.71 
Group B 2-1-1 3.41  2.92 
 2-1-2 15.50  8.28 
 
Table 4.11 Haplotype groups defined for DKK3 in the ICPS cohort. 
Two haplotype groups defined according LD patterns across SNPs in the ICPS cohort are 
shown. Major and minor alleles of SNP1 were used to determine haplotypes in each group. 
 
 
 
 
 
 
 
 
 
 
Figure 4.18 Analysis of the effect of three-SNP diplotypes of DKK3 on mRNA 
levels in controls and cases of the ICPS cohort. 
Levels of expression of DKK3 are shown in the figure for controls and cases carrying both 
haplotypes belonging to Group A (controls n=13; cases n=19) and those carrying at least 
one of the haplotypes from Group B (controls n=5; cases n=4). Two-way ANOVA was 
performed to compare mRNA levels between controls and cases in both haplotype groups. 
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4.3.3.2 Analysis of association of SNPs and haplotypes in DKK3 with disease 
status in the East UK cohort 
For analysis of association of DKK3 with schizophrenia the three selected 
polymorphisms in this gene were genotyped in controls and cases of the East UK 
cohort (Figure 4.19). A significant allelic association of SNP 2 with disease was 
observed. The odds ratio (OR) obtained for this variant indicated a large effect of the 
polymorphism on risk for disease (OR=2.27). In spite of this, the association did not 
remain significant after FDR correction (Table 4.12). No genotypic associations 
resulted from the analysis using a χ2 test to compare genotype frequencies between 
controls and cases. However, a significant effect of SNP 2 resulted from the 
application of logistic regression with an additive model of disease penetrance 
(where the risk of disease increases as DD >Dd> dd), although this association did 
not remain significant after correction (Table 4.13). 
A moving-window analysis revealed significant association with disease for four 
haplotypes. In all cases the risk for disease was increased in these haplotypes. 
Although OR values for all four haplotypes indicated a large effect, their frequencies 
were very low and none of these associations remained significant after FDR 
correction for multiple testing (Table 4.14). No significant differences in frequencies 
of more common haplotypes were observed between controls and cases (Figure 
4.20). Finally haplotypes were grouped according to their ancestral similarity and LD 
patterns across SNPs (Figure 4.21). Two haplotype groups were defined (Table 4.15) 
and frequencies haplotypes in groups A and B were compared between controls and 
cases using Fisher’s exact test. Moreover, PHASE v. 2.1 was also used to predict 
diplotypes for each individual in order to compare diplotype frequencies between 
 220
controls and cases using the χ2 test. No significant association of haplotypes with 
disease status resulted from this approach.  
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Frequency 
(%) 
 
  
False 
Discovery 
Rate 
East UK Samples n 
Minor 
Allele 
 
p value OR CI 95%  p value 
SNP 1 
rs2291599: Intron 5 
 
      
  A       
Schizophrenia 276 16.67  0.560 0.87 0.54-1.39  0.560 Controls 214 18.69  
SNP 2  
rs7480026: Intron 6  
       
  T       
Schizophrenia 288 8.68  0.031* 2.27 1.04-4.97  0.094 Controls 224 4.02  
SNP3  
rs3206824: Exon 8 [R/G] 
       
  A       
Schizophrenia 280 16.43  0.297 0.79 0.50-1.24  0.446 Controls 230 20.0  
 
Table 4.12 Summary of statistics for allele association of SNPs of DKK3 in the 
East UK cohort.  
Minor allele frequencies, calculated using SVS7 from Golden Helix©, for three SNPs in DKK3 
in the East UK cohort. A logistic regression model was used to calculate p-values and odds 
ratio (OR) values. False discovery rate was used to correct for multiple testing. Significant p 
values are indicated by * when p<0.05. 
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    Genotype   
 
 
  χ
2 Test  
Additive Model  
Logistic regression 
East UK 
Samples n Frequency (%)  
p value 
(FDR)  
p value 
(FDR) 
Odds Ratio 
(CI95%) 
SNP 1 
rs2291599: Intron 5 
 
 
  G/G G/A A/A    
 Schizophrenia 138 68.8 29.0 2.2  0.745 
(0.745) 
 0.556 
(0.556) 
0.87 
(0.54-1.39)  Controls 107 66.4 29.9 3.7   
SNP 2  
rs7480026: Intron 6 
 
 
  C/C C/T T/T    
 Schizophrenia 144 84.0 14.6 1.4  0.116 
(0.347) 
 0.035* 
(0.106) 
2.20 
(1.01-4.78)  Controls 112 92.0 8.0 0.0   
SNP3  
rs3206824: Exon 8 
[R/G] 
 
 
  G/G G/A A/A    
 Schizophrenia 140 69.3 28.6 2.1  0.393 
(0.590) 
 0.302 
(0.452) 
0.79 
(0.50-1.24)  Controls 115 65.2 29.6 5.2   
 
Table 4.13 Summary of statistics for analysis of genotypic associations of SNPs in 
DKK3 in the East UK cohort. 
The P-values and FDRs presented in the table were calculated using Golden Helix© from the 
application of a χ2 to identify genotype associations with disease. In addition, a logistic 
regression model was applied to test three genetic models to assess the effect of genotypes 
containing the disease allele ‘D’ to those with the wildtype allele ‘d’. Significant p-values are 
indicated by * when p<0.05.  
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Figure 4.20 Frequencies  of three-SNP haplotypes of DKK3 in East UK cohort. 
Frequencies of three-SNP haplotypes of DKK3 as calculated by Golden Helix©. No haplotype 
associations with disease were observed from moving-window analysis. 
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Figure 4.21 LD values for three SNPs of DKK3 in the East UK cohort.  
Linkage disequilibrium (LD) diagram obtained using Haploview for controls and cases of the 
East UK cohort. High D’ values (from 0.96 to 1) were seen for SNPs 1 and 2 and SNPs 2 and 
3 in both controls and cases. The main differences in LD patterns were observed between 
SNP 1 and 3 when comparing controls with schizophrenia cases.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Haplotype Frequency (%) 
  Controls  Cases 
Group A 1-1-1 72.90  69.91 
 1-1-2 5.22  5.41 
 1-2-1 4.29  8.60 
Group B 2-1-1 1.62  4.58 
 2-1-2 15.95  11.50 
 
Table 4.15 Haplotype groups defined for DKK3 in the East UK cohort. 
Haplotype frequencies in controls and cases calculated using PHASE v 2.1 for two groups of 
haplotypes of SNPs considering LD patterns calculated from Haploview.  
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Figure 4.22 Frequencies of two haplotype groups of SNPs in DKK3 in the East UK 
cohort.  
Frequencies of haplotypes in Group A were compared to those in Group B in controls and 
cases using Fisher’s exact test (A). Phased data was also used to perform a comparison of 
diplotype frequencies using χ2 test (B). No significant associations were observed from this 
analysis. 
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4.3.4 Analysis of epistatic interaction between genes involved in 
Wnt signalling pathway 
Analysis of epistatic interactions carried out using GAIA resulted in a significant 
interaction of SNP 1 (rs10206992) in FRZB and SNP 2 (rs1230348) in WISP3 (Figure 
4.23). Moreover, although no interactions of DKK3 with any of the other two 
candidate genes were observed, a significant association with disease of SNP 2 
(rs7480026) was obtained from the analysis (p=0.03519). These results are 
consistent with those obtained from analysis of association of DKK3 with 
schizophrenia, which revealed significant allelic and genotypic associations of this 
SNP. Corrections for multiple comparisons in this case were performed using an in-
built permutation test, part of the GAIA application. Empirical p values did not remain 
significant after 1000 permutations.  
 
Figure 4.23 Representation of epistatic interactions between polymorphisms in 
FRZB and WISP3.  
Evidence for statistical epistasis was obtained by analysis using GAIA. A significant increased 
risk for disease was observed for the interaction of SNP 1 in FRZB (rs10206992) and SNP 2 
in WISP3 (rs1230348).  
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4.4 Discussion 
4.4.1 Significant differences in expression levels of FRZB for a 
number of genotypes and diplotypes 
Analysis of selected polymorphisms in three candidate genes implicated in the Wnt 
signalling pathway substantiate the previous findings of significant differences in 
levels of expression between controls and cases and further extend this analysis to 
show that this extends to all genotypes and diplotypes for FRZB and WISP3 in the 
ICPS cohort. In the case of FRZB Bonferroni’s post-test comparisons revealed 
significant association of individual SNPs and diplotypes with levels of gene 
expression. Further analysis of the effect of four-SNP haplotypes also revealed 
consistent results. Classification of four-SNP haplotypes into two groups according to 
their likely evolution revealed a significant interaction of disease status and diplotype 
with respect to expression of FRZB suggesting that these SNPs might be in strong LD 
with regulatory variants. In particular SNP 4 (rs16823799) which is located in the 3’-
UTR of the gene, 58 bp and 86 bp away from the recognition sequences of the micro 
RNAs has-miR-629 and has-miR-1323, respectively, according to data from the 
miRDB database (http://mirdb.org/miRDB/index.html; Wang and El Naqa, 2008; 
Wang, 2008).  
The data used for analysis of DKK3 corresponded to samples from the ICPS cohort, 
different to those used in the expression study reporting reduced expression of the 
gene in schizophrenia in BA22 (Ftouh et al., 2005). In spite of the fact that no 
significant effects of either disease status or genotype/diplotype resulted from the 
correlation of three SNPs in DKK3 with mRNA levels in ICPS samples, this gene 
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remains an interesting candidate for analysis of association with disease considering 
the role it plays in the Wnt signalling pathway. 
4.4.2 No association of SNPs or haplotypes in Wnt signalling genes 
with schizophrenia 
Analysis of association of genetic variants with disease revealed significant nominal p 
values for allelic association of SNP 2 in DKK3 (rs7480026) as well as genotypic 
association of this SNP when using logistic regression to test an additive model of 
disease penetrance. However, these associations did not hold up after correction 
with FDR values, in spite of the large effect denoted by the OR values (2.3 for allelic 
association and 2.20 for contribution of genotype to risk of disease).  
In addition, moving-window analysis revealed association of four haplotypes in DKK3 
and three more in WISP3 with schizophrenia. Once more, these associations did not 
remain significant after correction for multiple testing. An important consideration to 
make in the case of DKK3, is the low frequency of the four associated haplotypes in 
both controls and cases. Comparison of LD patterns in controls and cases for all 
three genes also revealed interesting differences. In the particular case of 
polymorphisms in DKK3 and WISP3, where strong intermarker LD was observed, the 
association of haplotypes in spite of the lack of association of individual loci 
highlights the advantage of multi-locus analysis for detection of association with 
disease (Morris, 2005; Sanders et al., 2005). 
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4.4.3 Evidence for modest statistical epistasis between 
polymorphisms in FRZB and WISP3 contributing to the 
schizophrenic phenotype 
The final analysis of interactions between loci performed using the GAIA application 
provided evidence for epistatic interactions between SNP 1 (rs10206992) in FRZB 
and SNP 2 (rs1230348) in WISP3 in the East UK cohort. Although this interaction did 
not remain significant after correction for multiple testing, it is interesting given the 
close functional relation of these two genes. Although the mechanisms through 
which FRZB and WISP3 regulate Wnt signalling pathway are yet to be clearly 
elucidated, and might be cell type specific, the two proteins have been shown to 
interact with Frizzled receptors during defined developmental processes, leading to 
inhibition of Wnt signalling pathway (Leyns et al., 1997; Nakamura et al., 2007). 
Moreover, the presence of a significant interaction between polymorphisms in these 
genes in spite of the lack of association of individual SNPs with disease makes further 
exploration of possible gene-gene interactions worth pursuing.  
4.4.4 Conclusion 
The results described in this section confirm the significant downregulation of FRZB 
and the significant upregulaton of WISP3 observed in schizophrenia in BA10 and 
BA22 respectively, in previous microarray studies. Furthermore, significant 
association of genotype with expression was observed for individual SNPs in FRZB 
when comparing mRNA levels in controls and cases of the ICPS cohort. Further 
analysis of haplotype effect on gene expression supported the previous findings with 
individual haplotypes significantly associated with lower levels of expression when 
comparing controls and cases. These findings provide support for a candidate-gene 
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approach and for the use of available SNPs as markers for potential regulatory 
variants. Particularly interesting is SNP 4 (rs16823799) located within a hundred base 
pairs from the recognition sequences of two miRNAs.  
The results also support the consideration of FRZB as an important novel candidate 
gene in schizophrenia aetiology. Although the precise role of FRZB in regulation of 
Wnt signalling is still subject of investigation, down-regulation of the gene in BA10 of 
schizophrenic patients is intriguing considering the suggestion of an important role in 
cell proliferation (Qu et al., 2008; Hirata et al., 2010). This becomes more interesting 
in the light of reports of an important role of the disrupted in schizophrenia (DISC1) 
gene in neuronal progenitor proliferation through modulation of the β-catenin/GSK-
3β pathway (Mao et al., 2009).  
The analysis of genotype association with disease status revealed an allelic 
association of an intronic SNP (rs7480026) in DKK3 with schizophrenia. In addition, 
significant association of genotype with disease was also observed for this SNP 
consistent with an additive model of disease penetrance. Although these associations 
were not significant after correction for multiple testing it is important to recognise 
the limitations posed by the low MAF of this polymorphism. It is also important to 
consider the possibility that this SNP might be in strong LD with an associated 
variant. Moreover, four haplotypes of DKK3 and three more haplotypes of WISP3 
also were associated with disease. Although these associations did not hold up to 
multiple testing correction they further emphasise the increased power of haplotype 
analysis, which has been pointed out from previous associations studies of 
schizophrenia candidate genes such as COMT (Shifman et al., 2002; Handoko et al., 
2005) 
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Investigation of the role of the Wnt signalling pathway in schizophrenia aetiology 
remains an important subject to explore, not only due to the well established 
importance of this pathway in developmental processes and the more recent 
evidence of its involvement in synaptic plasticity. In the case of FRZB and DKK3 it is 
interesting that although both genes are considered generally as inhibitors of Wnt 
signalling pathway, data collected from a number of reports suggests that the 
mechanisms through which these genes modulate Wnt signalling might be cell-type 
specific and it might depend on stage of development (Kawano and Kypta, 2003; 
Nakamura et al., 2007; von Marschall and Fisher, 2010). 
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CHAPTER 5 A method for analysis of CpG island 
methylation in schizophrenia candidate genes 
designed using DKK3. 
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5.1 Introduction 
The dynamic nature of epigenetic mechanisms has provided the basis for the theory 
that these mechanisms might be involved in schizophrenia aetiology. In particular, a 
number of studies have provided evidence for aberrant methylation patterns in 
regions or genes previously linked to schizophrenia (Impagnatiello et al., 1998; 
Guidotti et al., 2000; Knable et al., 2004; Fatemi et al., 2005; Straub et al., 2007; 
Shifman et al., 2008; Liu et al, 2010). Moreover, a recent epigenomic profiling study 
(Mill et al., 2008) identified a number of genes differentially methylated in 
schizophrenia and bipolar disorder. Amongst the most significant changes in 
methylation patterns observed in major psychosis were those found in the zinc finger 
195 (ZNF195) gene and the gene coding for the switching B-cell complex 70 KDa 
subunit protein (SWAP70). Both of these genes are located in the chromosome 11p 
region, within 10Mb of DKK3. DKK3 remains the one member of the dickopff family 
of proteins whose precise role in modulation of Wnt signalling pathway is not yet 
known. Most of the data available to date on the mechanisms of action of DKK3, as 
well as its interaction with other proteins, has been gathered through extensive 
research on the involvement of DKK3 in proliferation of cancer cell lines (Tsuji et al., 
2000; 2001; Hsieh et al., 2004, Abarzua et al., 2005; 2007). A number of studies 
have found evidence for hypermethylation of the promoter region of DKK3 leading to 
downregulation of the gene in a variety of tumours. (Kobashashi et al., 2002; 
Roman-Gomez et al., 2004; 2007; Veeck et al., 2008b; Chim et al., 2008; Yue et al., 
2008; Lee EJ et al., 2009).  
The most common method for analysis of CpG island methylation in these and other 
candidate gene based studies is direct sequencing after conversion of unmethylated 
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cytosines to thymines through bisulphite modification of DNA. However, bisulphite 
sequencing frequently demands very specific conditions and optimisation is often 
required in order to obtain a good quality sequence where it is possible to determine 
not only full but also partial methylation (i.e. methylation of only one allele; Figure 
5.1). 
 
Figure 5.1 Example of partial methylation from Murphy et al. (2008).  
Panel A from this figure shows clear methylation at cytosines 8 and 20, with a prominent C 
signal and only traces of T, while panel B shows partial methylation of the same sites with an 
ambiguous signal called N.  
Many of the previously mentioned studies have used methylation specific PCR (MSP) 
as an alternative or complementary method for the analysis of the methylation status 
of CpG islands in the promoter region of DKK3 (Roman-Gomez et al., 2004; 2007; 
Veeck et al., 2008b; Chim et al., 2008; Yue et al., 2008). This method, first described 
by Herman et al. (1996) consists of designing a pair of primers specific for each one 
of the two different methylation states based on the principle that only unmethylated 
CpGs would be affected by bisulphite reaction (Figure 5.2).  
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Figure 5.2 Example of methylation specific PCR from Yue et al. (2009). 
Bands obtained from MSP analysis of the promoter region of DKK3 using a pair of primers 
designed for methylated DNA (M) and a second pair designed to amplify unmethylated DNA 
(U), after bisulphite modification. The authors used different methylated/unmethylated DNA 
ratios to demonstrate the sensibility of the assay to detect DNA methylation. 
The main objective of the last section of this study is to design a MSP based method 
in order to compare CpG methylation status of the selected candidate genes whose 
expression in schizophrenia has been found to be changed in schizophrenia cases 
compared to controls. In order to do this and taking advantage of the extensively 
documented use of bisulphite sequencing and MSP for the analysis of CpG island 
methylation of DKK3, this gene was used as the basis of this section in spite of the 
lack of association of SNPs in DKK3 with levels of expression in the ICPS cohort and 
the modest evidence for association of these SNPs with schizophrenia in the East UK 
cohort.  
5.1.1 Overview 
The initial step in the analysis of methylation of the promoter region of DKK3 in ICPS 
cohort controls and cases was the identification of the CpG islands in the gene. The 
online application CpG Island Plot from EMBL-EBI (http://www.ebi.ac.uk/Tools/ 
emboss/cpgplot/index.html) was used for this purpose. Once the region of interest 
was identified, optimisation of bisulphite modification was carried out using three 
different modification kits as well as appropriate controls in order to confirm that 
transformation was successful. This was a critical step particularly due to the fact 
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that the DNA used for this analysis was extracted from brain tissue samples 
corresponding to controls and cases from the ICPS cohort. In addition to the 
conversion rate of the kit used for bisulphite modification, it was important that the 
yield of the recovered DNA was as high as possible in order to maximise the 
possibility of a successful PCR amplification and sequencing of the modified template. 
Bisulphite modified DNA from tissue samples of controls and cases was then 
amplified using primers designed for a two round PCR reaction. Samples were 
subsequently prepared for sequencing at the MRC CSC Genomics Core Laboratory, 
Imperial College London. Direct sequencing of bisulphite modified DNA is not an easy 
task, due to the nature of bisulphite modified DNA and the presence of large thymine 
repeats. Two methods were tried in an attempt to improve the quality of the 
sequence. The first method was to use PCR to add a common sequencing primer tag 
(M13(-20)F or M13R) at the 5’ end of each CpG island. The second method was to 
introduce the CpG island fragment into a TA vector for subsequent sequencing. As 
this method does not allow for identification of partial methylation, at least 10 
constructs were sequenced for each sample analysed. 
Primers for the CpG island in the promoter region of DKK3 were designed for MSP 
and were used to amplify and sequence this region in controls and cases of the ICPS 
cohort. The aim was to compare both assays in order to confirm the efficiency of the 
MSP method in identifying methylation. As primer design is critical for the success of 
MSP, the primers used were based on the primers previously validated for this region 
(Yue et al., 2009) for analysis of the same CpG island in the promoter region of 
DKK3 as the one chosen for the present study. The overall aim of this section was to 
establish a quick and reliable method that could be used for analysis of a number of 
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selected candidate genes whose expression was changed in schizophrenia (Maycox 
et al., 2009; Barnes et al., 2011). 
5.2 Methodology 
5.2.1 Identification of CpG islands in the promoter region of DKK3 
In order to identify possible CpG islands in DKK3 a fragment from the promoter 
region of the gene (~ 2Kb) was analysed using the CpG Island Plot from EMBL-EBI 
(http://www.ebi.ac.uk/Tools/emboss/cpgplot/index.html). From this analysis two 
regions were recognized as putative CpG islands (Figure 5.3), consistent with the 
data reported by Yue et al. (2008). 
 
Figure 5.3 Output from the analysis of the promoter region of DKK3 using CpG 
Island Plot EMBL-EBI.  
Two CpG island were predicted from the analysis of a 2Kb region comprising the promoter 
region of both isoforms of DKK3. 
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5.2.2 Bisulphite Modification  
Modification of DNA with bisulphite salts is useful in the identification of methylated 
sites in CpG islands. The bisulphate reaction with cytosine results in their 
transformation to uracil, a subsequent PCR amplification then replaces these uracils 
with thymines. Methylation of cytosines prevents their reaction with bisulphite and 
therefore their transformation into thymines after PCR amplification (Figure 5.4)  
 
Figure 5.4 Schematic representation of DNA bisulphite modification. 
Bisulphite treatment of DNA leads to conversion of Cytosine (C) to Uracil (U) through 
reaction with bisulphite salts. Methylated Cytosines are protected from transformation and 
remain unchanged after PCR amplification while nonmethylated sites are converted to 
thymines. The figure shows the complementary strand of the PCR product where guanines 
(G) are paired with cytosines and adenines (A) are paired with thymines.  
Tissue samples from controls and cases from the ICPS cohort were used for analysis 
of possible methylation of CpG islands in DKK3. Methylated controls were prepared 
using a CpG methyltrasferase (NEB). Three bisulphite modification kits were tested. 
Two column-based kits were used for modification of DNA: the Imprint kit (Sigma-
Aldrich) and the Methylation Gold kit (Zymo Research). Modifications were carried 
out according to the instructions from the manufacturers. A total amount of 1µg of 
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template was used with herring sperm DNA (Promega) used as a carrier for some 
samples.  
The MethylEasy kit (Human Genetic Signatures) was also tested. More steps are 
used for DNA modification using this kit and instead of a column it uses precipitation 
for cleaning-up the modified DNA, ensuring a better product yield. The kit also 
includes two control samples, C1 (unmodified) and C2 (modified) and two pairs of 
control primers for nested PCR.  
5.2.3 Bisulphite Sequencing 
After transformation PCR was carried out for amplification of the selected CpG island 
in DKK3. Two pairs of primers were designed in order to perform a nested PCR 
amplification. In addition, two additional primers were designed to introduce the 
sequence from the M13 pair of primers, commonly used as sequencing primers for 
some plasmids (Table 5.1). For convenience, primers were designed for the sense 
strand. 
Each PCR amplification was performed using 38 cycles of 20 seconds at 95°C 
followed by 30 seconds at 55°C (the recommended temperature for this set of 
primers), and finally 90 seconds at 72°C. The amount of GoTaq polymerase 
(Promega) used was 2 units per reaction. Bands were excised from the gel and 
purified using QIAquick gel extraction kit (QIAGEN). Forward and reverse second 
round primers or M13 primers were used for sequencing at the MRC CSC Genomics 
Core Laboratory, Imperial College London.  
In order to increase the quality of the sequence obtained from bisulphite modified 
DNA was cloning the amplified fragments corresponding to the CpG island was 
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cloned into a pCR 2.1 TA vector (Invitrogen, Figure 5.5). Preparation, cloning and 
purification of constructs were carried out as described in sections 2.3.1 and 2.3.2. 
 
Figure 5.5 Map of the pCR2.1 TA vector. 
pCR2.1 vector (Invitrogen) was used for cloning bisulphite modified DNA fragments 
corresponding to the second CpG island in the promoter region of DKK3. Plasmid DNA for at 
least ten colonies for each sample was recovered and sequenced using an M13 sequencing 
primer (Invitrogen) 
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5.2.4 Methylation specific PCR (MSP) 
Three pairs of primers were designed for MSP corresponding to methylated DNA, 
unmethylated DNA and unmodified DNA, this last pair of primers were used as 
controls (Table 5.2). These primers were designed following the general 
recommendations for this type of assay (Herman et al., 1996; Clark et al., 2006) and 
particularly those from a previous study where the methylation status of DKK3 was 
analysed (Yue et al., 2009). All primers were designed for amplification of the sense 
strand, after bisulphite modification. Amplification of the CpG island of DKK3 for 
controls and cases was performed in two parts. First round sequencing primers were 
used to amplify the entire CpG island, using the MSP primers for a second round 
PCR. Each sample was amplified using both primer pairs, for methylated and 
unmethylated DNA. After performing a gradient to determine the annealing 
temperature that produced sharp bands, each amplification was performed using 38 
cycles of 20 seconds at 95° C followed by 30 seconds at 55° C, and finally 90 
seconds at 72° C with 2 units of GoTaq polymerase (Promega). PCR products were 
subsequently analysed by gel electrophoresis, using a 2% agarose gel.  
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5.3 Results 
For this section, analysis of one of two predicted CpG island in the promoter region 
of DKK3 was performed, which was the CpG island closest to the coding region of 
the gene. Bisulphite modification was achieved successfully using the MethylEasy kit 
(Human Genetic Signatures). Direct bisulphite modification was not successful, even 
after using the common sequencing primers M13(-20) and M13R to tag the CpG 
island fragments to be analysed. The only method that yielded a completely readable 
sequence involved cloning the bisulphite modified CpG island fragment into a TA 
vector before sequencing. This procedure, however, has the important drawback that 
only one allele of the gene is selected for each construct and therefore is not 
possible to know whether partial methylation is occurring. For this reason it was 
necessary to sequence more than one colony for each sample analysed, making it 
difficult to analyse a large number of samples. For comparison with MSP results, five 
controls and five cases from the ICPS cohort were sequenced, with 10 colonies per 
sample. 
All of the analysed samples presented some level of methylation, with the exception 
of one schizophrenia case (sample 73). In general, a low level of methylation was 
observed in this CpG island of DKK3, in both controls and cases. However, more 
methylated colonies were observed in cases compared to controls in the region 
between CpG sites 16 to 19. MSP was performed on the same samples that were 
cloned and sequenced. The assay proved to be successful in identifying methylation 
and most results seem to be consistent with those obtained from sequencing data, 
although some failed PCR samples and the presence of non-specific bands, together 
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with the low level of methylation found in DKK3 made it hard to determine the 
sensitivity of the MSP assay.  
5.3.1 Optimisation of Bisulphite modification 
Initially, the Imprint kit (Sigma-Aldrich) was used to modify four control samples and 
four schizophrenia samples from the ICPS cohort. In order to confirm that 
transformation was successful, all modified samples were amplified using primers 
designed for methylation specific PCR (MSP) for both methylated and unmethylated 
DNA. Unmodified DNA was also amplified using a pair of primers for the same 
fragment but without modified cytosines. Amplification was carried out using the 
standard conditions previously described (Section 5.2.3). For unmodified samples a 
band of the expected size was observed but no bands were present for modified 
DNA with either one of the three pairs of primers, after amplification (Figure 5.6).  
In order to assess the quality of DNA, PCR was also performed with a pair of primers 
previously used successfully. It was observed that unmodified DNA was successfully 
amplified with the pair of primers used for the SNP2 of DKK3, which indicated that 
the template was good enough to perform PCR. As expected, these primers were not 
successful in amplifying the samples after modification (Figure 5.7). However, further 
attempts to amplify modified samples using MSP and bisulphate sequencing primers 
did not yield any bands.  
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Figure 5.6 PCR amplification of samples before and after modification with the 
Imprint kit (Sigma-Aldrich).  
Three pairs of primers were designed to amplify the same region within the second CpG 
island. The pair of primers designed for unmodified DNA was also used in modified samples 
as a negative control. We observed bands of the expected size when amplifying unmodified 
samples but not for samples after modification. 
 
Figure 5.7 Amplification of unmodified and modified DNA with a control primer 
pair. 
 The pair of primers used for amplification of SNP2 of DKK3 used to verify the quality of the 
template and the success of the modification 
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A number of possible reasons were considered to explain the absence of bands when 
attempting to amplify the bisulphite-modified samples. The first possibility was that 
the bisulphite reaction was incomplete or unsuccessful. This seemed particularly 
likely as a previous PCR of six bisulphite modified samples using primers for 
unmodified, methylated and unmethylated DNA, yielded a band of the expected size 
only when using the pair of primers for unmodified samples (Figure 5.8). A second 
possibility was that PCR reaction conditions required optimisation. For this we chose 
to use the primer pairs designed for sequencing to perform a gradient of annealing 
temperatures using one sample from the ICPS cohort. A band of ~631 bp was 
observed with annealing temperatures between 60.3 and 65.2 °C (Figure 5.9). A new 
PCR was performed using 10 µl of the bisulphite modified samples and an annealing 
temperature of 64°C. We observed bands for three out of eight samples (Figure 
5.10). The bands were cleaned-up for sequencing, however the amount of DNA 
recovered was low and the resolution of the sequence obtained was very poor.  
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Figure 5.8 PCR performed with samples after modification with Imprint (Sigma-
Aldrich).  
Bands of the expected size were only observed when amplified with primers used for 
unmodified DNA. 
 
 
Figure 5.9 Annealing temperature gradient of a modified control DNA sample.  
PCR amplification was carried out after modification with the Imprint (Sigma-Aldrich) kit 
using the pair of primers designed for sequencing.    
 
 
Figure 5.10 Amplification of eight samples modified with the Imprint kit.  
PCR was performed using primers designed for sequencing (annealing temperature of 64ºC) 
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A new bisulphite modification was performed on a set of 10 samples, this time using 
the Methylation Gold kit (Zymo Research). In addition to the samples used above, 
two methylated controls were prepared using a CpG methyltransferase (NEB). No 
bands were observed and this result was persistent even after applying an annealing 
temperature gradient and semi-nested PCR amplification. Following this result and 
considering the low amount of DNA that was recovered from column-based kits a 
new modification was made using the MethylEasy kit (Human Genetic Signatures), 
which involves a precipitation clean-up step that ensures a better product yield. 
Initially four modified samples and two controls were successfully amplified with the 
control primers provided with intense bands observed after the second round PCR. 
Nested PCR for DKK3 using bisulphite sequencing primers was also successful for 
amplification of ICPS tissue samples as well as the controls provided by the kit 
(Figure 5.11).  
 
 
Figure 5.11 Bands obtained for amplification four ICPS samples after modification 
with MethylEasy (HGS) kit.  
Two controls, provided with the kit, were amplified as well. C1 is an unmodified control that 
was treated along with the samples while C2 is a positive control. Amplification was 
successful for control primers and DKK3 primers for bisulphite sequencing after second 
round PCR at an annealing temperature of 55º C. 
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5.3.2 Direct bisulphite sequencing was only possible from TA 
constructs 
Following the successful amplification of the desired fragment of the promoter region 
for DKK3 containing the CpG island of interest, bands from controls and cases were 
excised from the gel and cleaned up for sequencing. Although the amount of DNA 
recovered was sufficient for sequencing, the quality of the sequence obtained from 
many attempts was very low and it was impossible to clearly identify any possible 
methylated sites. 
In order to improve the quality of the sequence new primers were designed to 
introduce the sequence from the M13 pair of primers, commonly used as sequencing 
primers for some plasmids. The bands obtained from this amplification were excised 
from the gel and cleaned-up for sequencing. However, the quality of the sequence 
only improved enough to enable the reading of very few initial nucleotide bases and 
the majority of the CpG island remained illegible (Figure 5.12).  
 
 
Figure 5.12 DKK3 CpG island fragment tagged with an M13 sequencing primer.  
Sequence from the M13 sequencing primers was used to tag CpG fragments as an attempt 
to improve the quality of the sequence fluorogram. A slight improvement was observed but it 
was not possible to read most of the sequence.  
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A further attempt to obtain sequence of better quality involved cloning the amplified 
fragment corresponding to the CpG island of DKK3 into a pCR 2.1 TA vector 
(Invitrogen). One important limitation of this approach over direct sequencing is the 
fact that this method effectively implies the selection of one of the two copies of the 
gene and therefore it is not possible to identify whether a particular CpG site could 
be partially methylated. For this reason at least ten colonies were sequenced for 
each one of the tissue samples that were analysed using an M13 reverse primer 
(Invitrogen).  
Five cases and five controls from the ICPS cohort were selected for the study. The 
sequence obtained from the clones prepared confirmed that the DNA was 
successfully modified and revealed that methylation was indeed occurring in the 
second CpG island, in the promoter region of DKK3 (Figure 5.13). A number of 
methylated sites were observed in both controls and cases. A region between CpG 
sites 15 and 28 was identified where the degree of methylation was particularly high. 
Moreover this region appears to be more heavily methylated in cases compared to 
controls (Figure 5.14).  
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Figure 5.13 Sequence fluorograms of one colony from sample 70 (schizophrenia) 
and sample 44 (control) from the ICPS cohort. 
Arrows indicate a CpG site, which was methylated in S70 and appears as a cytosine (C), but 
not in C44 where it is shown as a tyrosine (T). Particular to this sequence was the site 
marked by asterisk, which appears to be an unmethylated CpG site but was in fact T from 
the original sequence.  
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Figure 5.14 Schematic representation of the methylation status of the 41 CpG 
sites in the analysed fragment from DKK3.  
Summary of the data obtained from sequencing ten colonies for each sample. A colour grade 
is used to represent different degrees of methylation for each site from 0/10 to >5/10. 
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5.3.3 MSP results compared to bisulphite sequencing findings 
In order to meet the main objective of this section, MSP was performed using the 
same five controls and five cases from the ICPS cohort that were cloned into the TA 
vector and sequenced, in order to compare the results from both analyses. 
Methylated controls prepared using a CpG methyltransferase (NEB) were also used 
and sequenced to confirm that all CpG sites contained within the analysed fragment 
were methylated (Figure 5.15). First round sequencing primers were used to amplify 
the entire CpG Island, using the MSP primers for a second round PCR. The fragment 
obtained from this procedure only includes CpG sites from 20 to 41, which coincide 
with the region identified as being more heavily methylated from the sequencing of 
colonies from controls and cases (Figure 5.14). 
All samples used for MSP, were amplified with the two pair of primers specific for 
each methylation status. Although non-specific bands were observed in both 
methylation cases and for all amplified samples, analysis of the unmethylated and 
methylated control samples produced a band of the expected size only present in the 
appropriate lane (Figure 5.16). When considering that the analysed CpG island was 
not completely methylated for any of the samples that we sequenced, it would be 
expected that both bands would be present in our MSP analysis. This was the case 
for most of the samples analysed. It is important to mention that this procedure was 
performed at least three times for each sample and the results were not consistent in 
all cases. One exception was the schizophrenia sample number 70 for which, in every 
attempt, a clear band was observed only when using the primer pair for the 
unmethylated case.  
 257
 
 
Figure 5.15 Sequence from a methylated control sample prepared by treatment 
with a CpG methyltransferase (NEB).  
Marked CpG sites are included in the fragment amplified by MSP primers. Non-CpG, 
unmethylated cytosines were converted and are marked with asterisks. The arrow indicates 
a thymine present in the fragment even before bisulphite treatment. 
 
Figure 5.16 MSP of controls and cases of the ICPs cohort. 
Bands obtained from methylation specific PCR (MSP) of seven control samples and eight 
schizophrenia cases from the ICPS cohort, including the ones previously sequenced. A 
control sample was included for each methylation status. 
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5.4 Discussion 
5.4.1 Successful bisulphite modification of DNA from brain tissue 
samples 
A successful modification of DNA was a critical step for the analysis of CpG island 
methylation of DKK3. An important consideration to make is that after modification 
the two strands of DNA are no longer complementary and therefore primers have to 
be design for each individual strand. It is important to consider that in general DNA 
isolated from tissue, as is the case of the samples from the ICPS cohort, might be 
more resistant to bisulphite conversion than DNA isolated from cultured cells 
(Warnecke et al., 2002). This was the main reason why three different kits had to be 
tested for the present analysis. It was determined that the MethylEasy kit (Human 
Genetic Signatures) was the most effective particularly because it involves a clean-up 
procedure that is based on precipitation of DNA after bisulphite modification and this 
results in a better yield of product.  
5.4.2 Methylation of a CpG island in the promoter region of DKK3 in 
schizophrenia cases and controls detected through bisulphite 
genomic clonal sequencing analysis 
We report methylation of a CpG island in the promoter region of DKK3 in 
schizophrenia cases and controls of the ICPS cohort. Although the degree of 
methylation observed was not extensive for any of the samples analysed, overall 
there was a larger number of prominently methylated sites in cases when compared 
to controls. Of particular interest was the region comprising CpGs 16 to 29 in which 
methylation appeared to be much heavier in cases compared to controls. These 
differences in methylation of specific sites in cases compared to controls is especially 
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noteworthy when considered in the context of the “critical site” model originated 
from reports where methylation of one or two cytosines was observed to be 
sufficient for downregulation of gene expression (Robertson et al., 1995; Pogribny et 
al., 2000).  
Even though limitations associated with the methodology made it hard to include a 
larger number of samples in the analysis, our data confirm the presence of CpG 
island methylation of DKK3 in samples from the ICPS cohort. Moreover, the level of 
detail achieved by using a clonal sequencing method allows for the identification of 
methylation in each CpG site at a single-molecular level. The resolution obtained 
from clonal bisulphite sequencing also allows for the identification of allele specific 
methylation, which is recently a subject of investigation in relation to complex 
disorders (Polesskaya et al., 2006; Meaburn et al., 2010). This is an advantage over 
direct bisulphite sequencing and any other methods available to date, which can only 
give a semi-quantitative measure of the level of methylation of the target sequence. 
To date, bisulphite clonal sequencing is the only method that has been recognised to 
be able to achieve this degree of resolution (Warnecke et al., 2002; Clark et al., 
2006).  
5.4.3 MSP as a rapid method for detection of methylation in brain 
tissue samples 
The results obtained from the MSP analysis of controls and cases appear to be 
consistent with the degree of methylation observed from those same samples from 
the clonal sequencing analysis. Moreover, the use of methylated and unmethylated 
control samples demonstrates that the primers designed are able to successfully 
differentiate each methylation status. However, there are important discrepancies 
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that together with the presence of non-specific bands suggest that mispriming might 
be occurring, causing false positives or false negatives. This made it difficult to 
assess the sensitivity of the method. It is also important to note that very few CpG 
sites were methylated in all samples analysed through bisulphite sequencing. This 
represents a drawback for the use of MSP because the primers designed for the 
assay only cover CpG sites from 20 to 23 (forward primers) and from 37 to 40 
(reverse primers). This could explain why control samples 51 and 52 are only 
amplified with the pair of primers specific for unmethylated DNA. 
5.4.4 Further investigation of the effect of DKK3 in β-catenin 
translocation in neuronal cells 
In addition to the notion of the implication of the canonical Wnt signalling pathway 
during developmental stages in the aetiology of schizophrenia, the important role of 
β-catenin in synaptic plasticity and memory consolidation (Maguschak and Ressler, 
2008) increases the interest for further investigation of this subject. Reports of 
NMDA-receptor activation leading to generation of more stable forms of β-catenin in 
hippocampal neurons (Abe and Takeichi, 2007) might provide the basis for further 
studies. In a recent study, Mao et al. (2009) provide evidence for an important role 
of the disrupted in schizophrenia (DISC1) gene in neuronal progenitor proliferation 
through this β-catenin/GSK-3β pathway. In a sophisticated analysis the authors 
demonstrate that DISC1 knock down significantly increases phosphorylation of β-
catenin, affecting progenitor cell proliferation in vivo and in vitro. Additionally, they 
showed that normal expression of DISC1 overrides this effect. Further investigation 
led to identification of a particular peptide of DISC1 that interacts directly with GSK-
3β with a strong inhibitory effect. Finally, GSK-3β has been proposed as a candidate 
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gene for psychotic disorders, due to the multiple functions of this enzyme in distinct 
metabolic pathways and its involvement in a number of processes in the CNS 
(Emamian et al., 2004; Beaulieu et al., 2007; Peineau et al., 2008; Freyberg et al., 
2010). 
DKK3 remains the one member of the dickopff family of proteins whose precise role 
in modulation of Wnt signalling pathway is not yet known (Wu et al., 2000; Brott and 
Sokol, 2001; Mao et al., 2001; 2002; Davidson et al., 2002; Mao and Niehrs, 2003). 
Data collected from a number of studies suggests that the roles of DKK3 in Wnt 
signalling regulation are varied and may be cell type specific (Caricasole et al., 2003; 
Hoang et al., 2004; Nakamura Y et al., 2007; Nakamura REI et al., 2010). Moreover, 
a number of reports suggests that the mechanisms through which DKK3 and other 
related genes modulate Wnt signalling might depend on whether they exert their 
function in developing or adult organisms (Kawano and Kypta, 2003; Nakamura et 
al., 2007; von Marschall and Fisher, 2010).  
Most of the data available to date on the mechanisms of action of DKK3, as well as 
its interaction with other proteins, has been gathered through extensive research on 
the involvement of DKK3 in proliferation of cancer cell lines (Tsuji et al., 2000; 2001; 
Hsieh et al., 2004, Abarzua et al., 2005; 2007). A number of studies have found 
evidence for hypermethylation of the promoter region of DKK3 leading to 
downregulation of the gene in a variety of tumours. Data from these studies also 
suggests that this decrease in expression of DKK3 leads to translocation of β-catenin 
into the cell nucleus and stimulation of cell proliferation (Kobashashi et al., 2002; 
Hoang et al., 2004; Roman-Gomez et al., 2004; 2007; Arjen et al., 2008; Veeck et 
al., 2008b; Chim et al., 2008; Yue et al., 2008; Lee EJ et al., 2009). 
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In an attempt to gain an insight into the functional relevance of down-regulation of 
DKK3 in the pathophysiology of schizophrenia, particularly with respect to the 
function of this gene in processes related to the Wnt signalling pathway an additional 
analysis was carried out based on reports of DKK3 being able to obstruct b-catenin 
translocation to the cell nucleus after activation of Wnt signalling pathway (Yue et 
al., 2008). Mouse neuroblastoma N2a cells were used as a neuronal cell line and 
COS7 cells were chosen as controls. However, this study could not be completed due 
to extensive optimisation required for this analysis. Preliminary results are presented 
in Appendix E as the basis for future investigation.  
Cells were transfected with GFP-DKK3 and an RFP-β-catenin constructs in order to 
observe the effect of expression of DKK3 in the nuclear translocation of β-catenin for 
gene transduction through TCF/Lef in the context of activation of the Wnt signalling 
pathway. This last objective was achieved by luciferase reporter assay using a TCF 
activated reporter (TOPFlash) and a second construct with the same TCF domain but 
containing mutations for inactivation was used as a negative control (FOPFlash). 
The distribution of GFP-DKK3 was observed to be cytosolic in both N2a and COS7 
cells (Supplementary Figure 1) consistent with other reports (Nakamura et al., 2007; 
Untergasser et al., 2008). Western blot analysis confirmed the expression of the 
secreted glycosylated form of DKK3. Expression of the RFP-β-catenin fusion protein 
was also confirmed by western blot, whilst its subcellular localization was observed to 
be primarily nuclear (Supplementary Figure 2) in both cell lines. Analysis of the 
luciferase activity of TOP and FOPFlash reporters later confirmed that transfection of 
the RFP-β-catenin construct induced activation of Wnt signalling in N2a cells and that 
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co-transfection of GFP-DKK3 resulted in significant inhibition of this activation 
(Supplementary Figure 3).  
These preliminary findings are a starting point for the investigation of the precise 
role of DKK3 in the regulation of β-catenin mediated gene transcription in neurons. 
The importance of elucidating the mechanisms through which schizophrenia 
candidate genes involved in the Wnt signalling pathway interact becomes evident 
when considering previous reports of increased Wnt activity in schizophrenia 
(Miyaoka et al., 1999; Kozlovsky et al., 2000; 2004; Beasley et al., 2001). Moreover, 
the data presented in this preliminary analysis leads to the formulation of interesting 
questions for future investigation. It can be hypothesised, for example, that through 
modulation of the Wnt signalling pathway, DKK3 might be playing a role in 
homeostasis and synaptic plasticity in the adult CNS. This idea becomes more 
intriguing when considering the important role of DKK3 and the canonical Wnt 
pathway in cell proliferation (Chen et al., 2001; Kobashashi et al., 2002; Yue et al., 
2008), which is in concordance with the evidence of a role of DISC1 in neuronal 
progenitor proliferation (Mao et al., 2009) and adequate integration of adult-born 
neurons in hippocampus (Duan et al., 2009). 
Finally, in the context of the growing evidence for the involvement of the β-
catenin/Wnt signalling pathway in modulation of synaptic function and memory 
consolidation in adult CNS in mammals (Hirabayashi et al., 2004; Chen et al., 2006; 
Beaumont et al., 2007; Wexler et al., 2008; Avila et al., 2010), extension of the 
investigation of the role of DKK3 in the canonical Wnt pathway would be worth 
perusing. One particular idea for the extension of the present study is based on 
recent evidence of the initiation of gene expression by β-catenin through a 
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mechanism involving activation of NMDA-receptor activation in hippocampal neurons 
(Abe and Takeichi, 2007). Specifically, the investigation of DKK3 modulation of 
canonical Wnt signalling as a response to activation or inhibition of NMDA receptors 
could be carried out using NSC34 cells. NSC34 have a close similarity to developing 
motor neurons and they are known for the expression of NMDA receptors and their 
ability to model early synapse formation (Cashman et al., 1992).  
5.4.5 Conclusion 
The use of MSP for analysis of CpG island methylation has been used successfully for 
the analysis of DKK3 and other genes in cancer cell lines and tumour tissue (Herman 
et al., 1996; Roman-Gomez et al., 2004; 2007; Veeck et al., 2008b; Chim et al., 
2008; Yue et al., 2008). In these cases, the density of methylation across the CpG 
island was greater than that observed for DKK3 in the ICPS cohort. The fact that the 
pair of primers designed for umethylated DNA failed to produce a band of the correct 
size for the methylated controls (and vice versa) seems to support the idea that a 
denser pattern of methylation is needed for MSP to be successful. Therefore, this 
method must not be excluded as a viable and rapid alternative for the investigation 
CpG island methylation of other candidate genes whose expression has been 
reported as changed in schizophrenia.  
Although, these findings might not be enough evidence to conclude that epigenetic 
mechanisms playing a part in the downregulation of DKK3 reported in schizophrenia 
(Ftouh et al., 2005), the location of the gene in a chromosomal region whose 
hypermethylation has been associated with major psychosis is encouraging (Mill et 
al., 2008). Further investigation of methylation status in the first CpG island, which 
was not included in the present study, could provide a more complete analysis. 
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6.1 Significant genotype and haplotype correlation with 
levels of expression for ZnT3, CACNA1E and FRZB in the 
ICPS cohort 
Analysis of the effect of SNP genotype and haplotype on levels of expression of the 
selected schizophrenia candidate genes revealed interesting correlations for three 
genes in particular. For all three genes ANOVA revealed a significant association of 
disease status with levels of expression. In the case of ZnT3, a significant overall 
effect was observed for genotypes and two-SNP haplotypes on levels of expression 
of the gene in BA10. This effect contributed to a significant interaction between 
disease status and genotype (or haplotype) with respect to gene expression. Unlike 
ZnT3, no overall significance was observed of SNPs in CACNA1E or FRZB with 
expression levels of the genes in BA22 and BA10, respectively. However, for these 
two genes, significant associations of individual genotypes and haplotypes with 
mRNA levels resulted from post-hoc Bonferroni comparisons.  
The fact that these associations of genotype with expression levels were present for 
CACNA1E and FRZB, in spite of their lack of genetic association with disease, brings 
up important questions. One of them is whether the changes in regulation of 
expression of these genes observed in schizophrenia are a result of the disease or 
rather a consequence of other factors (e.g. neuroleptic treatment). This is 
particularly intriguing considering the role of CACNA1E and FRZB in glucose 
methabolism and chronic inflammation (Matsuda et al., 2007; Bi et al., 2009; Hirata 
et al., 2010; Ekström et al., 2011). Extensive research is being conducted in order to 
elucidate the implications of both of these processes in the methabolic syndrome 
observed in schizophrenia patients subject to chronic antipsychotic treatment 
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(Thakore, 2005; Remington, 2006; Heald, 2010). Thus the SNPs in CACNA1E and 
FRZB identified as markers of expression, rather than markers of disease, might be 
correlated with endophenotypes representing metabolic disfuction. This may 
contribute to a better understanding of the mechanisms underlying the significant 
changes in the expression of these genes in schizophrenia cases compared to 
controls. 
Even though none of the SNPs for which association with expression was observed 
was a functional polymorphism, these SNPs are reported here as markers for regions 
within the genes that could be implicated in regulation of expression. Moreover, 
when considering LD patterns obtained across polymorphisms within these three 
genes, an interesting possibility for future studies is that one or more of the selected 
SNPs could be in strong linkage disequilibrium with other variants directly involved in 
regulation of gene expression (Skelly et al., 2009). Notably, there has been a 
suggestion that genetic variants that have an impact in mRNA or protein levels are 
likely to have an important contribution to disease susceptibility in complex disorders 
(Bray et al., 2003). This idea has been supported by recent studies, which have 
shown that amongst polymorphisms with a high probability of being also expression 
quantitative trait loci (eQLT) are enriched amongst those identified from GWAS as 
marginally associated with schizophrenia (Richards et al., 2011) and in general with 
complex traits (Nicolae et al, 2010). 
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6.2 Genetic association of the synaptic vesicle specific 
zinc transporter (ZnT3) with schizophrenia 
From the analysis of genetic association of genes involved in synaptic function and 
cellular communication with schizophrenia, ZnT3 gene was the most consistently 
associated with the disorder. Significant allelic association was observed for four 
SNPs with disease status in the East UK cohort. Also, genotypic associations were 
observed for all four SNPs, consistent with a dominant model for disease penetrance. 
Haplotype analysis further supported these associations with five haplotypes 
associated with risk for disease, even after multiple comparison correction.  
Our results are supported by a recent patent reporting a number of polymorphisms 
significantly associated with schizophrenia (Chissoe et al., 2008). This patent 
describes a study where polymorphisms within or in proximity of genes coding for 
proteins that could potentially be used as targets for drug design were analysed in 
two cohorts of controls and schizophrenia cases of Caucasian ancestry. The first of 
these cohorts comprised 511 schizophrenia cases and 500 controls collected from 
Munich. The second cohort was conformed of 546 and 669 controls collected from 
Aberdeen. Amongst the polymorphisms identified as significantly associated with 
disease in the Munich cohort, were rs2083363 and rs2485506. The first of these 
polymorphisms is located close proximity of ZnT3 at approximately 2.1 Mb from the 
3’ end of the gene. Both allelic (p=0.01926; OR=1.3) and genotypic (p=0.01993; 
OR=2.28) associations with schizophrenia were reported for this SNP. The second 
SNP (rs2485506), located in an intronic region of CACNA1E, was also found to be 
associated with disease in the Munich cohort at thte genotypic (p= 0.0462; OR= 
1.44) and allelic level (p= 0.0323; OR= 1.22). Furthermore, SNP rs7775, a non-
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synonimous variant in exon 6 of FRZB, was one of the polymorphisms that presented 
the most significant genotypic (p= 0.0042; OR= 1.82) and allelic (p= 0.0044; OR= 
1.67) association with schizophrenia in the Aberdeen cohort.  
It is interesting that three of the six selected candidate genes for the present study 
were reported as associated with schizophrenia in the previously described patent, 
particularly considering that the methodology followed for selection and analysis of 
these genes was different from the one used here. This provides support for the 
candidate gene approach used for this study, in which genes were selected for 
analysis on the basis of their function and their already established differential 
expression in schizophrenia.  In spite of this, no significant associations of SNP 
genotype with disease were identified for any of the candidate genes, other than 
ZnT3. For some of the markes in these genes, and particularly for those in CACNA1E, 
the small size effects observed might result in a reduced power of the study for 
detecting significant associations.  
Furthermore, it is important to consider other SNPs identified as associated with 
schizophrenia from previous GWAS studies and which are located in genes that might 
be functionally related to those analysed here. Examples of these include SNPs 
located in or close to, zinc finger and SCAN containing domain 23 (ZSCAN23), zinc 
finger, BED-type 4 (ZBED4) and the zinc finger and BTB domain containing 9 
(ZBTB9), as well as 22 (ZBTB22) proteins and a number of zinc finger proteins. 
Amongst the most significant are ZNF311, ZNF490, ZNF284, ZNF204, ZNF391, 
ZNF184 and ZNF274. Especially notable are ZNF322A, which was replicated in two 
studies (ISC, 2009; Shi et al., 2009) and ZNF804, which like ZNT3 is located in 
chromosome 2 (Williams et al., 2011; Zhang et al., 2011). Also relevant were two 
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more SNPs located in the CACNA1C gene with schizophrenia (ISC, 2009; Moskvina et 
al., 2009), which is different to the one reported previously as associated with 
bipolar disorder (Ferreira et al., 2008). In addition, association of genetic variants 
with schizophrenia has also been reported for polymorphisms in the secreted Wnt 
ligand Frizzled-3 (FZD3) in Chinese and Japanese populations (Yang et al., 2003; 
Zhang et al., 2004; Katsu et al., 2003), although attempts to replicate these findings 
and or reproduce them in other populations have not been successful (Ide et al., 
2004; Wei and Hemmings, 2004; Hashimoto et al., 2005; Jeong et al., 2006). Finally, 
association of a SNP in a region close to the WNT4 gene was reported in one of 
these GWAS (ISC, 2009).  
6.3 Modest evidence for statistical epistasis and insights 
into the possible disruption of particular functional 
pathways in schizophrenia 
The analysis of SNP association with gene expression levels and disease status 
presented here has its base on previous microarray studies where a number of genes 
were identified as significantly changed in schizophrenia. Candidate genes belonging 
to two major functional groups were analysed, genes implicated in synaptic function 
and cellular communication and genes involved in Wnt signalling pathway. This 
approach for the selection of the genes analysed was used as an attempt to identify 
not only particular genes associated with schizophrenia, but to highlight particular 
functional pathways that might be implicated in the aetiology of the disorder. In spite 
of the fact that consistent significant associations with schizophrenia were observed 
for only one of the candidate genes analysed here the evidence for statistical 
epistasis between genes within both functional groups provides support for further 
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investigation functional interactions between genes within each of these categories 
that might have important implications for biological function in schizophrenia, as has 
been suggested for the case of interactions between the GAD1 and COMT genes 
(Straub et al., 2007; Marenco et al., 2010).  
6.4 A method for investigation of possible CpG island 
methylation of DKK3 for application to other 
schizophrenia candidate genes 
The complex genetics known to be involved in the aetiology of schizophrenia as well 
as the prevailing onset of the disease during the adult life have made the 
involvement of epigenetic mechanisms in the pathophysiology of the disorder an 
exciting subject of investigation. Furthermore, the increasing evidence collected on 
the effect of promoter region methylation on down-regulation of schizophrenia 
candidate genes, such as GAD1 and REELN (Dong et al., 2005) makes this 
investigation worth pursuing. The analysis of CpG island methylation in candidate 
genes for schizophrenia will benefit from developments in high throughput 
techniques such as the use of microarrays and DNA-pooling techniques (Mill et al., 
2008; Docherty et al., 2010; Gu et al., 2010). 
For this study, it was considered important to determine the methylation status of 
the promoter regions of the selected candidate genes whose expression was 
changed in schizophrenia (Ftouh et al., 2005; Maycox et al., 2009; Barnes et al., 
2011). DKK3 was used as the basis of the analysis in order to establish a method 
that could be used for analysis of methylation of CpG islands of other candidate 
genes. The method was based on clonal bisulphite sequencing, which is the only 
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method available that allows for the determination of the methylation status of each 
CpG site (Clark et al., 2006). Results from sequencing of the promoter region of 
DKK3 in controls and schizophrenia cases were later compared to those obtained 
from MSP analysis. The objective of this was to establish whether MSP could be used 
as a rapid method for detection of CpG island methylation in candidate genes using 
post-mortem tissue samples from schizophrenia cases and controls.  
It was concluded from this analysis that while MSP is a sensitive method for 
detection of CpG island methylation using DNA from post-mortem brain tissue 
samples. However this technique seems to be more reliable in cases where the 
density of methylation is high. Since this was not the case of DKK3, there was the 
need to use clonal bisulphite sequencing as a complementary method. The laborious 
nature of this process meant that the number of samples that could be used was 
reduced, however this technique allows for the identification of the methylation 
status of each CpG site, which is not possible to achieve with any other method at 
the moment. Although from this study, it was not possible to conclusively state that 
epigenetic mechanisms are indeed responsible for the down-regulation of DKK3 
observed in schizophrenia, MSP might still be a suitable method for the analysis of 
other schizophrenia candidate genes showing more robust changes in expression in 
cases compared to controls. Moreover, the possibility of CpG “critical site” (Robertson 
et al., 1995; Pogribny et al., 2000) regulating expression of DKK3 in a subset of 
schizophrenia cases is an intriguing possibility and one that might be worthy of 
future investigation.  
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6.5 Conclusion  
Investigation of the genetic risk factor contributing to the aetiology of schizophrenia 
has been a challenging task. Very few loci associated with disease have been 
identified so far, in spite of the availability of data from genome-wide studies even 
with the use of large numbers of samples in some studies. Amongst the reasons 
proposed to explain this phenomenon is the fact that the individual effect of common 
variants in the risk of complex disorders tends to be relatively small. Genome-wide 
linkage and association studies have been extensively used for the elucidation of 
genetic factors contribution to the risk of schizophrenia. However, there are a 
number of limitations associated with the genome-wide approach. One of these 
limitations is that the interpretation of data becomes difficult due to the large number 
of loci analysed resulting in the need to adjust the threshold of significance 
depending on the conditions, in order to minimise the occurrence of false positive 
reports (Lander and Kruglyak, 1995; Morris, 2008). Other factors affecting the ability 
of GWAS to yield information about genetic factors contributing to the heritability of 
schizophrenia are population structure and the assumption that common variants will 
make the greatest contribution. Moreover, the tag-SNPs generally included in GWAS 
are not representative of haplotype blocks and therefore do not fully represent the 
genetic variation present in the population (Morris, 2005). 
The approach used in the present study consisted in selecting a number of candidate 
genes based on strong biological plausibility. Selected genes showed robust changes 
in expression in schizophrenia in brain regions implicated in functional abnormalities 
occurring in this condition (Maycox et al., 2009; Barnes et al., 2011). This approach 
has been used successfully in a number of studies (Voisey et al 2010a; Voisey et 
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2010b; Burdick et al 2010). Furthermore, in the paper by Burdick et al (2010), which 
was also highlighted in an Editorial (Cannon 2010), a cohort of 173 schizophrenia 
cases and 137 controls (310 individuals in total) was used for a candidate gene 
association study. This is a similar size cohort to that used in the present study for 
analysis of association with schizophrenia (320 individuals in East UK cohort).  
Significant correlations of expression with schizophrenia in all selected candidate 
genes arising from our previous microarray study were identified. A significant 
interaction between genotype and disease status with respect to gene expression 
was identified for ZnT3 using 3-way ANOVA. Significant association of particular 
genotypes and haplotypes with gene expression was also observed for CACNA1E and 
FRZB. A subsequent association study was carried out in a case-control cohort from 
East UK (East Anglia and East Yorkshire) using the same widely used analytical 
approach with correction for multiple tests that have been successfully used by 
Voisey et al (2010a: 2010b) in their studies of similar cohort size (160 schizophrenia 
cases and controls) and OR values.  
The results from the present study particularly substantiate ZnT3 as strong candidate 
gene for schizophrenia and provide support for the use of a candidate gene approach 
for the analysis of association with disease. The exclusive localization of ZnT3 to 
synaptic vesicles (SV) in different neuronal populations serving as the only source of 
metallic zinc (Paoletti et al., 2009) makes this gene a particularly interesting 
candidate from the functional point of view. Zinc enriched neurons are also 
glutamatergic neurons (Sindreu et al., 2003; Frederickson et al., 2005). Consistent 
with this is the finding that vesicular zinc uptake is not only regulated by ZnT3 but 
also by expression of the vesicular glutamate transporter type 1 (Vglut1) in PC12 
 275
cells (Salazar et al., 2005). There is evidence of zinc-mediated modulation of 
excitatory synapses through regulation of glutamate and γ aminobutiric acid (GABA) 
receptors (Xie et al., 1994). It has also been suggested that zinc might have an 
important role in modulatinon of synaptic plasticity through inhibition of NMDA 
receptors (Vogt et al., 2000; Sindreu et al., 2003). In spite of these findings, the 
precise role of vesicular zinc in glutamatergic synapse is still not well understood. 
However, the localization of zinc enriched neurons somata to either cortical or limbic 
structures suggests an important role of these neurons in linking these regions 
(Sindreu et al., 2003; Frederickson et al., 2005; Paoletti et al., 2009).  
Two recent studies have provided data supporting the role of vesicular zinc in 
hippocampus-dependent memory and learning processes (Sindreu et al., 2011; Pan 
et al., 2011). Using the ZnT3 KO mouse model, Sindreau et al. (2011) show that the 
absence of the ZnT3 gene contributes to important deficits in spatial working 
memory and contextual discrimination. These findings are particularly interesting in 
the context of the downregulation of ZnT3 in the prefrontal cortex (PFC) of 
schizophrenia cases (Maycox et al., 2009). Functional interaction between 
hippocampus and PFC is considered to have important implications in memory and 
learning processes (Yoon et al., 2008; Mölle and Borne, 2009). Furthermore, there is 
extensive evidence suggesting a disruption in connectivity between the hippocampus 
and PFC underlying schizophrenia pathophysiology (Harrison, 2004; Sigurdsson et 
al., 2010). In this study four SNPs in ZnT3 were found to be significantly associated 
with schizophrenia. Correlations of SNP genotype with cognitive endophenotype in a 
lager cohort of samples might be performed in the future, in order to further 
investigate the contribution of the genetic variation of ZnT3 to the disease.   
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The pathway approach taken in this study was supported by the evidence for 
statistical epistasis between polymorphisms in both groups of genes analysed. In 
consideration to this, it is perhaps important to draw attention to the polymorphisms 
that have been identified as risk factors for schizophrenia from GWAS in other genes 
related to synaptic processes or to modulation of the Wnt signalling pathway (ISC, 
2009; Moskvina et al., 2009; Stefansson et al., 2009; Shi et al., 2009). Particularly 
interesting were results reported in the study by Chissoe et al. (2008), where a 
number of polymorphisms were identified as significantly associated with 
schizophrenia. Amongst the more significantly associated polymorphisms were two 
SNPs located in ZnT3, one SNP located in CACNA1E and one more located in FRZB.  
Finally, in order to explore the possible epigenetic regulation of expression of the 
selected candidate genes, clonal bisulphite sequencing and MSP were used. The 
objective of the approach was to provide a quick and reliable method for 
determination of CpG island methylation. For the purpose of designing the method, 
DKK3 was used as MSP primers had already been used successfully to determine 
methylation in cancer cell lines (Yue et al., 2008). It was concluded from this analysis 
that MSP is a sensitive method for detection of methylation. However, the presence 
of some false positives and negatives resulted in the need to use clonal bisulphite 
sequencing as a complementary method. Additionally, the density of methylation in 
DKK3 was low in the ICPS cohort and therefore it was not possible to conclusively 
state that epigenetic mechanisms are indeed responsible for the down-regulation of 
the gene observed in schizophrenia. However, once established the conditions for 
successful bisulphite modification of post-mortem brain tissue samples, it is possible 
to use this method for analysis of CpG island methylation of other candidate genes 
whose expression has been identified as significantly changed in schizophrenia. 
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Glossary  
Allele A variant of polymorphism at a given locus. 
Diplotype A specific combination of two haplotypes in an individual. 
Disease penetrance The risk of disease in a given individual.  Genotype-specific 
penetrances reflect the risk of disease with respect to 
genotype. 
Epistasis A phenomenon where the effect of one gene are modified 
by one or more other genes to produce a given phenotype. 
Exon A section of a gene that is represented in the mature form 
of the mRNA transcript 
False discovery rate The proportion of non-casual or false positive significant 
SNPs in a genetic association study. 
Genotype The combination of two alleles across both chromosomes at 
a given locus in an individual. 
Haplotype A consecutive series of alleles at different loci on a single 
chromosome in an individual. 
Hardy-Weinberg 
equilibrium 
Given a minor allele frequency of p, the probabilities of the 
three possible unordered genotypes (a/a, A/a, A/A) at a 
biallelic locus with minor allele A and major allele a, are (1 − 
p)2, 2p (1 − p), p2. In a large, randomly mating, 
homogenous population, these probabilities should be 
stable from generation to generation. 
Intron A noncoding section of a gene that is removed from the 
mature mRNA sequence by a process called splicing. 
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Linkage 
disequilibrium (LD) 
The population correlation between two allelic variants 
(usually nearby) on the same chromosome. The variants 
are said to be in LD if they are inherited together more 
often than expected by chance.  
Moving-window 
haplotype analysis  
For this analysis haplotype blocks are generated according 
to specific settings. For example, in an analysis comprising 
four SNPs, one might opt for a case/control comparison of 
two, three or four SNP haplotype frequencies. The number 
of markers selected defines the size of the ‘window’ that 
slides across the LD spine to generate the haplotype blocks. 
A χ2 test is used subsequently to identify significant 
differences in haplotype block frequencies between controls 
and cases.  
Odds ratio A measure of association derived from case-control studies; 
it is the ratio of the odds of disease in the exposed group 
compared with the non-exposed. 
Population 
stratification or 
structure 
The mixture of individuals with heterogeneous genetic 
backgrounds. It refers to the presence of two or more 
subgroups with distinct genetic ancestry in a given 
population.  
Regulatory region A section of the DNA sequence that directly or indirectly 
affects the expression of a gene. 
TagSNP A SNP in a region of the genome featuring high LD, which is 
a proxy for others in close proximity and which can be used 
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to genotype individuals at a reduced cost, while maintaining 
power. 
Type I error In a hypothesis test, a type I error occurs when the null 
hypothesis H0, is rejected when it is in fact true. 
Type II error In a hypothesis test, a type II error occurs when the null 
hypothesis H0, is not rejected when it is in fact false. 
Untranslated region A section of the mRNA transcript that is not translated to 
amino-acid sequence. 
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Appendix A 
 
Gene Assay Probe BA22 Fold p value 
CACNA1E Taqman 242410_s_at 1.24 0.003 
S100A8 RT-PCR 202917_s_at 3.16 0.007 
WISP3 RT-PCR 210861_s_at 2.5 0.024 
 
Supplementary Table 1 Data from Barnes et al. (2011) 
Represented in the table are the changes in expression obtained for CACNA1E, S100A8 and 
WISP3 from the microarray study by Barnes et al. (2011). Validated fold values of each gene 
in BA22 of cases compared to controls is provides, as well as p values for those changes. 
Also in the table are specified the type of assay used for validation of the microarray data 
and the probe ID. 
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Appendix B 
 
ZnT3 (SLC30A3) 
 Forward (5’ to 3’) Reverse (5’ to 3’) Fragment Size (bp) 
 
SNP1 
rs6547521 
ACAGGATGCTTCCACCTGTTCC ACTTCATCACCATGAGGTGAG 380 
 
SNP2 
rs11126936 
CTGAGAATTGGACCAGAATG GTGGAGTGAAGTGTGGAGTG 442 
 
SNP3 
rs2083363 
AGATTACAGGGGAAACATTCAC TGTAATCCTGGCTACTCGGGAG 388 
 
SNP4 
rs11126931 
TCAATGATTGCTGCTTCCTG TGGTTCTGCTCTGCCTTTAC 233 
CACNA1E  
 
SNP1 
rs17743547 
GTCAGGGGAAAGGGTACA GATGTCTCTGCAGCCCAC 294 
 
SNP2 
rs2280865 
GGAAAGACCTTTGACCTTGA GGACATCTGCATGTGCTTCC 483 
 
SNP3 
rs35737760 
CATGTGTCCTGCCCTCTCACA GAAGAGGACTCCTTGCCTTCT 600 
 
SNP4 
rs4652678 
CCCCTATAACCAGCTATTGAA CTGCCTGTGTCACCTTCTCAA 599 
 
SNP5 
rs704326 
GGCTGAATGTGACAAATG CGGGCATAAACTAAGAGG 656 
CAMKK2 
 
SNP1 
rs3817190 
TCATTGTGGTCACCGAGTGT CAAGGTTCCCTGGAGTCAAC 460 
 
SNP2 
rs1132780 
GGAGTGGAAGGTTGGAAAAGG CTAGCCAAGCCTGAAGCCTAC 493 
S100A8 
 
SNP1 
rs3795391 
GAGAAACCAGAGACTGTAGCAAC CCCTGTAGACGGCATGGAAATTC 746 
 
SNP2 
rs3006488 
GGCTTCTTCCTCCTCAATC CAAGAGCCACATCTAAGAC 590 
 
Supplementary Table 2 Primers pairs for analysis of SNPs in genes involved in 
synapsis and intracellular signalling. 
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FRZB 
 Forward (5’ to 3’) Reverse (5’ to 3’) Fragment Size (bp) 
 
SNP1 
rs10206992 
ACCTGATGACTGAGATTGCC ACTGATGCACTCTGGCACTG 218 
 
SNP2 
rs7607737 
TAATGGTCAGGATGGAACCC TCAGTGGGAAGTGATAGTTCAC 349 
 
SNP3 
rs288329 
AGCATCCATCATTGACTAAG TGAGTCAATGAGTAAACATGG 366 
 
SNP4 
rs16823799 
AGGCCTGTATTTTAATCCACC GCCTGATTGAGAAGCACAAC 872 
WISP3 
 
SNP1 
rs2280153 
ATGGAGAGACACTGTTTCCCG TCTCCACTCTTCTGCTTGCTG 366 
 
SNP2 
rs1230348 
ACCTACTGGACATCTCCACC AAGGCATGGAAGGAGAGTGTG 468 
 
SNP3 
rs1230345 
ACTCCAGTCTCGTACCTAGG TTAGAGGCCTTATCCATGGG 607 
DKK3 
 
SNP1 
rs2291599 
GCTCTGCTCTCCATTGACAC CAAACAACATGACCAGAGGA 388 
 
SNP2 
rs7480026 
GACAGTGAGTGCTGTGGAGA GGCTTTTGCATCCTGAAGT 371 
 
SNP3 
rs3206824 
GCAGGCTCCCACGTTTAGAG GCTATTTCTATTGCACATCTACCC 293 
 
Supplementary Table 3 Primers pairs for analysis of SNPs in genes involved in the 
Wnt signalling pathway. 
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Appendix C 
 
ZnT3 (SLC30A3) 
  Frequency (%)  
 n Genotype  Minor Allele 
SNP1 rs6547521:5’  
    
  G/G G/C C/C C 
ICPS schizophrenia 30 46.7 46.7 6.7 30.0 
ICPS controls. 36 38.9 47.2 13.9 37.5 
SNP2 rs11126936: Intron 1  
    
  G/G G/T T/T T 
ICPS schizophrenia 36 61.1 30.6 8.3 23.6 
ICPS controls. 36 44.4 44.4 11.1 33.3 
SNP 3 rs2083363: 3’  
    
  G/G G/C C/C C 
ICPS schizophrenia 35 62.9 28.6 8.6 22.9 
ICPS controls. 31 45.2 45.2 9.7 32.3 
SNP 4 rs11126931: 3’  
    
  C/C C/T T/T T 
ICPS schizophrenia 33 60.6 30.3 9.1 24.2 
ICPS controls. 34 41.2 47.0 11.8 35.3 
CACNA1E 
SNP1 rs17743547: Intron 10 (Splice Site)  
   
  G/G G/A A/A A 
ICPS schizophrenia 36 69.4 27.8 2.8 16.7 
ICPS controls. 37 73.0 27.0 0.0 13.5 
SNP2 rs2280865: Intron 22 
   
 
  T/T T/C C/C C 
ICPS schizophrenia 36 38.9 47.2 13.9 37.5 
ICPS controls. 37 43.2 48.6 8.1 32.4 
SNP3 rs35737760: Exon 23 [D/E] 
    
  T/T T/A A/A A 
ICPS schizophrenia 34 88.2 11.8 0.0 5.9 
ICPS controls. 35 80.0 17.1 2.9 11.4 
SNP4 rs4652678: Exon 32  
    
  T/T T/C C/C C 
ICPS schizophrenia 36 58.3 36.1 5.6 23.6 
ICPS controls. 36 56.8 36.1 11.1 29.2 
 
Supplementary Table 4 Genotype and allele frequencies for ICPS samples. 
Summary of genotyping of four SNPs located in or near the ZnT3 gene, in controls and cases 
from the ICPS cohort used for correlation with expression.  
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  Frequency (%)  
 n Genotype Minor Allele 
SNP5 rs704326: Exon 47 [A/T]  
   
      
  G/G G/A A/A A 
ICPS schizophrenia 35 20.0 60.0 20.0 50.0 
ICPS controls. 36 25.0 41.7 33.3 54.2 
S100A8 
SNP1 rs3795391: Intron 1 
   
 
  A/A A/G G/G G 
ICPS schizophrenia 38 78.9 21.1 0.0 10.5 
ICPS controls. 27 70.4 29.6 0.0 14.8 
SNP2 rs3006488: 3’ UTR 
   
 
  T/T T/C C/C C 
ICPS schizophrenia 38 76.3 21.1 2.6 13.2 
ICPS controls. 29 75.9 24.1 0.0 12.1 
FRZB 
SNP1 rs10206992: Intron 1      
  T/T T/G G/G G 
ICPS schizophrenia 34 50.0 47.1 2.9 26.5 
ICPS controls. 34 52.9 35.3 11.8 29.4 
SNP2 rs7607737: Intron 1  
   
 
  C/C C/T T/T T 
ICPS schizophrenia 34 73.5 17.6 8.8 17.6 
ICPS controls. 31 87.1 12.2 0.0 6.5 
SNP 3 rs288329: Intron 3  
    
  C/C C/T T/T T 
ICPS schizophrenia 33 63.6 30.3 6.1 21.2 
ICPS controls. 33 84.8 15.2 0.0 7.6 
SNP 4 rs16823799: 3’   
    
  G/G G/A A/A A 
ICPS schizophrenia 34 79.4 20.6 0.0 10.3 
ICPS controls. 33 84.8 15.2 0.0 7.6 
WISP3 
SNP1 rs2280153: Intron 2      
  C/C C/T T/T T 
ICPS schizophrenia 31 35.5 61.3 3.2 33.9 
ICPS controls. 33 42.4 54.6 3.0 30.3 
SNP2 rs1230348: Intron 2  
   
 
  C/C C/T T/T T 
ICPS schizophrenia 33 54.5 39.4 6.1 25.8 
ICPS controls. 31 48.4 45.2 6.5 29.0 
SNP 3 rs1230345: Exon 3 [Q/H] 
    
  G/G G/T T/T T 
ICPS schizophrenia 33 33.4 63.6 3.0 34.8 
ICPS controls. 32 46.8 53.1 3.1 29.7 
 
Supplementary Table 4 (Continued)  
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DKK3 
  Frequency (%)  
 n Genotype Minor Allele 
SNP1 rs2291599: Intron 5 
   
 
  G/G G/A A/A A 
ICPS schizophrenia 36 77.8 19.4 2.8 12.5 
ICPS controls. 37 64.9 32.4 2.7 18.9 
SNP2 rs7480026: Intron 6  
   
 
  C/C C/T T/T T 
ICPS schizophrenia 38 86.8 13.2 0.0 6.6 
ICPS controls. 37 89.2 10.8 0.0 5.4 
SNP 3 rs3206824: Exon 8 [R/G]     
  G/G G/A A/A A 
ICPS schizophrenia 37 73.0 24.3 2.7 14.9 
ICPS controls. 36 44.4 52.8 2.8 29.2 
 
Supplementary Table 4 (Continued)  
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Appendix E 
There is growing evidence of the involvement of the canonical Wnt signalling 
pathway in the pathogenesis of schizophrenia. In this study, the effect of 
overexpression of DKK3 was investigated on nuclear translocation of β-catenin in 
neuronal cells, based on previous reports carried out using cancer cells (Yue et al., 
2008). However, extensive optimisation was required for the analysis, and the study 
was not completed as intended. The preliminary results are presented here as the 
possible basis of future investigation.  
A GFP-DKK3 construct was prepared using cDNA from human DKK3 (NM_013253; 
OriGene) cloned into a pCDNA3.1/NT-GFP-TOPO vector (Invitrogen) and an RFP-β-
catenin construct was made by cloning β-catenin cDNA (kindly provided by Dr. 
Magdalena Sastre) into a pDsRed2-C1 vector (Clontech Laboratories). Transfection of 
the constructs was carried out as described in section 2.3.3 using N2a cells and 
COS7 cells as a control. Cellular localization of the GFP-DKK3 fusion protein was 
observed in the cytosolic region of cells, whilst RFP-β-catenin construct had an 
exclusive nuclear distribution. The secreted glycosylated form of the DKK3 fusion 
protein (85 KDa) was observed from western blot analysis (described in section 
2.3.5) using a rabbit anti-GFP antibody (Abcam). Expression of the RFP fusion 
protein (119 KDa) and endogenous β-catenin (94KDa) was also confirmed by 
Western blot analysis using a rabbit anti-β-catenin antibody (Sigma-Aldrich). 
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Supplementary Figure 1 Expression of the glycosylated form of DKK3 in COS7 and 
N2a cells. 
Cytosolic distribution of the GFP-DKK3 fusion protein is observed in both cell lines (A). 
Western blot analysis (B) confirmed expression of the glycosylated form (85 KDa) in lysates 
(L) and media (M) of both cell lines but not in untransfected controls (UT). Scale bar in (A) is 
20µm 
 
Supplementary Figure 2 Expression of the RFP-β-catenin fusion protein in COS7 
and N2a cells 
Nuclear localization of the RFP-β-catenin fusion protein was observed in COS7 and N2a cells 
(A). Western blot analysis shows the 119 KDa band corresponding to the RFP-β-catenin 
protein only for cells transfected with the tagged construct (B). A second band of 94 KDa 
band, presumably from endogenous β-catenin, was also present in these cells, as well as 
cells transfected with an untagged β-catenin construct and untransfected cells (UT). Scale 
bars in (A) are 20 µm. 
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In order to quantify the effect of the expression of DKK3 on activation of β-
catenin/Wnt signalling luciferase reporter assays were carried out using the TCF 
activated TOPFlash reporter and the mutant FOPFlash plasmid as a negative control. 
A Dual-Luciferase Reporter Assay system (Promega) was used and experimental 
conditions are described in section 2.3.6. Firefly luciferase activity values obtained 
from the reporter plasmids were normalised to renilla luciferase activity values 
obtained from the vector pRL-CMV (Promega) used as a transfection control. Due to 
the variation observed between experiments, and the need for optimisation of the 
experimental conditions, only N2a cells were used. 
A significant decrease in β-catenin mediated activation of the TOPFlash reporter 
relative to transfection of the GFP empty vector was observed when GFP-DKK3 was 
co-expressed (p=0.0022, Supplementary Figure 3B).  
 
Supplementary Figure 3 Luciferase reporter assays showing significant inhibition 
of Wnt signalling by DKK3  
The data presented bellow is the result of a series of assays (n=6) conducted on N2a cells 
48 hours after transfection. Relative luciferase activity (RLA) units are used to represent the 
activation of the TOPFlash reporter (A). Although some non-specific activation of the mutant 
FOPFlash reporter was observed this was significantly minor to the response observed from 
TOPFlash (p=0.008). Transfection of the GFP-DKK3 construct resulted in inhibition of β-
catenin mediated TOPFlash activation (B) to a statistical significant level (p=0.002).  
